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ABSTRACT 
 
Antibody-drug conjugates (ADCs) are a type of targeted therapy for killing cancer cells.  
ADCs combine the power of antibodies to recognize and bind specific proteins on tumor cells 
with the power of newly developed highly potent cytotoxic drugs for killing cells.  Although the 
targeting idea appears simple, to date only two ADC drugs have received FDA approval. The 
goal of this IQP project was to evaluate ADC technology by assessing its technical and 
regulatory problems to help determine the obstacles for gaining FDA approval. Our team 
performed a review of the current research literature, and conducted interviews with academic, 
industry, and legal experts.  We conclude that ADCs have great potential, and in some cases 
have been shown to cause complete cancer remissions.  The few ADCs that have been approved 
target well-chosen antigens with excellent properties, and had years of research prior to approval.  
All ADCs cause adverse side-effects, but they are usually manageable, and are out-weighed by 
the need for new drugs for treating relapsed cancer that does not respond to other therapies. We 
recommend that ADC research be continued, especially in the areas of combination therapies, 
non-internalizing ADCs that target the tumor vasculature, immunotoxins and radioimmune 
therapies to complement ADCs, and site-specific conjugations to control the number and 
locations of drug attachments to the antibodies. 
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PROJECT GOALS 
 
 
The overall goal of this IQP project was to document and evaluate the technology of 
antibody-drug conjugates (ADCs) for targeting and killing cancer cells, to determine why only 
two of the approximately 40 ADCs currently in human testing have received FDA approval, and 
to map the steps for moving forward with other ADC drugs. 
 
The specific objectives were to: 
 
1. Develop a comprehensive assessment of the scientific experiments that led to the development 
of antibody-drug conjugates, and discuss the technique’s potential applications. 
2. Characterize what key scientific and IVF stakeholders believe are the strengths and 
weaknesses of this technology, and their legal hurdles. 
3. Evaluate the obtained evidence, and prioritize the remaining problems. 
4. Recommend potential solutions to the remaining problems. 
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EXECUTIVE SUMMARY 
 
Antibody-drug conjugates (ADCs) are a type of targeted drug therapy for specifically 
killing cancer cells.  ADCs combine the power of antibodies (that recognize and bind specific 
proteins) with the power of new highly potent drugs that kill cells in very small quantities.  An 
ADC drug contains an antibody directed against a tumor antigen (that is hopefully lacking in 
normal cells), chemically conjugated to a cytotoxic drug via a linker.  Although the ADC idea 
seems simple and powerful, ADCs have not achieved their full potential.  While over 30 
different ADCs are under development, only three have received FDA approval, and one of those 
was withdrawn from the market when it was shown to increase patient death.   
 
Some ADCs have undergone strong pre-clinical testing, including using human tumor 
cell lines grown in vitro, and using mouse xenograft models (mice growing human tumors in 
vivo).  But even when an ADC drug shows strong pre-clinical data, this does not guarantee a 
strong performance in clinical trials.  In the ADC clinical trials performed to date, all ADCs have 
adverse side-effects, but they appear to be mostly manageable, and the drugs appear to be 
relatively safe compared to the symptoms of the advanced cancer.  However, ADCs show 
varying levels of effectiveness.  If a drug has been shown to improve patient survival by only a 
few months, does this warrant FDA approval?  What types of side-effects are seen, and can they 
be minimized?  Do the needs of cancer patients with very poor prognosis (ADCs are given to a 
patient only if he no longer responds to other drugs) outweigh the adverse side-effects caused by 
the ADCs?  What are the key problems remaining for FDA approval of more ADCs? 
 
The overall goal of this IQP project was to document and evaluate the technology of 
antibody-drug conjugates, to assess their technical and legal problems, and to make 
recommendations for moving forward. The specific objectives were to: 1) develop a 
comprehensive assessment of the published scientific experiments related to ADCs (including 
pre-clinical experiments that led to the development of ADCs, the clinical trial data including 
safety, the legal hurdles for approving new ADC drugs, and the technique’s potential future 
applications), 2) characterize what key scientific stakeholders believe are the strengths and 
weaknesses of this technology, and their legal concerns, 3) evaluate all of the obtained evidence, 
and prioritize the remaining problems, and 4) recommend potential solutions to remaining 
problems. 
 
To accomplish objective-1, we performed a review of the current literature, including 
reputable academic journal articles, relevant books, scholarly websites, and other pertinent 
materials.  To accomplish objective-2, we conducted interviews with various researchers in 
academia and industry who had developed or tested ADCs in animals or humans.  We also 
interviewed legal experts to clarify remaining problems for gaining FDA approval for ADC 
drugs. After performing the Literature Review and interviews, the team synthesized the collected 
information to ascertain the strength of the evidence for and against ADC drugs, and created 
recommendations for moving forward. 
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Cancer and the Need for New Drugs 
 
 The National Cancer Institute defines cancer as a term for a group of diseases in which 
abnormal cells divide without control and which can invade nearby tissues (NCI, 2017).  At the 
cellular level, cancer has several hallmarks, including: genomic instability, deregulated cell 
signaling causing cell division and growth, sustained cell proliferation, resistance to cell death, 
and evasion from the patient’s immune system (Hanahan and Weinberg, 2011). As a result of 
these changes, cancer is difficult to treat.  A cancer statistics review performed by the National 
Cancer Institute shows that survival rates range widely, from about 8% to 18% for difficult to 
treat cancers (like pancreatic, lung, and liver cancers), to greater than 65% for cancers of the 
colon, breast, kidney, and prostate (that grow slowly and are easier to treat if detected early) 
(Howlader et al., 2017). The poor survival rates for some cancers are observed even when using 
the best anti-cancer therapies, such as chemotherapies to block dividing cells (e.g., taxanes, 
anthracyclines, platins), small-molecule inhibitors (to block specific cellular signal transduction 
pathways), or bio-therapeutics (e.g., therapeutic antibodies against cell surface receptors).  These 
therapies are not fully effective, and all of them have adverse side-effects, so scientists are 
constantly trying to develop new therapies that are more effective with fewer side-effects. 
 
 
Introduction to Antibodies 
 
 Antibodies are molecules secreted by a B-cell, a type of white blood cell.  Antibody 
molecules migrate through the blood and bind to a foreign protein (or parts thereof, antigens) to 
help inactivate it. Each antibody is highly specific for the protein it was designed to detect 
(Murphy and Weaver, 2016). The general structure of an antibody is the shape of a ‘Y’.  Each 
upper arm of the ‘Y’ (which bind the antigen) is referred to as the N-terminus (amino-terminus). 
The N-termini are variable between different antibodies and dictate their binding properties.  The 
lower base of the ‘Y’ is referred to as the C-terminus (carboxy-terminus) and is a constant region 
(Murphy and Weaver, 2016). The variable region is unique to each antibody, and the human 
immune system can produce over 5 x 1013 different types of antibodies (Murphy and Weaver, 
2016). There are five main classes of antibodies (IgA, IgD, IgE, IgG, and IgM), and the constant 
region remains the same within each class.  The constant regions allows the antibody to interact 
with effector molecules and phagocytic cells that internalize the antibody-antigen complex. Once 
an antibody binds its antigen, based on its type of constant region, it signals for a specific 
effector function that leads to destruction of the pathogen.  
 
 
Introduction to Antibody-Drug Conjugates 
 
 Based on the high specificity of interaction between an antibody and its antigen, scientists 
have engineered antibodies to bind to cancer cells.  With a few exceptions, in most cases simply 
attaching an antibody by itself to a cancer cell antigen does not necessarily kill the cell (Thomas 
et al., 2016). So, scientists have designed a new type of anti-cancer drug, antibody-drug 
conjugates (ADCs).  These consist of an antibody targeting a specific tumor antigen (usually on 
the cell surface) linked to a highly potent cytotoxic poison (the cargo). Most ADCs are designed 
to be “internalizing”: once the ADC binds to its target antigen, the cell engulfs the ADC and 
releases the toxin inside the cell, thus killing it (Pastan et al., 2006).  To make a good ADC, the 
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antibody should strongly bind the antigen, the antigen should be highly expressed on the tumor 
cell (not normal cells), the linker should be stable in the patient’s circulation to avoid releasing 
the toxin too soon, and the cargo drug should be highly potent since only a few molecules will 
enter the cell. 
 
 In the ADC production process, monoclonal antibodies against a particular surface tumor 
antigen are usually produced in cell culture, and are then bound to a toxin using a linker (Pastan 
et al., 2006; Chiu and Gilliland, 2016). It is essential that the target antigen is as specific as 
possible for the cancer, so that the ADC will mostly bind and kill the tumor cells not normal cells 
(Thomas et al., 2016). In some cases this may not be possible, such as with leukemia where the 
target antigen may also be present in a low amount on normal cells. Some ADCs have been 
modified to remove the domains that bind normal cells (Pastan et al., 2006). Currently, all ADCs 
are linked to their drugs covalently through one of four chemical methods: cysteine disulfide 
bond conjugation, glycol-conjugation, protein tags, or amino acid incorporation (Pastan et al., 
2006; Agarwal and Bertozzi, 2015; Thomas et al., 2016). The linker can be placed at various 
locations on the antibody, including the variable region, hinge region, constant region, or all 
three simultaneously (Agarwal and Bertozzi, 2015). Usually two to four cargo molecules are 
attached to each antibody such that the antibody retains all of its antigen-binding properties and 
is not cleared from the body too quickly (Hughes, 2010).  The linker functions to keep the drug 
bound to the antibody on its journey to the target, and becomes degraded once the ADC enters 
the cell (Thomas et al., 2016). Linkers have been designed to be sensitive to proteases, pH, or 
glutathione, and are cleavable or non-cleavable (Jain et al., 2015). Cleavable linkers utilize 
enzymes inside the target cell to release the drug from the antibody (Jain et al., 2015). This 
ensures that the linker is stable in the bloodstream, and breaks down only when being digested 
by a target cell. Non-cleavable linkers do not release the drug once they enter the cell; when the 
antibody and linker are digested, the drug is released (Jain et al., 2015).  
 
 ADCs are typically administered to the patient intravenously.  They bind to the target cell 
and are engulfed by an endocytic vesicle (Pastan et al., 2006; Bouchard et al., 2014). Once the 
intracellular vesicle fuses with a lysosome, the environment turns acidic and enzymes are 
released that digest the linker releasing the cargo into the cytoplasm where it works to kill the 
cell. Drugs commonly used in ADCs bind DNA (leading to its cleavage or alkylation), block 
tubulin (inhibiting cell division), or inhibit RNA polymerases (blocking RNA synthesis) 
(Thomas et al., 2016).  
 
 
Example ADCs 
  
Two ADCs are currently approved by the FDA: Trastuzumab emtansine (Kadcyla®) and 
Brentuximab vedotin (Adcetris®) (Thomas et al., 2016).  A third ADC, Gemtuzumab 
ozogamicin (Mylotarg®), was initially approved but later withdrawn (Richwine, 2010). 
Kadcyla® was developed by Genentech, and is manufactured by Lonza. It is used to treat 
HER2-positive metastatic breast cancer in patients who are resistant to other treatments 
(Niculescu-Duvaz, 2010; LoRusso et al., 2011; Lopus, 2011; Verma et al., 2012; About Kadcyla, 
2017). Kadcyla is composed of an antibody (Trastuzumab or Herceptin) against the HER2 
receptor on the surface of some breast cancer cells conjugated to the drug DM1 (a derivative of 
maytansine) using a non-cleavable thioether linker (Barok et al., 2014; Jain et al., 2015).  Of the 
various ADC drugs, Kadcyla is unique in that its antibody component by itself is sometimes 
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capable of blocking Her2-positive breast cancer. The binding of “naked antibody” Herceptin to 
Her2 receptor on the cell surface prevents receptor dimerization, inhibiting activation of the 
MAPK, PI3-kinase, AKT kinase pathways that otherwise stimulate cell division (Verma et al., 
2012).  Once ingested by the cell and released into the cytoplasm, DM1 inhibits microtubule 
assembly causing apoptosis (Barok et al., 2014; Jain et al., 2015; About Kadcyla, 2017). 
 
Adcetris® is marketed by Seattle Genetics Inc. in North America, and by Takeda 
Oncology in the rest of the world. It is used to treat CD30-positive lymphoproliferative disorders, 
including Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) (Van de Donk 
and Dhimolea, 2012; Brentuximab vedotin, 2016). Protein CD30 often occurs on the surface of 
cells of these tumor types, but rarely on normal cells (Küppers and Hansmann, 2005).  Adcetris 
contains an antibody (Brentuximab or cAC10) targeting CD30 on HL and ALCL tumors, 
conjugated to 3-5 molecules of the drug monomethyl auristatin E (MMAE) by a cathepsin-
cleavable linker (Van de Donk and Dhimolea, 2012). The antibody is produced in mammalian 
Chinese Hamster Ovary (CHO) cells, while the small molecule components are produced by 
chemical synthesis. Once engulfed by the cell and cleaved from its linker, MMAE binds to 
tubulin, inhibits mitosis, and initiates apoptosis (Van de Donk and Dhimolea, 2012; Francisco et 
al., 2003; Vaklavas and Forero-Torres, 2012). 
 
Mylotarg® is manufactured by Wyeth (now Pfizer), and was FDA approved in May of 
2000 to treat acute myeloid leukemia (Gemtuzumab Ozogamicin, 2015). Mylotarg is composed 
of an antibody (IgG4 κ hP67.6) against CD33 found on leukemia cells (Gemtuzumab 
Ozogamicin, 2015; Wyeth Pharmaceuticals, 2005), conjugated to 2-3 molecules of the drug 
calicheamicin (Gemtuzumab Ozogamicin, 2015). Calicheamicin binds to double stranded DNA 
causing breaks, leading to cell death (Wyeth Pharmaceuticals, 2005).  
 
Currently, more than 40 ADCs are in the clinical trial stages of development (Thomas et 
al., 2016), and the future of ADCs seems bright.  But in some cases the ADCs are not very 
effective, and all of the ADCs have adverse side-effects.  Therefore, it is necessary to continue 
developing improved ADCs that are more effective with fewer side-effects. 
 
 
Pre-Clinical ADC Testing 
 
 Pre-clinical testing of a drug in mice and on cell lines is necessary before proceeding to 
human clinical trials.  ADC pre-clinical testing includes the use of cancer cell lines in vitro, the 
use of human cancers xenografted into mice, and more rarely monkey experiments.  ADC drugs 
have been designed against a variety of surface antigens present on the surface of different types 
of tumor cells.   
 
Our review of the literature included summarizing the results of pre-clinical experiments 
for ADCs against: CD19 (ADC SAR-3419) (Lutz et al., 2006; Gerber et al., 2009; Al-Katib et 
al., 2009; Carol et al., 2013), CD22 (ADC Inotuzumab ozogamicin or CMC-544) (DiJoseph et 
al., 2004a; 2004b; 2006; Shor et al., 2015), CD30 (ADC Brentuximab vedotin, Adcetris®, SGN-
035) (Francisco et al., 2003; Hamblett et al., 2004; Okeley et al., 2010), CD33 (ADC 
Gemtuzumab ozogamicin, Mylotarg®) (Hamann et al., 2002), Her2 (ADC Trastuzumab 
emtansine, Kadcyla®, T-DM1) (Lewis-Phillips et al., 2008; Junttila et al., 2008; Kellogg et al., 
2011; Phillips et al., 2014), gpNMB (ADC Glembatumumab vedotin (CDX-011) (formerly 
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CR011-vcMMAE) (Tse et al., 2006; Pollack et al., 2007; Rose et al., 2010), Trop-2 (ADC 
Sacituzumab govitecan, IMMU-132) (Moon et al., 2008; Govindan et al., 2009; Cardillo et al., 
2011; Govindan et al., 2013), 5T4 (ADC A1mcMMAF) (Oncofetal Antigen, 2011; Sapra et al., 
2013; McGinn et al., 2017), DLL-3 (ADC SC16LD6.5) (Saunders et al., 2015), EpCAM (ADC 
chiHEA125-Ama) (Moldenhauer et al., 2012), Fibronectin-EDB (ADC SIP(L19)-PS) (Palumbo 
et al., 2011), and Mesothelin (ADC Anetumab Ravtansine, BAY 94-9343) (Golfier et al., 2014). 
 
Overall, the pre-clinical results showed that ADCs have the potential to slow or eliminate 
various types of cancers, both in vitro (cancer cell lines) and in vivo (xenograft models). The 
ADC drugs showed various degrees of effectiveness against a large variety of cancers, from 
inactive to complete tumor regressions.  Use of the antibody alone, or the cargo toxin alone, 
produced no tumor killing, providing a proof-of-principle that combining the antibody with 
cargo (as with ADCs) strongly elevates the anti-tumor effects of either agent alone.  In binding 
experiments, conjugation of the antibody to the cargo did not appear to alter the cell-binding 
ability of the antibody.  In some cases, the researchers were able to correlate the extent of anti-
tumor activity with the extent of target antigen expression on the tumor.  Because some tumors 
as they mature alter the expression of surface markers, this suggests that a best practice would be 
to frequently monitor the patient’s tumor for target antigen expression to determine which 
patients most likely will benefit from the therapy.  
 
The pre-clinical models allowed a more thorough testing than could be done with human 
clinical trials.  For example, for some ADCs the pre-clinical tests allowed the testing of a wide 
range of doses: doses as low as 1 mg/kg showed tumor reductions, and doses as high as 30 
mg/kg showed no signs of toxicity.  A variety of cargo loads were also tested, showing that 
ADCs with cargo loads of 4-8 molecules per ADC were generally more active than those with 
only 1-2. A variety of linkers were also tested, showing that linker optimization is important for 
each type of ADC.  The pre-clinical models also allowed the performance of specific types of 
experiments that could never be performed in humans, such as knocking down target antigen in 
tumor cell lines using small interfering RNAs to show decreasing surface antigen expression 
prevents destruction of the cell, and over-expressing the target antigen on normal cells to make 
them sensitive to the ADC.  This shows the importance of the target antigen to the cell 
destruction. Other pre-clinical studies showed that delivering the ADC drug long-term post-
cancer remission prevented disease re-occurrence (so long as the patient did not form antibodies 
against the ADC drug), so ADC use long-term might be tested in clinical trials to help ensure a 
patient’s cancer does not return.  Most of the pre-clinical studies showed relatively minor 
adverse-effects of the ADCs; but the most serious side-effect observed in mice was neutropenia, 
so this might be expected to be a problem in the clinical trials, and should be monitored closely.  
 
 
ADC Clinical Trials and Safety 
  
Over 30 different ADCs are currently being investigated in patients (Sasson and Blanc, 
2013), and this has provided a wealth of safety information for this new type of cancer drug. Our 
review of the literature in this area focused on some of the best investigated target antigens, 
including those with FDA approval.  We summarized the data from clinical trials using ADCs 
against the following antigens: CD19 (ADC SAR-3419) (Phase-I trials: Younes et al., 2009; 
Coiffier et al., 2011), CD22 (ADCs Inotuzumab ozogamicin and CAT-8015, Moxetumomab 
pasudotox) (Phase-I trials: Advani et al., 2010; Kreitman et al., 2012) (Phase-II trials: Kantarjian 
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et al., 2012; Wagner-Johnson et al., 2015), CD30 (ADC Brentuximab vedotin, Adcetris®) 
(Phase-I trials: Seattle Genetics, 2010; Younes et al., 2010; Younes et al., 2013) (Phase-II trials: 
Younes et al., 2012; Pro et al., 2012), CD33 (ADC Gemtuzumab ozogamicin, Mylotarg®) 
(Phase-III: Castaigne et al., 2012; Petersdorf  et al., 2013; Hills et al., 2014) (Phase-II:  
Daver et al., 2016), Her2 (ADC Kadcyla®, Trastuzumab emtansine, T-DM1) (Phase-I: Krop et 
al., 2010) (Phase-II: Burris et al., 2011; Perez et al., 2014; Phillips et al., 2014) (Phase-III: Verma 
et al., 2012; Krop et al., 2014), gpNMB (ADC Glembatumumab vedotin, CDX-011, formerly 
CR011-vcMMAE) (Phase-I: Hamid et al., 2010; Bendell et al., 2014) (Phase-II: Yardley et al., 
2015), and Trop-2 (ADC Sacituzumab govitecan, IMMU-132) (Phase-I: Starodub et al., 2015; 
Faltas et al., 2016). 
 
Overall, the review of the clinical ADC literature showed that ADC drugs have a wide 
range of activity, and generally produce relatively mild and treatable adverse-effects.  
Importantly, almost all of the clinical trials were performed on patients who had relapsed from 
cancer, or whose cancer did not respond to previous therapies; only one trial was performed on 
newly diagnosed patients. Thus, the overall patient prognosis without further treatment was very 
low.  An example of a strong response rate was seen with a CD22-targeting ADC that showed an 
overall response rate of 86%, with 46% achieving complete remission (Kantarjian et al., 2012).  
And another example was CD30-targeting Adcetris, where 21 of 22 patients (95%) achieved 
complete remission (Pro et al., 2012). 
 
Two best practices were identified in the review of the literature which may be worth 
following up in interviews.  The first best practice pertains to measuring chromosome 
cytogenetic abnormalities in the patients.  Cytogenetic abnormalities include chromosome 
inversions, insertions, translocations, etc. Some of the Mylotarg clinical trials for leukemia 
patients showed that the survival benefit of the drug was best in patients with no additional 
cytogenetic abnormalities (other than the initial abnormality causing the leukemia).  While in 
patients with adverse cytogenetics, Mylotarg provided no detectable benefit. This suggests that 
patients with additional chromosomal inversions or translocations incur new changes in cellular 
biochemistry that increase drug resistance. So, perhaps in best practice, patients should be 
monitored for cytogenetic abnormalities to help determine which patients are most likely to 
improve with ADC treatment. 
 
 The second best practice observed in the clinical trial literature was the assay of the 
extent of over-expression of target antigen in the patients. In several trials, patients with 
confirmed high expression levels of the target antigen showed higher response rates to the ADC, 
and the risk of cancer progression was lower.  Antigen levels were assayed by immuno-
histochemistry, reverse transcriptase polymerase chain reaction (RT-PCR), or in situ 
hybridization. Thus, pre-analyzing the patient’s tumor to determine the extent of target antigen 
expression might help predict which patients most likely will benefit from the ADC treatment. A 
patient whose tumor no longer expresses the target antigen will not be targeted by the ADC. 
 
 With respect to safety, from the clinical trial data it was determined that all ADC drugs 
show side-effects. Of three ADC drugs approved by the FDA, one has been withdrawn from the 
market due to patient deaths and an apparent lack of efficacy. And all three FDA-approved drugs 
carry “black box warning labels” on their packaging, informing physicians of the most serious 
side-effects. The follow-up interviews will help weigh the adverse effects of the ADCs and their 
management against the side-effects of standard chemotherapy treatments, and will also be 
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weighed against the very poor prognosis of patients with these types of relapsed cancers who 
have few other options.  But overall, the ADC side-effects appear to be more manageable than 
those caused by current chemotherapy treatments, and are far less worse than the very poor 
prognosis of patients with relapsed cancer.  Neutropenia (low neutrophil count) was almost 
always observed in the clinical trials, but it was not fatal.  As an example of safety data, a Phase-
II trial of Adcetris on 102 patients with refractory/relapsed Hodgkin’s lymphoma showed that the 
most common treatment-related adverse effects were peripheral neuropathy, nausea, fatigue, 
neutropenia, and diarrhea (Younes et al., 2012), while a second Phase-II study showed Grade 3 
or 4 (serious) adverse events of neutropenia (21%), thrombocytopenia (14%), and peripheral 
sensory neuropathy (12%) (Pro et al., 2012). 
 
However, it remains unclear from the literature what causes the side-effects.  Are the 
adverse reactions caused by expression of the target antigen in normal tissues in addition to the 
cancer?  Or are the side-effects caused by off-target effects, such as the release of the cytotoxic 
cargo into the surrounding cells?  Hopefully, the interviews can help resolve this issue, and will 
also help validate our conclusion that the side-effects are relatively manageable. In addition, 
interviews with the researchers might help determine whether the benefits observed of slowing 
or eliminating cancer outweigh the negative side-effects, especially in view of the poor prognosis 
of a patient with recurring cancer. The researchers who design ADCs might also suggest 
directions for future research.  
 
 
ADC Legalities 
 
 Three different ADCs have been approved by the U.S. Food and Drug Administration 
(FDA) for treating various forms of cancer.  One of the ADC drugs was subsequently withdrawn. 
The FDA approval process for new drugs is complex, with efficacy and safety likely being the 
main hold-ups for new ADC approvals. 
 
 In general, the purpose of the FDA approval process is to help protect consumers from 
drugs that are harmful or ineffective. Drug development and approval involves several key steps, 
including: pre-clinical testing, Investigational New Drug (IND) Application, Phase-I testing, 
Phase-II testing, Phase-III testing, New Drug Application (NDA), and Post-Marketing testing 
(Phase-IV) (Lipsky and Sharp, 2001). During pre-clinical testing, the FDA requires researchers 
to perform animal tests before humans are exposed to a new drug. For ADC drugs, this includes 
testing in vitro against cultured cancer cell lines, testing in mice engrafted with human cancer 
cells (xenograft mice), and (less frequently) testing in monkeys. The main objective of pre-
clinical testing is to obtain preliminary animal data on drug safety and activity.  If this data looks 
promising, the investigators file an IND application that includes drug chemical composition and 
manufacturing data, animal test results (including safety), the rationale for testing a new 
compound in humans, strategies for protecting human volunteers, and a plan for clinical testing 
(Stave and Joines, 1997). If the FDA approves the IND, the process heads into the three phases 
of clinical testing.  Phase-I focuses mostly on drug safety and pharmacology in humans at 
various doses (Lipsky and Sharp, 2001). Phase-II studies are designed to obtain data on drug 
effectiveness, optimum drug dose, best method of delivery (IV, oral, etc.), and dosing interval, 
all assayed while focusing on safety (Walters, 1992; Heilman, 1995). During Phase-III, 
researchers attempt to confirm their previous Phase-II findings using a larger group of patients. 
Only about 27% of IND drugs make it past Phase-III. If the Phase-III data look promising, the 
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investigators file a New Drug Application (NDA).  The NDA contains all the preclinical and 
clinical information obtained during the testing phase, including drug chemical composition, 
manufacturing procedures, toxicity, human pharmacokinetics (half-life and bio-distribution), 
clinical trial results (within the U.S. and elsewhere), and proposed labeling (Lipksy and Sharp, 
2001). If the drug is approved, it can be marketed. Sometimes, the FDA requests a Post-
Marketing Study (Phase-IV) to provide more data if something remains unclear or if new 
problems are identified with further use of the drug.   
 
Prior to the modernization acts discussed below, the overall FDA approval process took 
approximately 8-12 years (Heilman, 1995).  But the review time has now been shortened to 
about 12.6 months for normal drugs, and 6 months for an accelerated review (Drugs.com, 2013).  
All three of the FDA-approved ADC drugs (Mylotarg, Adcetris, and Kadcyla) received FDA 
approval under an accelerated review process. Accelerated reviews are sometimes granted when 
no other alternative drugs are available to treat a particular disease, or when the clinical trial data 
are very strong (Drugs.com, 2013). The Prescription Drug User Fee Act of 1992 (PDUFA) was 
designed to help shorten the FDA review time by allowing the FDA to collect user fees from 
IND filers to help enhance the review process (Walters, 1992). In addition, the FDA 
Modernization Act of 1997 (FDAMA) extended the use of the user fees, and streamlined the drug 
approval process (FDAMA, 1997).  
 
The first ADC drug approved by the FDA was Mylotarg® (Gemtuzumab ozogamicin).  
Based on the promising initial data observed in preliminary clinical trials, Mylotarg was FDA-
approved on May 17, 2000 under an accelerated FDA-approval process (FDA, 2000) for treating 
patients over the age of 60 with relapsed acute myeloid leukemia (AML), or for other AML 
patients not considered a candidate for standard chemotherapy (Bross et al., 2001). But within a 
year of Mylotarg’s initial approval, more serious adverse events were observed, including adult 
respiratory distress syndrome (ARDS), hepatotoxicity, anaphylaxis, veno-occlusive disease 
(VOD), and death (Nelson, 2010). The appearance of these more serious events resulted in the 
FDA requiring a “black box warning label” on Mylotarg’s package (Giles et al., 2001; Wadleigh 
et al., 2003).  In June 2010, Mylotarg was voluntarily withdrawn from the market when 
additional clinical trial data and post-marketing experience showed the drug increased patient 
death and was no better than conventional therapies (Nelson, 2010; Richwine, 2010). In 
September 2017, almost seven years after withdrawing it from the market, Pfizer resubmitted 
their application for FDA review as a Biologics License Application (BLA) (Stanton, 2017) 
based on favorable data obtained since 2010. 
 
The second ADC drug approved by the FDA was Adcetris®.  In North America Adcetris 
is marketed by Seattle Genetics Inc., and in the rest of the world by Takeda Oncology. It has 
undergone numerous clinical trials, generally showing high efficacy and relatively manageable 
side-effects. Seattle Genetics submitted an FDA application on February 28, 2011, to treat HL 
and ALCL patients (Fierce Biotech, 2011), and on August 19, 2011, the drug was granted an 
accelerated FDA approval (Genetic Engineering and Biotechnology News, 2011).  However, on 
January 13, 2012, the FDA announced that Adcetris had been linked to two cases of progressive 
multifocal leukoencephalopathy (defective formation of myelin), so the FDA now requires the 
manufacturer to add a “black box warning” to the drug packaging warning of this risk. Adcetris 
has also been approved in Europe by the European Medicines Agency (EMA).  In 2009, the drug 
initially received approval for use as an “orphan product” (a drug that is used to treat a disease 
that affects no more than 5 people in 10,000) (Hofland, 2011), but in view of favorable clinical 
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data, in 2016 it was given EMA marking authorization. The basis of the favorable review by the 
EMA was discussed in a 2016 European Public Assessment Report (EPAR), stating that the 
EMA strongly factored in the drug’s relatively manageable adverse effects, the patient’s poor 
expected outcomes during relapse, and the lack of other suitable drug treatments for relapsed 
patients (European Medicines Agency, 2016). 
 
The third ADC drug approved by the FDA was Kadcyla® (Trastuzumab emtansine). The 
antibody was developed by Genentech (a subsidiary of Roche), the linker and toxin were 
developed by ImmunoGen (Waltham, MA), and the complete ADC is manufactured by Lonza 
(Pollack, 2013).  Kadcyla underwent an accelerated 6-month FDA priority review, reserved for 
therapies for diseases with no alternative treatments, or that provide significant improvements 
over other marketed products (Drug.com, 2013).  In 2010, Genentech initially applied for 
accelerated FDA review on the basis of the results of a single Phase-II study, but on August 26th, 
2010, the FDA refused to review it in accelerated mode because all of the available treatment 
choices had not yet been tested in their patients (News-Medical.net, 2010).  So, Genentech 
continued their studies with an amended Phase-III trial after treating the patients with other 
treatment options.  Kadcyla was approved on February 22, 2013, based on the positive clinical 
trial data of women with advanced Her2-positive breast cancer who were already resistant to 
antibody treatment alone (Verma et al., 2012).  Kadcyla comes with its own set of side-effects 
which must be weighed against the potential benefit of blocking the breast cancer growth, but the 
adverse effects were tolerated better than those seen with standard chemotherapies. In the U.S., 
Kadcyla packaging carries a “black box warning” for liver toxicity, heart damage, and fetal harm 
if given to pregnant women. 
 
The high cost of ADC drugs is an important issue for consumers.  Kadcyla is a good 
example.  In the U.K., the National Institute for Health and Care Excellence (NICE) and the 
National Health Service England (NHS) determine whether a particular drug remains on the 
Cancer Drugs Fund (CDF) list of medicines paid by the government.  The normal CDF cut-off 
for an end-of-life drug like Kadcyla is about £50,000 per year (The Guardian, 2015) or £30,000 
per quality-adjusted life years (NICE, 2014).  Roche’s initial price was high, a reported £90,000 
per patient per year (Pollack, 2013), nearly double the CDF cut-off, placing the drug in jeopardy 
for being removed from the list. In 2014, a draft guidance document produced by NICE 
concluded that Kadcyla’s price was too high for the CDF list (NICE, 2014). But in 2015, Roche 
compromised and lowered their price to £5,900 per month.  At the new price, a typical 9.6 month 
treatment would cost about £56,640, bringing the drug close to the CDF cut-off. So, the NICE 
and NHS England committees have, for now, left Kadcyla on the list (The Guardian, 2015). 
Hopefully, other pharmaceutical companies will follow Roche’s lead of cutting ADC drug prices 
to be more affordable. 
 
 Overall, the legal portion of the ADC Literature Review summarized the FDA approval 
process for ADC drugs, and discussed the three approved ADCs. All three of the FDA-approved 
ADC drugs were reviewed under an accelerated program, either due to strong and clear clinical 
data better than other available treatments, or because the drugs provided a treatment for a 
disease with no other options available at the time of the review.  All three approved ADCs have 
side-effects requiring black box warnings on the packaging, but they mostly appear to be 
manageable, transient, and less prevalent than those seen with current chemotherapy treatments.  
A current ADC trend appears to be the testing of drug combinations, as demonstrated by 
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combining the ADC Adcetris with the immune checkpoint inhibitor Opdivo®, and we will 
obtain further information on this promising combination approach in interviews.  
 
 
ADC Recent Advances and Future Directions 
  
Although ADC drugs show great promise, they are not perfect. In all clinical trials 
performed to date, ADCs have caused adverse side-effects in the patient, and is sometimes 
ineffective against the cancer.  The future approval of ADCs under development may likely 
depend on improving their clinical performances to warrant their use (Panowski et al., 2014). 
Thus, there is room for continued ADC improvement. 
 
 The first-generation ADC drugs (1o-ADCs) as originally developed came with a variety 
of problems, including lack of efficacy and adverse side-effects.  Thus, much research has gone 
into creating second-generation ADCs (2o-ADCs) with superior properties (Thomas et al., 2016). 
1o-ADCs usually contained mouse monoclonal antibodies against the target protein. But injecting 
a mouse antibody into human patients often stimulated an immune response against the drug, 
lowering drug effectiveness. 2o-ADCs contain mouse-human chimera antibodies or fully 
humanized antibodies that produce less of a response in patients.  1o-ADCs also had short half-
lives in the blood, releasing their toxic payload too soon into the circulation instead of in the 
tumor cell.  In some cases the linkers released the payload too early, before reaching the tumor 
cell.  2o-ADCs use improved linker chemistries (such as the use of disulfide linkages, dipeptide 
linkages, and hydrazine linkages) to hold the payload tighter, releasing it only in the acidic 
environment of the internalization vesicle.  In addition, 1o-ADCs used first-generation cytotoxic 
payloads (such as doxorubicin, vinblastine, or methotrexate).  Those first-generation payloads 
had inhibitor concentration-50 values (IC50) in the micromolar range, while 2
o-ADCs use newly 
designed payloads (such as Calicheamicin, Maytansine derivatives like DM1, or Auristatins like 
MMAE) that are far more toxic, with IC50’s in the nanomolar range (same effectiveness at 1000-
fold lower concentrations). 
 
Several key steps must occur for ADCs to work properly (Loganzo et al., 2016).  These 
steps include: movement of the ADC through the patient’s circulation without losing its toxic 
cargo, binding of the ADC to the target antigen on the surface of the tumor cell, lack of targeting 
of the ADC to normal cells, internalization of the ADC into an endocytic vesicle, binding of the 
endocytic vesicle to a lysosome to acidify the compartment and release enzymes into the 
endosome, degradation of the linker and sometimes antibody to release the toxic cargo, 
movement of the cargo into the cytoplasm, and targeting of the cargo to a cellular component 
such as DNA or tubulin to prevent cell division.  Inefficient function of any one of these steps 
can create an inactive drug.  Problems independent of the tumor itself include: premature loss of 
the cargo drug into the blood, and poor pharmacokinetics (ADME) (poor absorption, 
distribution, metabolism, excretion) (Kraynov et al., 2016). In other cases, the environment 
surrounding the tumor limits access to large molecules like ADCs.  These environmental changes 
might include the increased formation of vascular barriers such as basement membranes or 
increased formation of extracellular matrix.  In other cases, the tumors themselves become 
resistant to the ADC treatment by altering one or more of the steps needed by ADCs to kill the 
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cell (Loganzo et al., 2016).  Each of these steps presents a research opportunity to improve 
second-generation ADCs relative to early versions of the drugs.   
 
ADC drug design is a subject of much research in the biotech industry.  One example of a 
company designing new ADCs is Tarveda Therapeutics (Watertown, MA), a clinical stage 
biopharmaceutical company (Tarveda.com, 2017). Their main technology is Pentarins™, which 
are potent, selective, miniaturized ADCs designed to penetrate more deeply into solid tumors 
than normal ADCs.  According to Richard Wooster, Tarveda’s President of Research and 
Development, “The result of our [Pentarin platform of miniaturization] is a drug that is about 15 
times smaller [than antibodies], and are likely to penetrate deeper into the tumor” (Ledford, 
2016). Another example of a biotech company investigating ADCs is Mersana Therapeutics 
(Cambridge, MA). This company uses a patented “Fleximer technology” to design biodegradable 
ADC drugs with improved drug solubility, pharmacokinetics, reduced immunogenicity, and 
optimized drug loading (Mersana.com, 2017). The platform attempts to increase control over 
when, where, and how the ADCs are released. According to Timothy Lowinger, Mersana’s Chief 
Scientific Officer, “This [technology] allows the company to attach 15 molecules of the drug to 
each polymer, rather than the usual 3-4 (Ledford, 2016).  Their most developed drug is XMT-
1522 that targets Her-2 in breast cancer, currently in Phase-I clinical trials (Mersana.com, 2017). 
 
 A future ADC direction is antibody-type switching. 1o-ADCs used murine antibodies 
which tended to produce immune responses against the ADCs, lowering their efficacy (Teicher 
et al., 2011).  2o-ADCs use humanized mouse-human hybrids or purely human antibodies which 
are less immunogenic in patients than mouse antibodies, and are 100 to 1000-fold more potent.  
An example of an ADC containing a mouse-human chimera antibody is Adcetris (Deng et al., 
2013), while an example of an ADC with a fully human antibody is CDX-011 (Keir and Vahdat, 
2012). 
 
 Another important future direction for ADC research is the identification of new target 
antigens. Some of the ADC side-effects occur when the targeted tumor antigen is also expressed 
to some extent in normal tissues, so new unique tumor antigens need to be identified. In other 
cases, only a portion of a patient’s tumor cells express the target antigen, or the tumor down-
regulates the antigen as it matures or metastasizes.  Cells not expressing target antigen are not 
targeted by the ADC, so it is important to keep identifying new target antigens. A recent example 
of a newly identified target antigen is Her-3 that is over-expressed in breast cancer cells 
metastasized to the brain (Kodack et al., 2017). Another example is CD32a which may be a 
marker for latently HIV-infected T-cells which might help eliminate this cell population 
(Descours et al., 2017).   
 
 Another ADC direction worth pursuing in the future is the use of dual-targeted 
therapies. This approach uses two ADCs targeting the same antigen but carrying different 
cytotoxic cargos, or alternatively uses two different ADCs targeting different antigens on the 
same tumor.  An example of the first approach is the use of the ADC Kadcyla to target Her-2-
positive breast cancer cells combined with Pertuzumab (Perjeta) that binds the Her-2 receptor 
preventing its dimerization (Phillips et al., 2014).  An example of the second approach has not 
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yet been done, but in theory could be done with Kadcyla (targeting Her-2-positive breast cancer 
cells) combined with an ADC against Her-3 (targeting metastasized cells).  
With respect to payload improvements, if a patient becomes resistant to a specific type 
of cytotoxic agent delivered by an ADC, perhaps using an ADC targeting the same antigen but 
carrying a different payload can overcome the resistance.  This approach has already been 
successful in mouse models of non-Hodgkin lymphoma (NHL) that became resistant to a CD22-
targeting ADC. Altering the payload from MMAE to nemorubicin (which targets DNA), while 
still targeting CD22, overcame the resistance even when delivering only half the payload per cell 
(Yu et al., 2015). For other payload alterations, switching to 2o-drugs with potent toxicities in the 
picomolar range might help. For example, PBD compounds bind DNA in a sequence specific 
manner in its minor groove have picomolar activity against tumors (Flygare et al., 2012). 
Another promising ADC payload is α-Amanitin (Flygare et al., 2012). This toxin is a cyclic 
peptide of eight amino acids, and is the most deadly of all the amatoxins found in mushrooms, 
such as the death cap or the destroying angel (Michelot and Labia, 1988).  α-Amanitin kills by 
inhibiting DNA transcription (the production of RNA from a DNA template), which is required 
by all cells. These payloads are in the early stages of testing, and have shown significant signs of 
success against a wide range of tumor cells. 
 
 Another future trend is the use of non-internalizing ADCs that target the tumor’s 
extracellular matrix. For example, the formation of new blood vessels (angiogenesis) is a 
common feature of many solid malignancies, and new vessel formation rarely occurs in normal 
adults, so targeting angiogenesis markers might be excellent targets for ADC therapy (Casi et al., 
2012). Since angiogenesis markers are similar for various tumors, one ADC of this type could be 
used to treat a variety of tumors. Work has already begun using human mAbs specific to the 
extra-domain B (EDB) of fibronectin, which has been identified as a marker of angiogenesis 
(Palumbo et al., 2011).  
 
Important ADC advances have also been made with linker chemistries. Linker stability 
is necessary to allow the conjugate to circulate in the bloodstream for an extended period of time 
without prematurely releasing its cytotoxic agent. Linker stability has a major influence on ADC 
properties such as pharmacokinetics, overall toxicity, and efficacy (Perez et al., 2014). ADC 
linkers currently under development fall under two main classes: cleavable and non-cleavable. 
For the cleavable linkers, there are three different release mechanisms: acid-sensitive linkers, 
lysosomal protease-sensitive linkers, and glutathione-sensitive linkers. For non-cleavable linkers, 
their main advantage is a greater stability in the circulation which prevents early release of the 
drug potentially eliminating the bystander effect. 
 
Conjugation chemistry is another future area of ADC research.  The 1o-ADC production 
methods produced heterogeneous mixtures of molecules (Panowski et al., 2014), with drugs 
being added to any solvent-accessible reactive amino acid (Agarwal et al., 2015).  But the 
structural heterogeneity produced molecules with different properties, resulting in a wide range 
of activities and unpredictable results in patients (Panowski et al., 2014; Agarwal et al., 2015). 
The newer methods of drug attachment to antibodies use site-specific conjugations that eliminate 
product heterogeneity and improve conjugate stability. These new methods include the use of: 1) 
engineered cysteine residues, 2) unnatural amino acids, or 3) enzymatic conjugation through 
glycol-transferases and transglutaminases.  
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 Radioimmunoconjugates are radioactive isotopes conjugated to antibodies targeting 
tumor cells. Radioimmunotherapy (RIT) has been under development for over 30 years, with 
little progress.  But with new advancements in the field of targeted antibody cancer therapy, 
there is new excitement for RIT. Similar to ADCs, the choice of antibody and cytotoxic agent are 
critical for RIT efficacy. “The path length of penetration of the radioactive emission should 
match the size of the targeted tumor” (with small tumors using RITs with short range emissions) 
(Kraeber-Bodéré et al., 2014). Clinical trials have shown some promising results for RIT drugs 
targeting CD-20 in non-Hodgkin B-Cell Lymphoma using Yttrium-90 as the radionuclide 
(Zevalin®; Spectrum Pharmaceuticals) (Kraeber-Bodéré et al., 2014). Other research is directed 
toward the development of radioimmunoconjugates targeting the Her-2 antigen expressed in 
breast cancer using Lu-177 as the radionuclide (Bhusari et al., 2017).  
 
 Immunotoxins (ITs) are very potent molecules consisting of an antibody (or antibody 
fragment) linked to a bacterial or plant toxin rather than a traditional chemotherapeutic drug 
(Hassan et al., 2015). Immunotoxins work in a manner similar to ADCs, targeting specific tumor 
antigens and internalization into a tumor cell, but the toxin kills the cell by inhibiting protein 
synthesis. Because immunotoxins carry a cargo that kills a cell by blocking translation instead of 
blocking cell division like ADCs, this allows immunotoxins to be used against tumors that are no 
longer actively dividing (Hassan et al., 2015). Immunotoxins targeting CD-22 have produced 
complete remissions in refractory hairy cell leukemia and acute lymphoblastic leukemia in 
children (Wayne et al., 2011; Kreitman et al., 2012).  As with ADCs, their large size may hinder 
penetration into solid tumors, so research has focused on creating IT’s with reduced size for both 
the antibody and toxin (Pastan et al., 2006).  For example, immunotoxin SS1P targets mesothelin 
on mesothelioma cells and contains Pseudomonas toxin PE38.  SS1P initially showed low 
activity due to antibody responses against the toxin, but when the patients were treated with an 
immunosuppressive regimen to lower the T and B cell responses, SS1P showed stronger activity 
(Mossoba et al., 2011; Hassan et al., 2013).  In patients with advanced treatment-refractory 
mesothelioma, treatment with pentostatin and cyclophosphamide (to lower the immune response) 
plus SS1P immunotoxin significantly decreased the formation of anti-SS1P antibodies, allowing 
more cycles of SS1P to be given, which resulted in durable and major tumor regressions in three 
of the ten evaluable patients (Hassan et al., 2013).  
 
Overall, this section of the project identified several different steps that are required for 
an ADC drug to function.  Loss of any one of these steps can result in an inactive drug.  New 
second-generation ADCs are being designed to overcome tumor resistance, be more active, and 
have fewer side-effects.  Areas of future ADC research include: antibody-type switching, the 
identification of new target antigens, dual-targeted therapies, payload improvements, non-
internalizing ADCs, improvements in linkers and conjugation chemistries, and the use of 
radioimmunoconjugates and immunotoxins. In addition, more research should be performed to 
identify mechanisms for how tumors become resistant to ADCs.  To facilitate this, in vitro and in 
vivo mouse models could be developed for ADC resistance for various types of tumors by 
treating them long-term with an ADC until resistance occurs, and then characterizing the 
mechanism of the resistance.   
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Executive Summary Conclusions 
 
Based on the research performed for this IQP project, our team made several conclusions 
and recommendations.  It was initially unclear from our review of the literature why, with few 
exceptions, naked antibodies (not conjugated to a cytotoxic drug) do not efficiently kill cancer 
cells.  Our interviews with immunologists and oncologists indicated that an active population of 
natural killer cells (NKs) is critical for killing the cancer cell, but NKs are low in concentration 
in the tumor environment.  In addition, relatively few antibodies actually bind to the surface of 
the tumor cell.  So, a more efficient mode of killing is required, such as using ADCs conjugated 
to highly potent drugs.  ADCs have the additional advantage of killing a tumor cell regardless of 
the function of the surface antigen, while naked antibodies need to block growth pathways.   
 
But if ADCs are such a good idea, why are only two currently approved by the FDA?  
From our interviews, the consensus appears to be that the two successful ADCs (targeting CD30 
and HER2) were developed early on, when ADCs were relatively novel, making their approval 
easier as no other drug served the same purpose.  And they were among the earliest ADCs 
researched, providing more time for the lengthy FDA approval process.  In addition, the CD30 
and HER2 target antigens are among the best targets in the entire cancer field: they are abundant 
on the tumor cell surface, expressed by a majority of the tumor cells, highly accessible to the 
ADC antibody, and are capable of internalizing the ADC.  Subsequent ADC targets have not 
been able to provide the high degrees of efficacy and survival improvements that are needed for 
gaining FDA approval.  We conclude that the choice of target antigen is critical in determining 
ADC activity, and we recommend that research be continued into identifying new targets. 
 
Our review of the literature showed that all ADC drugs tested to date have adverse side-
effects.  Even the two currently approved ADCs have “black box” warnings on their packages 
concerning their side-effects.  But it was unclear from the literature what caused the side-effects.  
Our interviews with physicians using ADCs in clinical trials indicated that the side-effects vary 
with each ADC: in some cases they are caused by off-target effects, where the cytotoxic drug 
released from the ADC diffuses out of the target cell into a nearby cell, killing it.  In other cases, 
the physicians stated their side-effects were caused by the surface antigen being present on 
normal cells, decreasing their function.  Several interviewees indicated their side-effects were 
manageable by using other drugs.  One best practice seems to be the development of a linker that 
leaves a positive charge on the payload drug when cleaved.  This makes the drug unable to 
diffuse out of the target cell to cause off-target effects. We recommend that this best practice be 
explored further. 
 
 Our review of the literature also showed that ADCs are expensive.  In this report we 
discussed the example of Kadcyla in the U.K. whose initial price for a typical treatment was 
£56,640.  But based on pressure from cancer charities and government committees, the 
manufacturer agreed to lower the price, keeping it on the list of drugs paid by the British 
government.  We hope that other ADC manufacturers follow suit.  However, ADC research and 
development is also expensive.  In the U.S., it remains unclear even after interviewing co-chairs 
of the Moonshot Blue Ribbon Panel whether money for the Cancer Moonshot pertains to ADCs, 
so developing new ADCs may need to rely on other sources of funding. 
 
Our review of the literature also identified several potential new directions for ADC 
research.  These directions include the use of combination ADC therapies (the use of two or 
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more ADCs targeting different antigens or carrying two different cargos), the use of non-
internalizing ADCs targeting the extracellular matrix (ECM), the use of immunotoxins, the use 
of radio-immunoconjugates, and the use of site-specific conjugations.  Our interviews with 
scientists performing dual ADC therapies indicated that toxicities are a problem with this 
approach, as different sets of side-effects are caused by different ADCs, so this should be 
carefully monitored.  The non-internalizing ADC approach has already had some success in 
animal models by blocking newly forming tumor vasculature.  If this approach can be further 
developed, the ADC could, in theory, be used to treat any type of tumor that requires new 
vasculature, including a majority of solid tumors. Our interviews with scientists using 
immunotoxins (ITs) indicated that it is important to alter the toxins to minimize patient immune 
responses against the drug which lowers their effectiveness.  Using both ADCs and ITs with two 
methods of killing the cell has promise, and should be tested further.  With respect to site-
specific attachment, new chemistries allow researchers to control the number of cytotoxic drugs 
attached to each antibody, and to control the exact site of attachment.  Our interview with 
scientists using this technology indicated that the number of drugs per antibody, and their 
locations, strongly affect ADC activity.  So, we conclude that these parameters are important, 
and should be optimized for each ADC drug. 
 
Overall, we conclude that ADCs represent an interesting method for fighting cancer that 
in some cases kill tumor cells more efficiently than “naked” antibodies alone.  Some ADCs have 
been shown to cause complete tumor regressions in some patients.  The few ADCs already 
approved by the FDA likely did so because of their excellent choice of target antigen and their 
long history of research prior to approval.  Although all ADCs currently have adverse side-
effects, they appear to be manageable in most cases, and are far better than the patient’s poor 
prognosis without treatment.  We recommend that ADC research be continued, especially on the 
use of combination therapies, non-internalizing ADCs targeting the tumor vasculature, the use of 
immunotoxins and radioimmune therapies to complement ADCs, and site-specific conjugations 
to control the number and locations of drug attachments to the antibodies. 
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Cancer and the Need for New Drugs 
 
 The National Cancer Institute defines cancer as a term for a group of diseases in which 
abnormal cells divide without control, which can invade nearby tissues (NCI, 2017).  The main 
types of cancer include: 1) carcinomas (cancers that initiate in skin or tissues that line or cover 
internal organs), 2) sarcomas (cancers that initiate in bone, cartilage, fat, muscle, blood vessels, 
or other connective tissues), 3) leukemia (cancers that initiate in blood-forming tissue, such as 
the bone marrow), 4) lymphomas and myelomas (cancers that initiate in cells of the immune 
system), and 5) central nervous system cancers (cancers that initiate in the tissues of the brain 
and spinal cord) (NCI, 2017).   
 
At the cellular level, cancer has several hallmarks; these include: genomic instability, 
deregulated cell signaling causing cell division and growth, sustained cell proliferation, 
resistance to cell death, and evasion from the patient’s immune system (Hanahan and Weinberg, 
2011). As a result of these changes, cancer is difficult to treat.  A cancer statistics review 
performed by the National Cancer Institute shows that the average 5-year cancer survival rate in 
the U.S. for all cancers is about 69% (Howlader et al., 2017). The survival rates range widely, 
from about 8% to 18% for difficult to treat cancers like pancreatic, lung, and liver cancers, to 
greater than 65% for cancers of the colon, breast, kidney, and prostate, that grow slowly and are 
easier to treat if detected early.   
 
The wide range of cancer survival rates are seen even with the best cancer treatments.  
Research over the past several decades has improved cancer survival using a variety of types of 
drugs, including: traditional chemotherapy to block dividing cells (e.g., taxanes, anthracyclines, 
platins), small-molecule inhibitors of specific cellular signal transduction pathways (e.g., kinase 
inhibitors), or bio-therapeutics (e.g., therapeutic antibodies against cell surface receptors).  But 
these drugs are not fully effective, and all of them have adverse side-effects, so scientists are 
constantly trying to develop new therapies that are more effective with fewer side-effects.   
 
The main topic of this IQP project is a new class of anti-cancer therapy termed antibody-
drug conjugates (ADCs).  ADCs are a type of targeted therapy in which a specific type of 
antibody (that targets the drug to a specific protein on the surface of a tumor cell) is conjugated 
to a cytotoxic drug (that kills the tumor cell) (Pastan et al., 2006; Bouchard et al., 2014).  ADCs 
combine two important properties: the high specificity of an antibody-antigen interaction and the 
ability of newly designed highly potent toxins to kill cells.  ADCs represent a line of therapy 
often given to a patient after all other therapies have failed, and they have proven to be a great 
method at treating cancers that do not respond to chemotherapy or radiation alone. To introduce 
the reader to the topic of ADCs, a brief discussion of the immune system and antibodies is first 
provided. 
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Introduction to the Immune System and Antibodies 
 
Pathogens are everywhere, and it is well known that there are more foreign cells in and 
on the human body than cells composing it. How is it that people do not become sick from all of 
these organisms that surround us? The answer lies within the body’s immune system which 
protects the body against infectious agents, pathogens, and toxins using a variety of mechanisms 
(Murphy and Weaver, 2016). In recent years, scientists have begun to understand the immune 
system in great detail, and these advances have aided the development of immunological 
therapies.  
 
 The body’s first line of defense is the presence of anatomic barriers such as skin, mucosa, 
and epithelium (Murphy and Weaver, 2016). The pathogen must pass these barriers to enter the 
body and cause an infection. Anatomic barriers sometimes contain a variety of antimicrobial 
proteins that attempt to kill the microbes (Murphy and Weaver, 2016). Once the foreign invader 
breaches an anatomic barrier, the body has additional proteins that signal infection and target cell 
death. One important class is the complement system that consists of more than thirty different 
plasma proteins that signal numerous effector mechanisms that lead to a systemic eradication of 
the pathogen (Murphy and Weaver, 2016). This response then triggers other responses of the 
immune system. 
 
The immune system is divided into two main categories: innate and adaptive immunity. 
All the body’s immune cells are derived from hematopoietic stem cells (HSCs) (Figure-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: Differentiation of Hematopoietic Stem Cells (HSCs). HSCs 
produce myeloid lineages (innate immunity) (diagram left), and 
lymphoid lineages (adaptive immunity) (diagram right) (Bartis and 
Pongracz, 2011). 
 
 
25 
HSCs differentiate to form myeloid lineages (innate immunity) and lymphoid lineages 
(adaptive immunity) (Bartis and Pongrácz, 2011). The differentiated cells of the innate immune 
system do not have specific interactions with a foreign pathogen, but instead indiscriminately kill 
anything they detect as “foreign”. One example of an innate immune cell is a macrophage which 
migrates throughout the body engulfing and digesting foreign particles and signaling additional 
immune responses such as fever and inflammation. Other innate immune cells bind to pathogens 
and kill them in other ways. Some signal for the complement system, while others release 
cytotoxic granules and enzymes onto the pathogen’s surface (Murphy and Weaver, 2016). The 
cells of the adaptive immune system (B cells and T cells) recognize and target one specific type 
of antigen by producing antibodies or cytotoxic T cells, respectively. 
 
 T and B cells originate by differentiation from the “Common Lymphoid Progenitor Cell” 
(Figure-1, upper right) which occurs in the bone marrow (Bartis and Pongrácz, 2011; Murphy 
and Weaver, 2016). Immature T cells migrate to the thymus where they mature. Immature B 
cells remain and mature in the bone marrow. As B and T cells begin to mature, they undergo 
random gene rearrangements to produce an array of receptors.  However, once the cells are 
activated by binding to a foreign antigen presented by an antigen presenting cell (APC), they 
mature further to commit to that antigen. The APC or dendritic cell is the link between innate 
and adaptive immunity (Murphy and Weaver, 2016). The APC indiscriminately ingests a 
pathogen, breaks it down into small peptides, and presents the foreign peptide/MHC complex to 
a T cell. Once the T cell and APC successfully bind, the T cell proliferates and differentiates into 
effector T cells (helper T (TH) cells or cytotoxic T cells) (Murphy and Weaver, 2016). The 
cytotoxic T cells bind to the foreign antigen on an infected cell and initiates cell death. B cell 
receptors also bind to antigens, engulf them, and present them to the TH cells. The TH cell then 
produces cytokines which signal the B cell to proliferate and secrete antibodies (Murphy and 
Weaver, 2016).  
 
 Antibodies are molecules secreted by a B cell.  These molecules migrate through the 
blood and bind to the antigen they are specific for once they encounter it. Each antibody has a 
specific antigen to which it binds, and can also bind other effector molecules (Murphy and 
Weaver, 2016). The general structure of an antibody is the shape of a ‘Y’ (Figure-2).  Each 
upper arm of the ‘Y’ (which bind the antigen) is referred to as the N terminus (amino-terminus). 
The N-termini are variable between different antibodies.  The lower base of the ‘Y’ is referred to 
as the C-terminus (carboxy-terminus) and is a constant region (Murphy and Weaver, 2016).  
 
 
 
 
Figure-2: Diagram of a Typical 
Antibody Structure.  The N-termini 
contain the variable regions (red) that 
specifically bind an antigen, and the C-
terminus contains the constant regions 
(blue) (Murphy and Weaver, 2016). 
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The variable region of the antibody binds antigen, and it has a unique binding pocket for 
the antigen. The variable region is unique to each antibody, and the human immune system can 
produce over 5 x 1013 different antibodies (Murphy and Weaver, 2016). The vast diversity of 
antibodies results from random DNA recombination and joining of different segments of variable 
domain-encoding genes in maturing B cells.  The constant region remains the same within an 
antibody class so that it can interact with effector molecules and phagocytic cells that internalize 
the antibody-antigen complex. A different view of the antibody structure (Figure-3) shows it is 
composed of two heavy chains (green in the diagram) and two light chains (yellow in the 
diagram) which are linked by disulfide bonds. Each light chain is identical, so each arm of the 
‘Y’ is able to bind to two identical antigens. The hinge region of the antibody (located at the 
junction of the ‘Y’) allows the antibody be flexible so that it can bind to antigens at different 
distances from each other. This allows the antibody to have increased binding strength for the 
antigen, increasing its avidity. Antibodies and antigens fit into each other’s shape and bind by 
non-covalent forces (Murphy and Weaver, 2016). 
 
 
 
 
 
 
Figure-3: Diagram of Antibody Chains.  
Shown are the heavy chains (green) and light 
chains (yellow) of a typical antibody 
(Murphy and Weaver, 2016). 
 
 
 
 
 
 
 There are five common classes of antibodies, each with their own unique constant 
regions: immunoglobulin A (IgA), immunoglobulin D (IgD), immunoglobulin G (IgG), 
immunoglobulin M (IgM), and immunoglobulin E (IgE) (Murphy and Weaver, 2016). A single B 
cell undergoes class switching that joins the antigen-binding variable region to different constant 
regions. This class producing process always begins with IgM, followed by IgD, IgG, IgA, and 
finally IgE (Murphy and Weaver, 2016). Once an antibody has bound to its antigen, based on its 
type of constant region it signals for a specific effector function that leads to destruction of the 
pathogen. There are three main ways that an antibody can help destroy a pathogen (Figure-4). 
One method is neutralization (diagram left), where the antibody binds to and blocks the binding 
site of the pathogen or toxin keeping it from binding to a cell, or facilitates its uptake into a 
macrophage cell. Secondly, antibody-antigen complexes can become opsonized (diagram center) 
which facilitates its uptake into macrophage cells. Thirdly, the constant region of antibodies can 
induce complement system activation which signals plasma proteins to bind to and puncture the 
pathogen’s membrane, leading to cell lysis (diagram right). The complement system also coats 
the pathogen’s membrane with proteins that attract phagocytic cells (Murphy and Weaver, 2016). 
The various immune responses generated by each antibody class are summarized in Figure-5.  
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Figure-4: Three Main Methods of 
Pathogen Destruction by Antibodies. 
Antibodies can help cause destruction of 
pathogens in 3 main ways: neutralization 
(diagram left), opsonization (diagram 
center), and complement activation 
(diagram right) (Murphy and Weaver, 
2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-5: Functions of the Five Main Classes of Antibodies. The class 
of antibody is specified by its constant region, and this specifies how the 
antibody helps inactivate the pathogen (Murphy and Weaver, 2016). 
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Antibody-Drug Conjugates 
 
 Due to the highly specific nature of the interaction of an antibody with its antigen, 
scientists have engineered antibodies to bind to specific types of cancer cells.  Many patients 
suffer from cancers that are unable to be treated by chemotherapy or radiation treatments. 
Unfortunately, in most cases, simply attaching an antibody alone to a cancer cell does not 
necessarily lead to its demise (Thomas et al., 2016). So, scientists have designed a new type of 
anti-cancer drug, antibody-drug conjugates (ADCs) that consist of an antibody against a specific 
antigen on the surface of a tumor cell, conjugated to a cytotoxic poison that can kill a malignant 
cell (Figure-6) (Thomas et al., 2016). Once the ADC binds to its targeted antigen, the cell will 
engulf the ADC and release the toxin inside the cell, thus killing it (Pastan et al., 2006).  The 
antibody should have high affinity for the tumor antigen, the antigen should be highly expressed 
on the tumor cell (not normal cells), the linker should be stable in the patient’s circulation to 
avoid releasing the toxin too soon, and the drug should be highly potent since only a few 
molecules will be present in the tumor cell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-6: Diagram of ADC General Structure. Shown is the general 
structure of an antibody-drug conjugate, consisting of an antibody 
(diagram left), bound to a cytotoxic drug (green) using a linker (diagram 
center). Also shown are desirable properties of each structural 
component (Thomas et al., 2016).   
 
 
 In the ADC production process, monoclonal antibodies against a particular surface tumor 
antigen are produced in cell culture, and are bound to a toxin using a linker (Pastan et al., 2006; 
Chiu and Gilliland, 2016). It is essential that the target antigen is as specific as possible for the 
cancer, so that the ADC will only bind and kill the tumor cells, not normal cells (Thomas et al., 
2016). In some cases this may not be possible, such as with leukemia where the target antigen 
may also be present in a low amount on normal cells, so adverse side effects can be observed in 
the clinical trials. The drug or toxin must also not bind normal cells by itself, so in some cases its 
cellular binding domains may be removed (Pastan et al., 2006). The antibody then becomes 
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linked to the toxin or drug.  All ADCs are linked to their drugs covalently through one of four 
chemical methods: cysteine conjugation, glycol-conjugation, protein tags, or amino acid 
incorporation (Agarwal and Bertozzi, 2015; Thomas et al., 2016). The most common linkers 
have disulfide bonds or other peptide linkages (Pastan et al., 2006). The linker can be placed at 
various locations on the antibody, including the variable region, hinge region, constant region, or 
all three simultaneously (Agarwal and Bertozzi, 2015). Usually two to four drug molecules are 
attached to each antibody so that the antibody retains all of its antigen binding properties and is 
not cleared from the body too quickly (Hughes, 2010).  The linker functions to keep the drug 
bound to the antibody on its extracellular journey to the target, and becomes degraded once the 
ADC enters the cell (Thomas et al., 2016). Linkers have been designed to be sensitive to 
proteases, pH, and glutathione, and are cleavable or non-cleavable in nature (Jain et al., 2015). 
Cleavable linkers utilize enzymes inside the target cell to release the drug from the antibody 
(Jain et al., 2015). This ensures that the linker is stable in the bloodstream, and breaks down only 
when being digested by a target cell. Non-cleavable linkers do not release the drug once they 
enter the cell; when the entire antibody and linker are digested, the payload is released 
(sometimes with part of the linker attached) (Jain et al., 2015).  
 
 ADCs are typically administered to the patient intravenously.  They bind to the target cell 
and are engulfed by an endocytic vesicle (Figure-7) (Pastan et al., 2006; Bouchard et al., 2014). 
Once the vesicle fuses with a lysosome, the environment turns acidic and enzymes are released 
that digest the linker releasing the drug into the cytoplasm. There the drug works to kill the cell, 
for example by strongly binding tubulin to prevent its polymerization thus blocking cell division.  
Drugs commonly used for ADCs either bind DNA leading to its cleavage or alkylation, block 
tubulin, or inhibit RNA polymerase II and III blocking RNA synthesis (Thomas et al., 2016).  
 
 
 
 
 
Figure-7: General ADC 
Function.  ADCs (upper left) 
bind to a surface marker on the 
target cell (green) and become 
endocytosed into a vesicle 
(upper center). The vesicle 
binds with a lysosome that 
acidifies the compartment and 
releases enzymes that degrade 
the linker or the entire ADC, 
releasing the drug (red) into the 
cytoplasm that causes cell death 
(Bouchard et al., 2014). 
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ADC Drug Examples 
 
 Currently, only two ADC drugs have been approved by the FDA: Trastuzumab emtansine 
and Brentuximab vedotin (Thomas et al., 2016).  A third ADC, Gemtuzumab ozogamicin 
(Mylotarg), was initially FDA approved but was later withdrawn (Richwine, 2010). 
 
Trastuzumab emtansine, commercially named Kadcyla, was developed by Genentech (a 
subsidiary of Roche), and is manufactured by Lonza. It is used to treat HER2-positive metastatic 
breast cancer in patients who are resistant to other treatments (Niculescu-Duvaz, 2010; LoRusso 
et al., 2011; Lopus, 2011; Verma et al., 2012; About Kadcyla, 2017). It is composed of an 
antibody (Trastuzumab or Herceptin) against the HER2 receptor conjugated with the drug DM1 
(a derivative of maytansine) using a non-cleavable thioether linker (Barok et al., 2014; Jain et al., 
2015).  Of the ADC drugs, Kadcyla is unique in that its antibody component by itself is 
sometimes capable of blocking Her2-positive breast cancer. The binding of Herceptin to Her2 
receptor on the cell surface prevents receptor dimerization, inhibiting activation of the MAPK, 
PI3-kinase, AKT kinase pathways that otherwise would lead to cell division (Verma et al., 2012).   
 
Kadcyla’s FDA approval was based predominantly on encouraging clinical trial data of 
women with advanced Her2-positive breast cancer who were resistant to the antibody treatment 
alone (Verma et al., 2012).  The ADC drug improved the median patient survival by about 5.8 
months (30.9 months versus 25.1 months) compared to standard chemotherapy.  It was FDA 
approved on February 22, 2013, specifically for women with Her2-positive metastatic breast 
cancer that does not respond to antibody treatment alone or to chemotherapy (Pollack, 2013). 
 
Kadcyla is injected intravenously (IV) where it travels through the patient’s circulation to 
the tumor where it binds the HER2 receptor, and becomes endocytosed (Figure-8) (Barok et al., 
2014). Once the vesicle (named early endosome in the diagram) fuses with a lysosome (diagram 
lower left), the antibody and linker are digested by lysosomal enzymes stimulated by the acidic 
environment, and the DM1 (unaffected by enzymes) is released into the cytoplasm where it 
inhibits microtubule assembly (diagram lower right), causing apoptosis (Barok et al., 2014; Jain 
et al., 2015; About Kadcyla, 2017). 
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Figure-8: Mechanism of Action 
of Trastuzumab emtansine 
(Kadcyla). The ADC binds to the 
HER2 receptor (upper left) and 
becomes endocytosed into an 
early endosome. When the 
endosome fuses with a lysosome 
(lower left), enzymes from the 
lysosome degrade the antibody 
and linker, releasing DM1 into 
the cytoplasm which inhibits 
microtubule formation (lower 
right), ultimately resulting in 
apoptosis (Barok et al., 2014). 
 
 
 
 
 
 
 
The other current FDA-approved ADC drug is Brentuximab vedotin, commercially 
named Adcetris. Adcetris is marketed by Seattle Genetics Inc. in North America, and by Takeda 
Oncology in the rest of the world. It is used to treat CD30-positive lymphoproliferative disorders, 
including Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) (Van de Donk 
and Dhimolea, 2012; Brentuximab vedotin, 2016). Protein CD30 often occurs on the surface of 
cells of these tumor types, but rarely on normal cells (Küppers and Hansmann, 2005).  Adcetris 
contains an antibody (Brentuximab or cAC10) (yellow in the diagram) engineered to bind 
receptor CD30 present on HL and ALCL tumors, conjugated to 3-5 molecules of the drug 
monomethyl auristatin E (MMAE) (purple in the diagram) by a cathepsin-cleavable linker (blue 
in the diagram) (Figure-9) (Van de Donk and Dhimolea, 2012). The antibody is produced in 
mammalian Chinese Hamster Ovary (CHO) cells, while the small molecule components are 
produced by chemical synthesis. 
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Figure-9:  Structure of Adcetris.  This antibody-drug conjugate 
consists of a mouse-human chimeric monoclonal antibody against CD30 
(yellow) linked via a cathepsin-cleavable linker (blue) to 3-5 units of the 
cytotoxic drug monomethyl auristatin-E (MMAE) (purple) that strongly 
binds tubulin and blocks cell division (Francisco et al., 2003).  
 
 
Adcetris is administered to the patient intravenously, and with a half-life of 4-6 days, 
travels through the circulation to the tumor where it binds the CD30 receptor and is endocytosed 
into an endosome. Once the endosome fuses with a lysosome, the linker is cleaved by cathepsin 
lysosomal enzyme, releasing (MMAE) into the cytoplasm. MMAE binds to tubulin, inhibiting 
mitosis and initiating apoptosis (Van de Donk and Dhimolea, 2012; Francisco et al., 2003; 
Vaklavas and Forero-Torres, 2012).   
 
Adcetris has undergone numerous trials, and has shown high efficacy and manageable 
side-effects. For example, in a 2010 clinical trial of HL patients (Seattle Genetics Press Release, 
2010), 34% of the patients showed complete remission, 40% showed partial remission, and 94% 
showed tumor reductions. Additionally, in a 2010 clinical trial of ALCL patients (Miller, 2010) 
97% of the patients showed measurable tumor reductions.  On August 19, 2011, the drug was 
granted an accelerated FDA approval (Genetic Engineering and Biotechnology News, 2011; 
Fierce Biotech, 2011).  
 
The third ADC drug approved by the FDA (although it was later withdrawn) is 
Gemtuzumab ozogamicin, commercially named Mylotarg. It was manufactured by Wyeth (now 
Pfizer), and was FDA approved in May of 2000 to treat acute myeloid leukemia (Gemtuzumab 
Ozogamicin, 2015). Mylotarg is composed of an antibody (IgG4 κ hP67.6) against the CD33 
antigen found on leukemic cells (Gemtuzumab Ozogamicin, 2015; Wyeth Pharmaceuticals, 
2005), conjugated with two to three molecules of the drug calicheamicin (N-acetyl-γ-
calicheamicin) by a linker (4-(4-acetylphenoxy)butanoic acid) (Gemtuzumab Ozogamicin, 
2015). Mylotarg is intravenously injected into the patient where it migrates to the CD33 antigen 
on the tumor cells. Upon binding with its antigen, the ADC is endocytosed, and fuses with a 
lysosome. The drop in pH caused from lysosomal fusion degrades the linker, releasing the drug 
into the cytoplasm (Gemtuzumab Ozogamicin, 2015).  Calicheamicin binds to double stranded 
DNA and causes breaks, leading to apoptosis (Wyeth Pharmaceuticals, 2005).  
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In clinical trials, Mylotarg initially showed promise, resulting in its accelerated review 
and FDA approval in 2000. But in later clinical trials, Mylotarg caused serious side-effects, 
including myelosuppression (suppression of bone marrow) in 98% of the patients (likely because 
CD33 is also present on normal hematopoietic cells), respiratory problems, and veno-occlusive 
disease (VOD), so the FDA required a “black box” warning label on the packaging (Giles et al., 
2001; Wadleigh et al., 2003). A clinical study of five years showed that Mylotarg led to 
increased death rates (4.3% higher than placebo), and had no apparent benefits to patients, so 
Pfizer withdrew Mylotarg from the market in October of 2010 (Richwine, 2010).  
 
Currently, more than 40 ADCs are in the clinical trial stages of development (Thomas et 
al., 2016). The future for immunological therapies including ADCs has endless possibilities. But 
in some cases, the ADCs are not 100% effective, and all ADCs have some adverse side-effects 
(discussed later), so it is necessary to continue investigations of the human immune system, and 
to invest in research that aims to engineer antibodies against otherwise untreatable cancers. With 
further research, newer more effective ADCs with fewer side-effects can be engineered to 
improve human health.  
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Section-2: Pre-Clinical ADC Testing 
William Mosby 
 
 
 The purpose of this section of the Literature Review is to discuss some of the pre-clinical 
testing done with various antibody-drug conjugates (ADCs).  Pre-clinical testing includes the use 
of cancer cell lines in vitro, the use of human cancers xenografted into mice, and monkey 
experiments.  These pre-clinical experiments laid the groundwork for subsequent human clinical 
trials which are discussed later in Section-3. This chapter is divided into sub-headings based on 
the antigen targeted by the ADC. 
 
 
CD19 
 
CD19 is a transmembrane glycoprotein belonging to the immunoglobulin Ig superfamily 
(Del Nagro et al., 2005).  Its expression is restricted to B-cells; it is expressed from early pre-B 
stages through B-cell differentiation, including mature B-cells.  It is then down-regulated at the 
plasma cell stage. Thus, CD19 acts as a broad marker of B-cells.  For example, it is a broader 
marker of B-cells than CD20 which is expressed only in the later stages of B-cell development. 
CD19 is expressed in all B-cell cancers, including all types of B-cell lymphomas, B-cell chronic 
lymphocytic leukemia, and non-T acute lymphoblastic leukemia (ALL) (the latter cannot be 
targeted by CD20) (Anderson et al., 1984; Scheuermann and Racila, 1995). 
 
 CD19 has been the target of antibody-drug conjugates (ADCs) to kill B-cell tumors.  For 
example, SAR-3419 is an ADC drug containing a humanized monoclonal antibody against 
CD19 linked via a cleavable linker to 3-4 molecules of the tubulin inhibitor DM-4 (Blanc et al., 
2011). In pre-clinical testing using lymphoma xenograft models, SAR-3419 induced complete 
tumor regressions and improved mouse survival (Lutz et al., 2006).  SAR-3419 has also shown 
in vivo efficacy in a diffuse large B-cell lymphoma (DLBCL) model (Al-Katib et al., 2009). In 
both of these pre-clinical models, SAR-3419 caused complete tumor remission at the highest 
doses, while the lower doses caused tumor growth delays.  In the Lutz et al. study, 100% of the 
mice were tumor-free by the end of the study, while treatment with the DM4 agent alone or the 
antibody alone produced no significant tumor regressions.  This shows that the conjugation of 
the two components together is required for the observed antitumor effect. 
 
In 2009, scientists in the Department of Pre-Clinical Therapeutics at Seattle Genetics 
investigated the use of an anti-CD19 ADC against non-Hodgkin lymphoma (NHL) cell lines and 
xenograft mice (Gerber et al., 2009). The drug showed potent tumor cell killing against CD19-
positive NHL cells in vitro, including cancer cells resistant to antibody treatment alone.  The 
ADC drug also showed durable tumor regressions in vivo against NHL tumors xenografted into 
mice.  Importantly, CD19 had previously been reported to form dimers with CD21, raising 
worries that over-expression of CD21 on the tumor surface might interfere with drug interaction 
with CD19, but this potentially negative effect was not observed in vitro or in vivo (Gerber et al., 
2009). 
 
In a more recent SAR-3419 study (Carol et al., 2013), scientists at the Children's Cancer 
Institute for Medical Research, University of New South Wales (Sydney) tested SAR-3419 in 
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mouse xenograft models of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and in 
models of mixed lineage leukemia ALL (MLL-ALL).  SAR-3419 was administered either as a 
single agent or in combination with chemotherapy.  Their data showed that SAR-3419 
significantly delayed the progression of 4 of 4 (100%) BCP-ALL mice, and 3 of 3 (100%) of 
MLL-ALL mice, although the mouse numbers were relatively small.  Importantly, the drug 
effectiveness was found to correlate with the extent of CD19 surface expression on the tumor 
cells, so perhaps a future best practice will be to monitor antigen expression in the patients to 
ensure they can benefit from the ADC drug.  The ADC was also found to delay cancer 
progression in chemo-resistant xenografts by up to 82 days.  When the drug was administered 
long-term post-remission, it prevented disease re-occurrence, so this provides interesting data 
that ADCs might be used to prevent cancer re-occurrence. 
 
 
CD22 
 
CD22 is a molecule belonging to the SIGLEC family of lectins (Hatta et al., 1999).  It is 
found on the surface of mature B-cells and to a lesser extent on immature B-cells, but it is not as 
broadly expressed in B-cells as CD19.  CD22 has also been the target of ADCs.  One example of 
an ADC targeting CD22 is Inotuzumab ozogamicin (CMC-544).  This ADC was developed by 
Pfizer and Union Chimique Belge (UCB) for patients with Non-Hodgkin Lymphoma (NHL).  It 
consists of a humanized monoclonal antibody against CD22 (Inotuzumab) linked to a cytotoxic 
derivative of calicheamicin which damages DNA (Takeshita et al., 2009).   
 
In 2004, scientists in the Department of Oncology Discovery at Wyeth Research (Pearl 
River, NY) investigated the activity of CMC-544 against CD22-positive B-cell lymphoma (BCL) 
lines in vitro (DiJoseph et al., 2004a; 2004b). Their data showed that CMC-544 had potent 
cytotoxic activity in the model. With respect to binding affinity, the ADC bound B-cells in the 
same nano-molar range as free antibody, indicating that conjugation of the antibody to the drug 
cargo did not alter cell binding. In xenograft mouse models, CMC-544 prevented the initial 
establishment of BCL tumors in the mice, and potently inhibited the growth of pre-established 
BCL tumors.  The use of non-conjugated antibody or the drug cargo alone were ineffective in 
their assays, indicating the conjugation of drug to antibody was the basis for the blocked tumor 
growth (DiJoseph et al., 2004a; 2004b).  The same team followed this 2004 study with another in 
2006, comparing the activity of CMC-544 with that of Rituximab antibody alone (which targets 
CD20) (DiJoseph et al., 2006).  Their data showed that the antibody alone somewhat reduced the 
growth of NHL cells in vitro, but the addition of CMC-544 was more effective. In xenograft 
experiments, CMC-544 was more effective at inhibiting the growth of established NHL grafts 
and increased the lifespan of the mice.  90% of the CMC-544 treated mice lived at least 125 
days, while only 20% of the antibody alone group survived that long (DiJoseph et al., 2006). 
 
In 2015, a team of scientists in the Oncology Research Unit at Bio-Conjugates Discovery 
and Development, Pfizer Worldwide Research and Development (Pearl River, NY) published a 
summary of their pre-clinical testing of Inotuzumab ozogamicin against Non-Hodgkin’s 
lymphoma (NHL) (Shor et al., 2015).  They concluded that the drug potently induced tumor 
regressions in mouse xenograft models of NHL, either when used alone or when used in 
combination with anti-CD20 Rituximab antibody. 
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CD30 
 
ADCs targeting CD30 are among the best characterized of all the ADCs.  CD30 is a cell 
membrane protein belonging to the tumor necrosis factor receptor (TNFR) family (Gorzyca et 
al., 2003).  It is expressed by activated, but not by resting T- and B-cells, and is also associated 
with anaplastic large cell lymphoma (ALCL) and classic Hodgkin lymphoma (HL). An example 
of an ADC targeting CD30 is Brentuximab vedotin (Adcetris, SGN-035), one of only two 
current FDA-approved ADCs (Deng et al., 2013). Adcetris consists of a mouse-human chimeric 
monoclonal antibody against CD30 (Brentuximab or cAC10) linked to 3-5 units of the cytotoxic 
drug monomethyl auristatin-E (MMAE) that binds tubulin and keeps it from polymerizing. 
 
With respect to pre-clinical data, monoclonal antibodies (alone without cargo) targeting 
CD30 (such as cAC10) have shown activity in vitro against HL and ALCL cancers, increasing 
tumor cell arrest and DNA fragmentation (Wahl et al., 2002).  But the antibody alone had only 
modest data in clinical trials, so ADCs targeting CD30 were developed.  In 2003, scientists at 
Seattle Genetics showed that Adcetris released only 2% of its cargo into human plasma when 
incubated for 10 days, but quickly released it cargo once it was internalized in a cell (Francisco 
et al., 2003).  The release of MMAE into the cell blocked mitosis at the G2/M stage and induced 
apoptosis.  The drug was strongly potent against CD30-positive cancer cell lines in vitro (IC50 < 
10 ng/ml), and was 300-fold less active against CD30-negative cells.  In xenograft models of HL 
and ALCL, Adcetris caused tumor reductions at doses as low as 1 mg/kg.  Mice treated with 30 
mg/kg showed no signs of toxicity (Francisco et al., 2003). 
 
In addition, a lab at Seattle Genetics tested Adcetris with various cargo loads of 2, 4, and 
8 MMAE molecules per antibody (named E2, E4, and E8, respectively) (Hamblett et al., 2004).  
Their data indicated that the activity in vitro was directly dependent on the extent of cargo 
loading: E8 had the highest load and the highest activity.  In vivo, E4 and E8 were similarly 
active, but E2 required higher doses. The maximum tolerated dose of E2 was at least double that 
of E4 and E8. They concluded that the amount of drug loading is an extremely important ADC 
design parameter (Hamblett et al., 2004). Given this data, it will be important to use drugs of 
equal loading when trying to compare the data of various clinical trials. 
 
Adcetris strongly induced cell death in vitro for CD301 macrophage cell lines, and in 
mouse ALCL or HL xenograft models it showed anti-tumor activity at doses as low as 1 mg/kg 
(Okeley et al., 2010).  When combined with chemotherapy agents, such as doxorubicin, 
bleomycin, vinblastine, dacarbazine, or gemcitabine, Adcetris increased their efficacy (Oflazoglu 
et al., 2008).   
 
 
CD33 
 
 CD33 (also called Siglec-3; sialic acid binding Ig-like lectin-3) is a transmembrane 
receptor expressed mostly on myeloid cells, but it is also found on some lymphoid cells 
(Garnache-Ottou et al., 2005).  CD33 binds sialic acids, therefore it is a member of the SIGLEC 
family of lectins.  An example of an ADC drug in this category is Gemtuzumab ozogamicin 
(Mylotarg).  Mylotarg is a humanized anti-CD33 monoclonal antibody covalently linked 
to a derivative of calicheamicin. Mylotarg was the first ADC drug approved for use in the U.S. 
(Bross et al., 2001).  It was FDA-approved in 2000, marketed by Wyeth, and manufactured by 
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Pfizer to treat acute myelogenous leukemia (AML).  But Mylotarg was withdrawn in 2010 when 
its clinical trials showed it increased patient death and was no better than conventional therapies 
(Nelson, 2010; Richwine, 2010). 
 
 A pre-clinical testing of various Mylotarg linkers allowed the optimization of drug design 
(Hamann et al., 2002).  The authors attached the cargo (calicheamicin) to the CD33 antibody 
using a bi-functional linker which is stable at physiological pH 7.4.  This allows efficient release 
of the cargo at the acidic pH inside lysosomes. The average loading of calicheamicin on the 
antibody was determined to be about 2.5.  The optimized Mylotarg ADC showed significantly 
increased activity against HL-60 leukemia cells in vitro. 
 
 
Her2 
 
 Human epidermal growth factor-2 (Her2) (also known as CD340, Neu, or ERBB2) is a 
member of the epidermal growth factor family of cell surface receptors (Mitri et al., 2012). Over-
expression of Her2 occurs in approximately 15-30% of breast cancers, and is strongly associated 
with increased cancer recurrence and poor patient prognosis (Tan and Yu, 2007).  Her2 over-
expression can also occur on cancers of the ovary, stomach, lung, and uterus (Rüschoff et al., 
2012; Buza et al., 2014).  
 
An example of an ADC targeting Her2 is Trastuzumab emtansine (Kadcyla, T-DM1) 
(Niculescu-Duvaz, 2010; LoRusso et al., 2011; Lopus, 2011).  Kadcyla is one of the two ADC 
drugs currently approved by the FDA. It was developed by Genentech (Roche), manufactured by 
Lonza, and contains a humanized antibody against Her2 (Trastuzumab or Herceptin) linked via a 
non-reducing thioether linker to the cytotoxic drug emtansine (DM-1).  DM1 strongly binds to 
tubulin in the cell to inhibit microtubule assembly, and does so with greater potency than either 
vincristine or vinblastine (Widdison et al., 2006). The parent compound of DM1 is maytansine, 
which is a highly cytotoxic natural product.  Maytansine failed human cancer trials due to a high 
level of systemic toxicity, but it does well linked to a targeting antibody.  Scientists at 
ImmunoGen, Inc. (Cambridge, Massachusetts) synthesized a series of second-generation 
maytansinoids (including DM1) with disulfide or thio substitute groups which are even more 
potent than maytansine (Widdison et al., 2006).  
 
 In pre-clinical testing at Genentech (South San Francisco, CA), Kadcyla showed 
favorable activity and toxicity profiles (Lewis-Phillips et al., 2008).  The drug activity was tested 
in vitro against both tumor cells and normal cells.  In vivo activity was determined in mouse 
breast cancer models.  Toxicity was tested in rats as measured by body weight loss.  Their data 
showed that the toxicity of Kadcyla with its stable non-reducing linker was negligible compared 
to the high toxicity of free DM1 or to ADCs containing reducing linkers (presumably the 
reducing linkers were broken down in the blood releasing their toxic cargo too soon).  Potent 
cell-killing activity was observed against all Her-2 over-expressing tumors, but not against 
normal cells or tumor cells low in Her-2 (Lewis-Phillips et al., 2008).  In addition, Kadcyla 
seems to retain the anti-tumor properties of the anti-Her-2 Herceptin antibody alone.  Kadcyla 
was found to inhibit Her-2 signaling pathways, and to flag Her-2-positive tumor cells for 
destruction by antibody-dependent cellular cytotoxicity (ADCC) (Junttila et al., 2008). 
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 More recently, scientists at ImmunoGen, Inc. (Waltham, MA) investigated the in vitro 
and in vivo activity of various types of linkers used to attach the maytansine cargo to the Her2 
antibody (Kellogg et al., 2011).  Their data showed that conjugates with sterically hindered 
disulfide linkages were resistant to reduction in plasma.  In xenograft mouse models in vivo, 
ADC conjugates with an intermediate level of disulfide bond stability in the linker showed the 
highest activity, while all the ADCs showed the same activity in vitro.  The authors concluded 
that the magnitude of drug activity is strongly affected by the type of linker. 
 
Kadcyla is unique among the various ADC drugs in that its antibody component by itself 
(without the DM-1) can sometimes inhibit Her2-positive breast cancer cells; the binding of the 
antibody to the Her2 receptor prevents its dimerization, inhibiting activation of the MAPK, PI3-
kinase, AKT kinase pathways that would normally lead to cell division (Verma et al., 2012).  
Scientists at Genentech Inc. (South San Francisco, CA) showed that Kadcyla in vitro retains the 
same ability to inhibit PI3 kinase and AKT kinase pathways, and increase antibody-dependent 
cellular cytotoxicity (ADCC) as the parent antibody alone (Junttila et al., 2011).  
 
In 2014, a study coordinated by scientists in the Departments of Biostatistics, Product 
Development Oncology, and Translational Oncology at Genentech, Inc. (South San Francisco, 
CA) performed pre-clinical testing on Her-2-positive cultured cells and on mouse xenograft 
models using an interesting dual-targeting approach (Phillips et al., 2014).  The treatment 
combined the ADC Kadcyla with Pertuzumab (Perjeta) that prevents dimerization of the Her-2 
receptor.  Receptor dimerization leads to activation of growth stimulating signal transduction 
pathways.  Their data showed that the combined treatment synergistically inhibited cancer cell 
proliferation in vitro, and enhanced anti-tumor efficacy in vivo.  This combined treatment 
approach using two drugs that target the same receptor using different mechanisms may be a 
trend of the future, and is worth gaining additional information in IQP interviews. 
 
 
Glycoprotein NMB (gpNMB) 
 
Glycoprotein non-metastatic melanoma protein-B (gpNMB) (also called GPNMB or 
osteoactivin) is a transmembrane protein expressed in a variety of cell types, including 
melanocytes, osteoclasts, osteoblasts, and dendritic cells (Weterman et al., 1995).  gpNMB is 
also over-expressed in aggressive melanoma, glioma, and breast cancer (Tse et al., 2006; Kuan et 
al., 2006; Rose et al., 2007).  An example of an ADC directed against gpNMB is 
Glembatumumab vedotin (CDX-011) (formerly CR011-vcMMAE). CDX-011 consists of a 
fully human monoclonal antibody against gpNMB conjugated via a valine-citrulline linker to the 
potent microtubule inhibitor monomethyl auristatin-E (MMAE) (Naumovski and Junutula, 2010; 
Keir and Vahdat, 2012). 
 
 In pre-clinical studies performed at CuraGen Corporation (Branford, CT), an antibody 
against gpNMB by itself did not inhibit the in vitro growth of melanoma cells, but when the 
antibody was linked to MMAE, the ADC potently and specifically inhibited the growth of 
gpNMB-positive melanoma cells (Tse et al., 2006).  This group also showed that knocking down 
gpNMB protein expression in tumor cells using small interfering RNAs prevented destruction of 
the cell, and that over-expressing gpNMB on normal cells using genetic engineering made the 
cells sensitive to destruction by the ADC.  So, this data shows the importance of the target 
antigen to the cell destruction.  In mouse xenograft models, the ADC showed anti-tumor effects 
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that were directly dependent on the dose of the ADC, including some complete remissions at 
doses as low as 1.25 mg/kg (Tse et al., 2006). 
 
 In 2007, the same team at CuraGen Corporation extended their pre-clinical testing of 
CDX-011 (then termed CR011-vcMMAE) by performing dose titrations (Pollack et al., 2007). 
The ADC was found to induce melanoma tumor regression in mouse xenograft models at doses 
ranging from 1.25 to 80 mg/kg, delivered IV every 4 days for 4 treatments.  The regressions did 
not regrow during the 200 day observation period.  The drug had a half-life of about 10.3 days in 
mice.  Injecting the drug either as a single bolus injection, or performing intermittent dosing, 
showed no differences in drug activity.  Injecting antibody alone or MMAE alone produced no 
anti-tumor effect, again showing the importance of linking the drug to the antibody (Pollack et 
al., 2007). 
 
In 2010, scientists in the Department of Medicine at the Goodman Cancer Research 
Centre of McGill University (Montréal, Canada) showed that the gpNMB antigen expression 
correlates with a more invasive phenotype for breast cancer cells and reduces patient survival, 
and the presence of gpNMB antigen sensitized breast cancer cells in vitro to killing from the 
CDX-011.  (Rose et al., 2010).  Thus, gpNMB is a prognostic marker for poor outcome in breast 
cancer patients, and the CDX-011 ADC drug targeting this antigen should be developed 
clinically. 
 
 
Trop-2 
 
Trophoblast cell-surface antigen-2 (Trop-2) (also known as tumor-associated calcium 
signal transducer-2, or epithelial glycoprotein-1 antigen, EGP-1), is a member of a cell surface 
receptor family with at least two other members (Linnenbach et al., 1993). Trop-2 is over-
expressed on many types of epithelial tumors, especially the more aggressive types, but it is also 
expressed at low levels on normal tissues (Cubas et al., 2009; Trerotola et al., 2013; Ambrogi et 
al., 2014).  An antibody-drug conjugate targeting Trop-2 is Sacituzumab govitecan (IMMU-
132) (Cardillo et al., 2011).  IMMU-132 is a humanized monoclonal antibody against Trop-2 
(hRS7) linked to SN-38, the active metabolite of irinotecan, an inhibitor of topoisomerase-I.  
Blocking topoisomerase keeps DNA from unwinding during replication, killing the cell.   
 
IMMU-132 has undergone much pre-clinical testing, especially from a team of 
researchers at Immunomedics, Inc. (Morris Plains, New Jersey).  This team evaluated several 
types of linkers for release of the SN-38 cargo from the antibody (Moon et al., 2008; Govindan 
et al., 2009; Cardillo et al., 2011; Govindan et al., 2013).  Some linkers released the cargo within 
a few hours, while other linkers released only after several days.  The linker selected by the team 
as best optimized contains a short hydroxyl residue to enhance solubility, and it had an 
“intermediate level” half-life which the researchers preferred.  The SN-38 cargo was released 
both within the acidic environment of the lysosome and within the tumor micro-environment.  A 
safety study performed in monkeys indicated that neutropenia is the dose-limiting factor.  The 
only other side-effect observed frequently was diarrhea (Cardillo et al., 2011). 
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5T4 
 
Trophoblast glycoprotein (5t4) (also known as TPBG), is an onco-fetal antigen expressed 
on tumor-initiating cells (TIC) (Sapra et al., 2013). TICs represent the most aggressive cells in 
the tumor; if they remain in the patient following conventional therapies, they can relapse, so 
targeting TICs directly could improve patient survivability (Sapra et al., 2013). 5T4 is also a cell 
surface antigen that internalizes rapidly, giving it the potential to efficiently deliver ADC’s into 
tumor cells. 5T4 is largely located in solid carcinomas, especially Non-Small Cell Lung Cancer 
(NSCLC), and is limited in normal adult tissue.  
 
An antibody-drug conjugate targeting 5T4 is A1mcMMAF. A1mcMMAF contains a 
humanized anti-5T4 antibody linked to the potent tubulin inhibitor monomethylauristatin F 
(MMAF) by a non-cleavable maleimidocaproyl (mc) linker (Sapra et al., 2013). In 2011, a group 
of scientists from the Oncology Research Unit at Pfizer (Pearl River, NY) did pre-clinical tests 
on A1mcMMAF (Oncofetal Antigen, 2011). In a mouse model using patient-derived NSCLC 
xenografts, the ADC caused tumor regressions without regrowth for up to 3 months, while 
treatment with vehicle or toxin conjugated to control antibodies showed no activity (Oncofetal 
Antigen, 2011).  In 2013, the same team of scientists extended the pre-clinical testing (Sapra et 
al., 2013). The ADC showed potent antitumor activity both in vitro and in vivo against a variety 
of 5T4-positive tumors. The results for the in vitro test showed that the ADC inhibited the 
growth of 5T4-expressing tumor cell lines (MDAMB435/5T4, MDAMB468, and MDAMB361- 
DYT2) in a concentration-dependent manner, but as expected was not active against 5T4-
negative lymphoma cells. In the in vivo experiment, the ADC caused complete inhibition of 
growth or regression of 4 different kinds of 5T4-tumors (37622A1 PDX, MDAMB468, 
MDAMB361DYT2, H1975).  The ADC induced long-term tumor regressions for up to 100 days, 
with each model showing responses to the drug, even at doses as low as 3 mg/kg dosed every 4 
days.  No deaths or significant adverse events were recorded throughout the observation period.  
When given to monkeys at high doses of 10 mg/kg, the ADC showed no obvious toxicities, and 
had a half-life of approximately 5 days (Sapra et al., 2013). 
 
 Further experiments with the ADC mentioned above were done in 2017 at the University 
of Manchester (UK) using tumor cells derived from patients with acute lymphoblastic leukemia 
(ALL) (McGinn et al., 2017). They showed that antigen 5T4 was highly expressed in tumor cells 
derived from patients with high levels of residual cancer following initial treatment with 
chemotherapy.  Treatment of mice engrafted with 5T4-positive ALL leukemia cells significantly 
improved survival, and showed no apparent toxicity.  In mice engrafted with patient-derived 
5T4-positive ALL leukemia cells, treatment with dexamethasone plus the ADC significantly 
improved survival (p=0.0006) relative to either therapy alone. 
 
 
DLL3 
 
Delta-like 3 (DLL3) is a protein expressed on the surface of small-cell lung cancer 
(SCLC) and large-cell neuroendocrine carcinoma (LCNEC), but it is rarely expressed in healthy 
adult tissue, which makes it an ideal target for ADCs (Saunders et al., 2015). An ADC targeting 
DLL3 is SC16LD6.5. Which combines a humanized anti-DLL3 monoclonal antibody to a DNA 
damaging dimer toxin pyrrolobenzodiazepine (PBD) (Saunders et al., 2015).   
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In 2015, scientists at Stemcentrx Inc. (South San Francisco, California) tested 
SC16LD6.5 in pre-clinical trials (Saunders et al., 2015). They implanted NOD/SCID mice, a 
strain of inbred immunodeficient mice, with patient-derived SCLC or LCNEC tumor cells.  They 
observed that the ADC induced durable tumor regressions across multiple models.  They also 
used serial transplantation experiments to show a lack of tumor recurrence after the exposure. 
The tumor regressions directly correlated with DLL3 expression, showing the importance of the 
target antigen in the therapy. The observed toxicities consisted of reversible myelosuppression, 
mild kidney degeneration, skin thickening, and hyperpigmentation. The adverse effects appear to 
be due to off-target effects of the drug. There were no reported animal deaths or other significant 
adverse events (Saunders et al., 2015). 
 
 
EpCAM 
 
 Human epithelial cell adhesion molecule (EpCAM) (also known as CD326) is a type I 
membrane glycoprotein expressed in tumor initiating cells (TICs), making it a potential target for 
ADCs (Moldenhauer et al., 2012). Anti-EpCAM antibodies showed promise in past studies, but 
showed no tumor regression in a phase II clinical trial. α-amanitin-glutarate-chiHEA125 
(chiHEA125-Ama) is an ADC that targets EpCAM. This ADC was created by chemical cross-
linking α-amanitin (a toxin that inhibits DNA transcription) with chiHEA125 (a human-mouse 
chimera anti-EpCAM monoclonal antibody) (Moldenhauer et al., 2012).  This ADC was 
investigated in pre-clinical testing by a team of scientists at the German Cancer Research Center 
(Heidelberg, Germany) using both in vitro and in vivo methods (Moldenhauer et al., 2012). For 
their in vitro experiment, they used a [3H]-thymidine incorporation assay to measure the effect of 
the ADC on DNA replication in human pancreatic (BxPc-3 and Capan-1), colorectal (Colo205), 
breast (MCF-7), and bile duct (OZ) cancer cell lines. The ADC inhibited growth of all the cell 
lines tested, with IC50’s ranging from 0.25 nanomolar to 5.4 picomolar (extremely active).  In 
their in vivo experiment, they injected subcutaneous human BxPc-3 pancreatic carcinoma 
xenograft tumors into mice and found that a single 50 µg/kg dose of the ADC inhibited tumor 
growth by 79%.  Two doses of 100 µg/kg given a week apart led to complete tumor regression in 
nine out of ten mice. When treated at extremely high doses, the authors reported 30%-50% of the 
mice experiencing pronounced liver toxicity, but there were no reports of death or other 
significant adverse events at the lower doses (Moldenhauer et al., 2012). 
 
 
Fibronectin 
 
 Fibronectin is a glycoprotein of the extracellular matrix that binds to membrane-spanning 
receptor proteins called integrins (Palumbo et al., 2011). The EDB domain of fibronectin can be 
used as a marker for tumor angiogenesis, as blood vessel formation is rare in healthy adults. 
Fibronectin molecules containing the EDB domain are synthesized during the formation and 
growth of a majority of tumors. An ADC that targets fibronectin-EDB could eradicate cancer by 
destroying the tumor’s blood vessels, starving the tumor. An example of an ADC that targets 
fibronectin-EDB is SIP(L19)-PS. This ADC was synthesized by combining PS (a photo-
sensitizer that absorbs in the red spectrum), and L19 (a human monoclonal antibody against 
fibronectin-EDB (Palumbo et al., 2011).  In 2010, a study done by scientists at the Swiss Federal 
Institute of Technology (Zurich, Switzerland) tested this ADC in two mouse models of cancer 
(F9 and A431). Their results showed the ADC when activated by radiation lead to disruption of 
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the tumor vasculature, and complete and long-lasting cancer eradication. They also showed that 
natural killer cells (NKs) are essential for the tumor eradication. There was no mention of any 
adverse side-effects (Palumbo et al., 2011). Their results show that shutting down the tumor 
vasculature can cause tumor death. 
 
 
Mesothelin 
 
Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein, and is 
overexpressed in several human tumors, including the majority of ovarian and pancreatic 
adenocarcinomas, and in 100% of epithelial mesotheliomas (Golfier et al., 2014). Expression in 
normal tissues is mostly restricted, being found mainly in single cell layers lining the pleura, 
pericardium, and peritoneum. Mesothelin may play a role in the metastatic spread of cancer cells 
in the ovaries.  Anetumab Ravtansine (BAY 94-9343) is an example of an ADC that targets 
mesothelin. It consists of a human anti-mesothelin antibody conjugated to the maytansinoid 
tubulin inhibitor DM4 via a disulfide-containing linker (Golfier et al., 2014).  
 
In a 2014 study performed by scientists at Bayer HealthCare Pharmaceuticals 
(Berlin/Wuppertal, Germany), they examined the binding properties of BAY 94-9343 and its 
effects on tumor cells in vitro and in vivo in xenograft mice (Golfier et al., 2014). In vitro, BAY 
94-9343 demonstrated potent and selective cytotoxicity against mesothelin-expressing cells with 
an IC50 of 0.72 nmol/L, without affecting mesothelin-negative or non-proliferating cells. In vivo, 
BAY 94-9343 localized specifically to mesothelin-positive tumors and inhibited tumor growth, 
in both subcutaneous and orthotropic xenograft models. In addition, BAY 94-9343 was able to 
induce a bystander effect on neighboring mesothelin-negative tumor cells (likely from DM4 
released from nearby apoptotic tumor cells). There was no mention of adverse effects or death in 
the report (Golfier et al., 2014). 
 
 
Section-2 Conclusions 
 
The pre-clinical results described in this section of the Literature Review show that 
antibody-drug conjugates have the potential to slow or eliminate various types of cancers, both in 
vitro using cultured cancer cell lines and in vivo using mouse xenograft models. The ADC drugs 
showed various degrees of effectiveness against a large variety of cancers, including complete 
cancer remissions in some cases.  Use of the antibody alone, or the cargo toxin alone, produced 
no tumor killing, providing a proof-of-principle that combining the targeting property of an 
antibody with the potent cell killing ability of new cytotoxic drugs strongly elevates the anti-
tumor effects of either agent alone.  Targeting the cytotoxic drug directly to the tumor allows it 
to be used at concentrations far in excess of what could be tolerated with a systemic 
administration of the toxin.  Some of the pre-clinical studies assayed antibody binding affinity to 
the surface antigen, showing that the ADC drug bound in the same nano-molar range as free 
antibody.  This shows that conjugation of the antibody to the drug cargo did not alter its cell 
binding ability.  Other studies performed pre-clinically assayed the amount of free unconjugated 
toxin in the blood, and found very little.  This shows that the ADC linkers held together until the 
drugs were internalized in the cancer cells.  With respect to side-effects, most of the pre-clinical 
studies showed relatively minor adverse-effects; the most serious side-effect observed in mice 
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was neutropenia, so this might be expected to be a problem in the clinical trials, and should be 
monitored closely.   
 
With respect to best practices, some of the pre-clinical studies showed that the extent of 
anti-tumor activity directly correlated with the extent of over-expression of target antigen on the 
tumor. If the tumor no longer expressed the target antigen, the ADC drug was inactive against 
that tumor.  So, this data implies that a best practice would be to frequently monitor the patient’s 
tumor for the level of target antigen expression to determine which patients most likely will 
benefit from the therapy or whether the ADC therapy should be continued. Other pre-clinical 
studies showed that delivering the ADC drug long-term post-cancer remission prevented disease 
re-occurrence (so long as the patient did not form antibodies against the ADC drug), so ADC use 
long-term might be tested in clinical trials to help ensure a patient’s cancer does not return. 
 
Overall, the pre-clinical data discussed in this section support moving forward with 
human clinical trials for most of the ADC drugs, while using the best practice of frequently 
assaying for the presence of the target antigen to determine which patients will most likely 
benefit from the therapy. 
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Section-3: ADC Clinical Trials and Safety 
Alex Gallant 
 
  
The purpose of this section of the Literature Review is to discuss some of the data 
obtained in human clinical trials using various antibody-drug conjugates (ADCs). Over 27 
different ADCs are currently being investigated in patients (Sasson and Blanc, 2013), and this 
has provided a wealth of safety information for this type of drug. Special attention is paid to the 
safety of those ADCs that have been FDA approved.  This section is divided into subsections 
based on the surface antigen targeted by the ADC. 
 
 
CD19 
 
 Cluster of differentiation-19 (CD19) (also known as B-lymphocyte antigen) is a protein 
found on the surface of B-cells, a type of white blood cell that produce antibodies (Scheuermann 
and Racila, 1995).  Because it is a marker for B-cells, CD19 has long been used to help diagnose 
cancers that arise from B-cells, such as lymphoma and leukemia, and cells strongly expressing 
CD19 are found in these types of tumors (Del Nagro et al., 2005). An example of an antibody-
drug conjugate (ADC) directed against CD19 is SAR-3419.  SAR-3419 contains a humanized 
monoclonal antibody against CD19, linked via a cleavable linker to 3-4 molecules of the tubulin 
inhibitor DM-4 (Blanc et al., 2011).  SAR-3419 was designed to treat B-cell malignancies of all 
types, including all B-cell lymphomas, B-cell chronic lymphocytic leukemia, and non-T acute 
lymphoblastic leukemia (ALL) (the latter cannot be targeted by CD20). 
 
 Two Phase-I clinical trials have been performed using SAR-3419 in patients with 
relapsed B-cell non-Hodgkin’s lymphoma (NHL). NHL is one of the most common cancers in 
the United States, accounting for about 4% of all cancers. In 2017, approximately 72,240 people 
(40,080 males and 32,160 females) will be diagnosed with NHL, and about 20,140 people will 
die from this cancer (American Cancer Society, 2017).  In the SAR-3419 clinical trials, the 
patients were dosed once every 3 weeks (Younes et al., 2009), or once every week (Coiffier et 
al., 2011).  In the 2009 trial, other than ocular problems (such as blurred vision) no other 
clinically significant toxicities were observed in over 10% of the patients.  There were no 
clinically significant hematologic or gastrointestinal toxicities, so the linker held up well, and 
there was little evidence of free toxic DM-4 in the blood.  The drug lasted from 4-6 days in the 
patients, independent of dose. Tumor reduction was seen in more than half of the 35 evaluable 
patients. No effect was observed on normal B-cells (that also express CD-19), perhaps because 
their count was low due to previous therapies (Younes et al., 2009).  In the 2011 trial (Coiffier et 
al., 2011), ocular toxicity was also noted, but the incidence (2%) and severity were lower.  The 
hematological toxicity was insignificant, and a majority of patients showed a reduction in their 
lymphoma, which is highly encouraging. Thus, both of these phase-I tests showed no significant 
toxicity with some anti-tumor activity.  
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CD22 
 
CD22 is a molecule belonging to the SIGLEC family of lectins.  It is found on the surface 
of mature B-cells, and to a lesser extent on immature B-cells (Hatta et al., 1999) . CD22 is not as 
broadly expressed in B-cells as CD19.  An example of an antibody-drug conjugate targeting 
CD22 is Inotuzumab ozogamicin (also called CMC-544 or INO).  This ADC was developed 
by Pfizer and Union Chimique Belge (UCB) for patients with Non-Hodgkin Lymphoma (NHL), 
and consists of a humanized monoclonal antibody against CD22 (Inotuzumab) linked to a 
cytotoxic agent of the class calicheamicin (which damages DNA) (Takeshita et al., 2009).  
Binding of the drug to a tumor cell and its internalization allows hydrolysis of the acetyl butyrate 
linker and the release of the cytotoxic calicheamicin which kills the cell (Advani et al., 2010). 
 
With respect to clinical trials, in 2010, scientists in the Department of Hematologic 
Oncology and Blood Disorders at the Cleveland Clinic (Cleveland, OH) published the results of 
their Phase-I trial of Inotuzumab ozogamicin for treating 79 patients with refractory B-cell Non-
Hodgkin’s Lymphoma (NHL) (Advani et al., 2010).  The purpose of the Phase-I was to 
determine maximum tolerated dose (MTD), drug safety, and preliminary efficacy.  The drug was 
delivered by IV once every 3-4 weeks, at doses ranging from 0.4 to 2.4 mg/m2.  The MTD was 
determined to be 1.8 mg/m2.  Common adverse effects at the MTD were thrombocytopenia 
(decrease in platelets) (90% of patients), asthenia (weakness) (67%), nausea (51%), and 
neutropenia (decrease in neutrophils) (51%).  The overall response rate was 39% for all 79 
patients, which increased to 68% for patients with follicular NHL. The authors concluded that 
the drug demonstrated efficacy against NHL, with reversible thrombocytopenia as the main 
adverse event (Advani et al., 2010). 
 
 In 2012, a team of scientists at the National Cancer Institute of the National Institutes of 
Health (Bethesda, MD) reported the results of their Phase-I trial of CAT-8015 (Moxetumomab 
pasudotox) in patients with hairy cell leukemia (HCL) (Kreitman et al., 2012).  CAT-8015 
contains an antibody against CD22 fused to a truncated peptide of Pseudomonas endotoxin.  The 
drug is a second-generation ADC, modified from a previous ADC (CAT-3888) at the antigen-
binding site to facilitate a 14-fold increase in CD22 binding affinity.  The Phase-I trial enrolled 
28 HCL patients previously refractory to two prior chemotherapy treatments, and was a dose 
escalation to test safety and preliminary responses.  The doses ranged from 5-50 µg/kg, delivered 
every other day for 3 doses, with up to 16 cycles repeated at 4-week intervals.  At these doses, no 
dose-limiting toxicity was observed.  Minor side-effects, seen in 25-64% of the patients, 
included: hypo-albuminemia (low serum albumin), aminotransferase elevations (mild liver 
damage), edema, headache, hypotension, nausea, and fatigue. Interestingly, 10 of 26 evaluable 
patients initially made neutralizing antibodies against the drug (which could have diminished 
drug effectiveness), but after the first cycle of treatment, this antibody response diminished.  The 
overall response rate was 86%, with 46% of the patients achieving complete remission (Kreitman 
et al., 2012). Based on these impressive Phase-I results, the U.S. National Cancer Institute has 
initiated a Phase-III trial (not yet published) of CAT-8015 (Hirschler, 2013). AstraZeneca 
indicated the Phase III clinical trial would test Moxetumomab pasudotox in patients with hairy 
cell leukemia who have not responded to (or relapsed from) previous therapies.  
 
 Another clinical trial performed in 2012 was in the Department of Leukemia at the MD 
Anderson Cancer Center (Houston, TX) (Kantarjian et al., 2012).  This was a Phase-II trial 
(identifier NCT-01134575) of 49 patients with refractory or relapsed acute lymphocytic 
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leukemia (ALL) treated with Inotuzumab ozogamicin.  The dose was 1.8 mg/m2 IV every 3-4 
weeks.  CD22 was expressed in more than 50% of the blasts in all patients.  The overall response 
rate was 57%.  The most frequent adverse effects were: fever (41%), hypotension (26%), and 
grade 1-2 liver problems (24%).  Two patients died within 4 weeks of starting treatment, but it 
was not clear whether the deaths resulted from the treatment or the cancer (Kantarjian et al., 
2012). 
 
 In 2015, a large team of scientists at ten different medical centers (based at Washington 
University School of Medicine, St. Louis, MO) published the results of their Phase-II trial of 63 
patients with high-risk relapsed/refractory diffuse large B-cell lymphoma (DLBCL).  The 
patients were treated with Inotuzumab ozogamicin (INO) plus rituximab antibody (R-INO), 
followed by high dose chemotherapy and an autologous stem cell transplant (SCT) (Wagner-
Johnson et al., 2015). Of the 18 patients that underwent the SCT plus the ADC treatment, 61.1% 
showed 2-year progression-free survival.  For all patients, the 1-year and 2-year progression-free 
survival rates were 28.9% and 25.3%, respectively. Common grade 3 or 4 side-effects during the 
R-INO portion of the treatment included: thrombocytopenia, lymphopenia, and neutropenia. 
 
Thus, with respect to ADC drugs targeting CD22, two have undergone clinical trials, 
including two Phase-II trials for NHL, where the initial data appeared good.  In 2013, Pfizer 
discontinued a Phase-III trial for its CD22-targeting ADC when it appeared to not extend patient 
lifespan (Pfizer, 2013), but ten other CD22 clinical trials are still ongoing, including a Phase-III 
for acute lymphoblastic leukemia (ALL) (Trial Identifier: NCT01564784) (Clinical Trials.gov). 
 
 
CD30 
 
CD30 is a cell membrane protein belonging to the tumor necrosis factor (TNF) receptor 
family.  CD30 is expressed on activated, but not resting, T- and B-cells, and is associated with 
anaplastic large cell lymphoma (ALCL) and classic Hodgkin lymphoma (HL) (Gorzyca et al., 
2003). Drugs targeting CD30 are one of the best investigated of all the ADCs. A well 
characterized example in this class is Brentuximab vedotin (Adcetris®, SGN-035), one of only 
two currently FDA-approved ADCs (Deng et al., 2013). Adcetris consists of a mouse-human 
chimeric monoclonal antibody against CD30 (Brentuximab or cAC10) linked to 3-5 units of the 
drug monomethyl auristatin-E (MMAE) that binds tubulin and keeps it from polymerizing.  
 
With respect to clinical trials, in 2010 scientists at Seattle Genetics, Inc. released their 
data from the first clinical trial of Adcetris for 102 patients with refractory/relapsed HL.  The 
data was presented at the 52nd American Society of Hematology meeting in Orlando (Seattle 
Genetics, 2010). Their results showed that 75% of the patients achieved an objective response, 
and 34% achieved complete remission.   
 
 Also in 2010, another team of scientists in the Department of Lymphoma and Myeloma 
at the University of Texas MD Anderson Cancer Center (Houston, TX) published the results of 
their Phase-I multi-center testing of Brentuximab vedotin on 45 patients with refractory/relapsed 
HL and ALCL (Younes et al., 2010).  They tested doses ranging from 0.1 to 3.6 mg/kg body 
weight delivered every 3 weeks.  The data showed that the maximum tolerated dose was 1.8 
mg/kg, and at this dose 50% of the patients showed a response.  Tumor regressions were 
observed in 36 of 42 measurable patients, with 11 complete remissions.  The most common side-
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effects were fatigue, pyrexia, diarrhea, nausea, neutropenia and peripheral neuropathy (Younes et 
al., 2010). 
 
 In 2012, the same MD Anderson team mentioned above extended their clinical analysis 
of Brentuximab vedotin with a Phase-II study of 102 patients with refractory/relapsed HL who 
had received an autologous (self) stem cell transplant (Younes et al., 2012).  The patients were 
treated IV with 1.8 mg/kg Adcetris for 3 weeks.  Their data showed an overall response rate of 
75%, with complete remission in 34% of the patients.  After a median observation time of 1.5 
years, 31 patients (30%) were alive and free of documented disease.  The most common 
treatment-related adverse effects were peripheral neuropathy, nausea, fatigue, neutropenia, and 
diarrhea (Younes et al., 2012). 
 
 Also in 2012, a different team of scientists at the Fox Chase Cancer Center (Philadelphia, 
PA) published the results of their Phase-II multicenter trial of Brentuximab vedotin in 58 
patients with relapsed/refractory anaplastic large-cell lymphoma (ALCL) (Pro et al., 2012). The 
patients received a dose of 1.8 mg/kg IV every 3 weeks on an outpatient basis.  50 of the 58 
patients (86%) showed responses: 33 (57%) showed complete remission, and 17 (29%) showed 
partial remission.  Grade 3 or 4 adverse events included neutropenia (21%), thrombocytopenia 
(14%), and peripheral sensory neuropathy (12%) (Pro et al., 2012). 
 
 The MD Anderson team mentioned previously also investigated the use of Brentuximab 
vedotin on newly diagnosed patients with HL, using either the ADC alone or ADC combined 
with standard treatments (Younes et al., 2013). The team performed a Phase-I dose-escalation 
study on 51 patients, testing from 0.6 to 1.2 mg/kg drug IV every 2 weeks (study identifier 
NCT01060904). The maximum tolerated dose (MTD) when combined with standard treatment 
was not exceeded at the highest dose tested here.  21 of 22 patients (95%) achieved complete 
remission!  Adverse events were generally grade 1 or 2, but occurred in 41% of all patients.  
However, the authors stated that an “unacceptable” number of patients showed pulmonary toxic 
effects (44%) when the ADC was combined with a chemotherapy containing bleomycin, so the 
authors recommended omitting bleomycin from the combination (Younes et al., 2013). 
 
Thus, for ADCs against CD30, several Phase-I and II studies have been performed.  The 
data included several complete remissions in patients with HL and ALCL, which the Adcetris 
drug manufacturer termed “unprecedented responses with manageable toxicity” with very high 
overall response rates (Vaklavas and Forero-Torres, 2012).  Adcetris remains one of only two 
ADC drugs currently FDA-approved. 
 
 
CD33 
 
 CD33 (also called Siglec-3; sialic acid binding Ig-like lectin 3) is a transmembrane 
receptor expressed on myeloid cells, but it is also found on some lymphoid cells (Garnache-
Ottou et al., 2005).  CD33 binds sialic acids, therefore it is a member of the SIGLEC family of 
lectins.  An example of an ADC drug that targets CD33 is Gemtuzumab ozogamicin (GO; 
Mylotarg), containing an antibody against CD33 linked to the cytotoxic drug calicheamicin 
(DNA damaging) (Tsimberidou et al., 2006).  Mylotarg was the first ADC drug approved for use 
in the U.S. (Bross et al., 2001), and it has the highest number of Phase-III trials for any ADC 
drug.  Mylotarg was FDA-approved in 2000, marketed by Wyeth, and manufactured by Pfizer 
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for treating patients with acute myelogenous leukemia (AML).  However, in 2010, Mylotarg was 
withdrawn from the market when clinical trials showed it increased patient death and was no 
better than conventional therapies (Nelson, 2010; Richwine, 2010). 
 
 Since Mylotarg’s withdrawal in 2010, a few additional clinical trials have been 
performed where the drug shows significant anti-cancer activity.  In 2012, a large team of 
scientists at the Hôpital Mignot, Université Versailles-Saint Quentin (Le Chesnay, France) 
reported their results of a Phase-III randomized study of Mylotarg on 280 patients with newly 
acquired acute myeloid leukemia (AML) (Castaigne et al., 2012). The study was performed at 26 
different hematology centers in France. The authors stated that the data from previous Phase-III 
trials on Mylotarg were contradictory, so they decided to compare two groups: Mylotarg at a 
dose of 3 mg/m2 plus a chemotherapy treatment versus a group with chemotherapy alone 
(control) to determine whether the combination was too toxic. Comparing the control versus the 
ADC/chemo combination, their data showed an increase in patient event-free survival (EFS) 
from 17.1% to 40.8% (p=0.0003).  The relapse-free survival (RFS) increased from 22.7% to 
50.3% (p=0.0003).  With respect to adverse effects, persistent thrombocytopenia increased from 
3% to 16% (p<0.0001), however this did not increase the death rate.  The authors concluded that 
the use of lower doses of GO allowed a successful simultaneous addition of chemotherapy 
treatment to significantly improve patient outcomes, and that further Phase-III trials with GO are 
warranted (Castaigne et al., 2012). 
 
In 2013, scientists at the Fred Hutchinson Cancer Research Center (Seattle, WA) reported 
the results of their Phase-III study of GO at 6 mg/m2 combined with “induction therapy” 
(daunorubicin and cytarabine) compared to induction therapy alone, in 637 patients with acute 
myeloid leukemia (AML) (Petersdorf  et al., 2013).  The patient’s complete remission rate was 
about the same between the two groups: 69% for GO/induction compared to 70% for induction 
alone (p = 0.59).  And the 5-year relapse-free survival rate was also about the same, 43% 
GO/induction versus 42% for induction alone (p=0.40). The authors concluded that the addition 
of GO to induction therapy provided no additional benefit (Petersdorf  et al., 2013). 
 
In 2014, scientists in the School of Medicine at Cardiff University (Cardiff, UK) 
performed a Phase-III meta-analysis of published PubMed reports and data obtained from 
individual trial lists on 3325 patients with acute myeloid leukemia (AML) (Hills et al., 2014).  
They compared two groups: Mylotarg + induction therapy versus a control of induction therapy 
alone. Their data showed that the addition of Mylotarg to the induction therapy did not improve 
the rate of complete remissions (p=0.3), but Mylotarg did lower the risk of cancer relapse 
(p=0.0001), and it improved overall patient survival at the 5-year mark (p=0.01).  At 6 years, the 
survival benefit of GO was especially pronounced (p=0.0006) in patients with “favorable 
cytogenetics”.  This group showed no additional chromosomal translocations or inversions.  In 
patients having adverse cytogenetics, Mylotarg provided no detectable benefit (p=0.9).  With 
respect to adverse effects, doses of Mylotarg at 3 mg/m2 were associated with fewer early deaths 
than the higher dose of 6 mg/m2 (both doses showed equal efficacy).  The authors concluded that 
Mylotarg provides significant survival benefits to patients that have no adverse cytogenetic 
alterations, and that the drug should be re-assessed for approval (Hills et al., 2014). This study 
points out an excellent method for helping determine which patients may best benefit from 
Mylotarg treatments, those with no observable cytogenetic abnormalities, and perhaps assaying 
for cytogenetic abnormalities should be performed as a best practice. 
 
57 
In 2016, scientists in the Department of Leukemia at the University of Texas MD 
Anderson Cancer Center (Houston, TX) published a Phase-II study of Mylotarg at a dose of 3 
mg/m2 combined with decitabine (a DNA synthesis inhibitor) (Daver et al., 2016).  The study 
was performed on 110 patients with relapsed acute myeloid leukemia (AML) or with high-risk 
myelodysplastic syndrome.  The authors speculated that the decitabine might open up the 
chromatin structure in the leukemia cells making them more sensitive to damage from the 
calicheamicin component of the Mylotarg which binds to bind to the DNA molecule to induce 
double-stranded breaks.  Complete remission (CR) was seen in 3 of 5 patients (60%) in their 
group-2, which included patients with refractory disease that lasted longer than one year.  The 
most frequent side-effects observed were nausea, mucositis, and hemorrhage (Daver et al., 
2016). 
 
 
Her2 
 
 Human epidermal growth factor receptor-2 (Her2) (also known as CD340, Neu, or 
Erbb2) is a member of the epidermal growth factor family of cell surface receptors (Mitri et al., 
2012). Over-expression of Her2 occurs in approximately 15-30% of breast cancers, and is 
strongly associated with increased cancer recurrence and poor prognosis (Tan et al., 2007).  Her2 
over-expression can also occur on cancers of the ovary, stomach, lung, and uterus (Rüschoff et 
al., 2012; Buza et al., 2014). 
 
 An example of an antibody-drug conjugate against Her2 is Kadcyla® (Trastuzumab 
emtansine; T-DM1).  Kadcyla was developed by Genentech/Roche, and is one of two current 
FDA-approved ADC drugs (the other is Adcetris against CD30).  Kadcyla contains a humanized 
antibody against Her2 (Trastuzumab or Herceptin) linked to cytotoxic drug emtansine (DM-1) 
that binds microtubules preventing their polymerization (Niculescu-Duvaz, 2010; LoRusso et al., 
2011; Lopus, 2011).  Kadcyla is unique among ADCs in that its antibody component by itself 
(without the DM-1) can sometimes inhibit Her2-positive breast cancer cells; the binding of the 
antibody to the Her2 receptor prevents its dimerization, inhibiting activation of the MAPK, PI3-
kinase, AKT kinase pathways that otherwise leads to cell division (Verma et al., 2012).   
 
The first Kadcyla clinical trial was performed in 2010 by scientists at the Dana-Farber 
Cancer Institute (Boston, MA) (Krop et al., 2010). They reported the findings of their Phase-I 
study of Kadcyla for treating breast cancer patients who relapsed after receiving antibody 
therapy alone.  They performed a dose escalation from 0.3 to 4.8 mg/kg once every 3 weeks, and 
then monitored safety, pharmacokinetics, and preliminary efficacy.  Their data showed that 
thrombocytopenia was dose-limiting at the highest dose tested (4.8 mg/kg), so the authors 
concluded that the maximum tolerated dose (MTD) was slightly lower at 3.6 mg/kg.  The drug 
half-life was 3.5 days.  The most common drug-related adverse events were thrombocytopenia, 
elevated transaminases, fatigue, nausea, and anemia.  No serious cardiac events that would have 
required drug lowering were observed.  The confirmed response rate at the maximum tolerated 
dose was 44%.  The authors concluded that Kadcyla caused mild and reversible toxicity, and it 
appeared to be active in the relapsed patients (Krop et al., 2010). 
 
 The same team of scientists (led by HA Burris who was senior author on the previous 
study, but was now associated with the Sarah Cannon Research Institute in Nashville, TN) 
published the results of their Phase-II study of  Kadcyla for 112 breast cancer patients who had 
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relapsed after receiving antibody therapy alone (Burris et al., 2011). The team stayed with the 
previously identified maximum tolerated dose of 3.6 mg/kg once every 3 weeks.  The overall 
response rate was 25.9%, with a median progression-free survival of 4.6 months.  The drug 
appeared to be well tolerated; the most frequent side-effects were only at grade-1 or -2 (mild).  
Observed grade-3 (serious) problems included hypokalemia (lowered serum potassium levels) 
(8.9%), thrombocytopenia (8.0%), and fatigue (4.5%), although these were observed only in a 
small minority of patients.  The authors concluded that the treatment was generally well tolerated 
(Burris et al., 2011).  Importantly, the response rates were higher in patients with confirmed Her-
2-positive tumors (assayed by immuno-histochemistry or by reverse transcriptase polymerase 
chain reaction), so this best practice of verifying the presence of the surface antigen target in a 
patient’s tumor should be continued. 
 
In 2012, a Phase-III trial coordinated by scientists at the Sunnybrook Odette Cancer 
Center (Toronto) investigated the use of Kadcyla on 991 patients with refractory breast cancer 
(trial number NCT00829166) (Verma et al., 2012). The patients were resistant to antibody 
therapy alone plus a taxane chemotherapy, and were randomly assigned to two groups: Kadcyla 
versus a control group that received a chemotherapy combination of lapatinib and capecitabine. 
Comparing the control group to the Kadcyla group, the data showed that progression-free patient 
survival increased from 6.4 months to 9.6 months (p<0.001), overall survival increased from 
25.1 months to 30.9 months (p<0.001), and the patient response rate increased from 30.8% to 
43.6% (p<0.001).  Grade-3 (serious) adverse events decreased from 57% to 41%.  
Thrombocytopenia and liver damage were higher with Kadcyla, while diarrhea, nausea, 
vomiting, and erythrodysthesia were higher with the chemotherapy.  The authors concluded that 
Kadcyla significantly improved progression-free and overall patient survival, with less toxicity 
than chemotherapy. 
 
On the basis of the previously mentioned clinical trials, the FDA approved Kadcyla on 
February 22, 2013, for women with Her2-positive metastatic breast cancer that had not 
previously responded to antibody treatment alone or to chemotherapy (Pollack, 2013). 
 
 Even after FDA approval, the clinical trials for Kadcyla continued. In 2014, the team of 
scientists mentioned previously at the Dana-Farber Cancer Institute (Boston) published their 
Phase-III data of 602 patients in 22 countries of Kadcyla against refractory Her2-positive 
advanced breast cancer (Krop et al., 2014).  They compared two patient groups: Kadcyla and a 
physician’s choice chemotherapy.  Their data showed that Kadcyla increased progression-free 
survival from 3.3 to 6.2 months (p<0.0001), slightly improved overall survival (p=0.0034), and 
decreased level-3 adverse events (from 43% to 32%).  The Kadcyla group showed higher 
incidence of thrombocytopenia (5% versus 2%), but had lower incidence of neutropenia and 
diarrhea.  The authors concluded that due to the strong safety and efficacy profile of Kadcyla, it 
should now be considered the new standard for treating patients with refractory Her2-positive 
breast cancer (Krop et al., 2014). 
 
 Also in 2014, another team of researchers based at the Mayo Clinic in Jacksonville, FL, 
published their Phase-II study using Kadcyla in patients with previously untreated Her2-positive 
breast cancer (clinical trial identifier NCT00679341) (Perez et al., 2014).  They compared two 
groups: Kadcyla (T-DM1, N=67) versus trastuzumab antibody and docetaxel (HT) (N=70).  
Importantly, this team assayed the level of Her2 expression in the tumors using immuno-
histochemistry, in situ hybridization, and reverse transcriptase polymerase chain reaction (RT-
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PCR).  They found that the risk of disease progression was lower with T-DM1 treatment than 
with HT (hazard ratio 0.59), and the disease risk lowered further in patients whose tumors 
showed levels of Her2 greater than the mean (hazard ratio 0.39) (Perez et al., 2014). This data 
shows that when using ADCs to treat tumors, pre-analyzing the tumors to determine the extent of 
antigen expression might help predict which patients are most likely to benefit from the ADC 
treatment. 
 
 Another Her-2 clinical trial performed in 2014 was coordinated by scientists in the 
Departments of Biostatistics, Product Development Oncology, and Translational Oncology at 
Genentech, Inc. (South San Francisco, CA) (Phillips et al., 2014).  This Phase-I/II trial was 
performed on 3 patients (Phase-I), and 9 patients (Phase-II), with Her-2-positive breast cancer 
using a dual-targeting approach that used the ADC Kadcyla combined with Pertuzumab (Perjeta) 
to prevent dimerization (activation) of the Her-2 receptor.  Dimerization of the receptor leads to 
activation of signal transduction pathways that induce cell growth.  The patients had been pre-
treated with antibody alone and chemotherapy, and the cancer had metastasized.  They were 
treated with the maximum tolerated ADC dose of 3.6 mg/kg every 3 weeks plus a standard dose 
of Perjeta.  Their data showed that the combined treatment caused only mild grade-1 and -2 
adverse events which were treatable, so the authors concluded that the combination should be 
tested further in larger trials (Phillips et al., 2014).  This combination approach, at least for the 
Her-2 situation, appears to be an interesting future application of ADCs, and is worth gaining 
additional information in IQP interviews. 
 
 
Glycoprotein NMB (gpNMB) 
 
Glycoprotein non-metastatic melanoma protein-B (gpNMB) (also called GPNMB,  
osteoactivin, dendritic cell-heparin integrin ligand, or hematopoietic growth factor inducible 
neurolinin-1) is a transmembrane glycoprotein expressed in a variety of cell types, including 
melanocytes, osteoclasts, osteoblasts, and dendritic cells (Weterman et al., 1995).  gpNMB is 
also over-expressed in aggressive melanoma, glioma, and breast cancer (Tse et al., 2006; Kuan et 
al., 2006; Rose et al., 2007).  In one study, gpNMB was detected in 71% of breast tumors (Burris 
et al., 2009), but others state it is more likely found in 40-60% of breast cancers (Bendell et al., 
2014).  An example of an antibody-drug conjugate directed against gpNMB is Glembatumumab 
vedotin (CDX-011) (formerly CR011-vcMMAE). CDX-011 consists of a fully human IgG2 
monoclonal antibody against gpNMB conjugated via a valine-citrulline linker to the potent 
microtubule inhibitor monomethyl auristatin-E (MMAE) (Naumovski and Junutula, 2010; Keir 
and Vahdat, 2012). 
 
Relatively few clinical trials have been done with ADCs against gpNMB.  In 2010, 
scientists published a Phase-I data of melanoma patients treated with CDX-011 (Hamid et al., 
2010). This study identified a dose of 1.88 mg/kg once every 3 weeks as the maximum tolerated 
dose (MTD), and recommended a Phase II study be performed in melanoma patients. 
 
In 2014, scientists at the Sarah Cannon Research Institute (Nashville, TN) published their 
Phase-I/II study of Glembatumumab vedotin in 42 patients with locally advanced or metastatic 
breast cancer (Bendell et al., 2014).  Initially, the maximum tolerated dose (MTD) was 
determined to be 1.34 mg/kg (limited by the patient’s worsening neuropathy), but the MTD was 
increased to 1.88 mg/kg (their formal Phase-II dose) after eliminating patients with baseline 
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neuropathy.  Of 19 patients tested for the presence of gpNMB-positive tumors, 16 (84%) were 
positive for the target antigen.  At the Phase-II dose, median progression-free survival was 9.1 
weeks for all patients, and 18.0 weeks for patients with gpNMB-positive tumors, indicating the 
presence of the target antigen increased patient survival without tumor growth. The authors 
concluded that CDX-011 has an acceptable safety profile, and the preliminary evidence of anti-
tumor activity is promising and requires future confirmation (Bendell et al., 2014). 
 
In 2015, this same team published their Phase-II “EMERGE” trial for Glembatumumab 
vedotin in 124 patients with advanced refractory breast cancer (Yardley et al., 2015). The 
investigators compared the ADC versus an investigator choice (IC) chemotherapy.  The data 
showed that the overall response rates were approximately equal for the two groups, but when 
analyzing a subset of patients that over-expressed gpNMB to ≥ 25% of control cells, the response 
rate increased from 9% to 30%.  The ADC drug showed less hematologic toxicity than the 
chemotherapy, but produced more rashes, pruritus (itching), neuropathy, and alopecia.  The 
authors concluded that the ADC was well tolerated, and although their primary end point was not 
met for all enrolled patients, the drug activity was pronounced in patients that strongly over-
expressed gpNMB (Yardley et al., 2015).  So, this data shows that patients having tumors that 
strongly over-express the target antigen will best benefit from the ADC treatment. 
 
 
Trop-2 
 
Trophoblast cell-surface antigen-2 (Trop-2) (also known as tumor-associated calcium 
signal transducer-2, or epithelial glycoprotein-1 antigen), is a carcinoma-associated cell surface 
glycoprotein receptor that is a member of a family with at least two other members (Linnenbach 
et al., 1993). Trop-2 is over-expressed on many types of epithelial tumors, especially the more 
aggressive types, but it is also expressed on some normal tissues (Cubas et al., 2009; Trerotola et 
al., 2013; Ambrogi et al., 2014). An antibody-drug conjugate targeting Trop-2 is Sacituzumab 
govitecan (IMMU-132) (Cardillo et al., 2011).  IMMU-132 consists of a humanized monoclonal 
antibody against Trop-2 (hRS7) linked to SN-38, the active metabolite of irinotecan, an inhibitor 
of topoisomerase-I.  Blocking topoisomerase keeps DNA from unwinding during replication, 
killing the cell. 
 
The first-in-human Phase-I clinical trial of IMMU-132 was published in 2015 by a team 
of scientists at the Indiana University Health Goshen Center for Cancer Care (Goshen, Indiana) 
(clinical trial NCT01631552) (Starodub et al., 2015).  The authors performed a dose-escalation 
experiment on 25 patients with various types of solid tumors to determine the maximum 
tolerated dose (MTD). The doses ranged from 8-18 mg/kg.  The MTD was determined to be 12 
mg/kg for one cycle of treatment, but that dose could not be continued for additional cycles due 
to the formation of neutropenia.  After extended treatments at a lower dose of 10 mg/kg, no 
level-4 (serious) adverse events were observed, and grade-3 toxicities were fatigue, neutropenia, 
diarrhea, and leukopenia.  With respect to preliminary anti-cancer activity data, 16 of the 25 
patients (64%) maintained stable disease, which was the best response observed (there were no 
complete remissions), but the authors did not pre-select their patients on the basis of Trop-2 
expression.  The authors concluded that IMMU-132 had acceptable toxicity and encouraging 
activity (Starodub et al., 2015). 
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In 2016, scientists in the Division of Hematology and Medical Oncology, Weill-Cornell 
Medical College (New York) published their Phase-I data on Sacituzumab govitecan in patients 
with metastatic platinum-resistant urothelial carcinoma (PRUC) (clinical trial NCT01631552) 
(Faltas et al., 2016).  PRUC patients currently have no FDA-approved therapies.  Of the six 
patients tested, three (50%) showed progression-free survival.  The drug was well tolerated, so 
the authors have initiated a new Phase-II study. 
 
 In addition to the published literature, several other clinical trials are ongoing for various 
ADC drugs; some these are summarized in the table below.  Some scientists have estimated that 
over 27 ADCs are undergoing clinical evaluation (Sasson and Blanc, 2013). 
 
 
Table of Antibody-Drug Conjugates in Clinical Trials as of June, 2016. 
Data obtained from: Lancet Oncology, 17: e254-e262. 
 
Drug 
Antigen 
Target 
Cytotoxic 
Payload 
Cancer 
Target 
Clinical 
Trial 
Phase 
Clinical 
Trials.gov 
Identifier 
Sacituzumab 
govitecan 
(IMMU-132) 
TROP2 SN-38 
Triple-negative 
breast cancer 
3 
NCT02574455 
NCT02161679 
Inotuzumab 
ozogamicin 
(CMC-544) 
CD22 Calicheamicin 
Acute 
lymphoblastic 
leukaemia 
3 NCT01564784 
Anetumab 
ravtansine 
(BAY 94-9343) 
Mesothelin DM4 Mesothelioma 2 NCT02610140 
Gemtuzumab 
ozogamicin 
CD33 Calicheamicin 
Acute myeloid 
leukaemia, acute 
promyelocytic 
leukemia 
2 
NCT01409161 
NCT01869803 
Depatuxizumab 
mafodotin 
(ABT-414) 
EGFR MMAF Glioblastoma 2 
NCT02573324 
NCT02343406 
Glembatumumab 
vedotin 
(CDX-011) 
GPNMB MMAE 
Osteosarcoma, 
melanoma, 
triple-negative 
breast cancer 
2 
NCT02487979 
NCT02302339 
Denintuzumab 
mafodotin 
(SGN-CD19A) 
CD19 MMAF 
Diff use large B-
cell lymphoma 
2 NCT02592876 
Mirvetuximab 
soravtansine 
(IMGN-853) 
Folate receptor 
α 
DM4 
Folate receptor α-
positive 
epithelial ovarian 
cancer 
2 NCT02631876 
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AGS-16C3F54 ENPP3 MMAF 
Renal cell 
carcinoma 
2 NCT02639182 
Rovalpituzumab 
tesirine 
(Rova-T; 
SC16LD6.5) 
DLL3 
Pyrrolobenzo-
diazepine 
Small-cell lung 
cancer 
1/2 NCT01901653 
Labetuzumab 
govitecan 
(IMMU-130) 
CEACAM5 SN-38 
Colorectal cancer, 
epithelial cancers 
1/2 NCT01605318 
BMS-986148 Mesothelin Not disclosed 
Mesothelin-
expressing 
cancers 
1/2 NCT02341625 
Humax-TF-ADC Tissue factor MMAE 
Tissue factor 
expressing tumors 
1/2 NCT02001623 
Vadastuximab 
talirine 
(SGN-CD33A) 
CD33 
Pyrrolobenzo-
diazepine 
Acute myeloid 
leukaemia 
1/2 NCT02614560 
TAK-264 (MLN-
0264) 
Guanylyl 
cyclase C 
MMAE 
Gastrointestinal 
cancers 
1/2 NCT02391038 
Milatuzumab-
doxorubicin 
(CD74-DOX) 
CD74 Doxorubicin 
Chronic 
lymphocytic 
leukaemia, non-
Hodgkin 
lymphoma, 
multiple myeloma 
1/2 NCT01101594 
 
 
 
Safety of Gemtuzumab Ozogamicin (Mylotarg)  
 
The first ADC drug approved by the FDA was Mylotarg (Gemtuzumab ozogamicin, 
GO), a humanized antibody against CD33 (frequently over-expressed on the surface of acute 
myeloid leukemia cells), linked to a cytotoxic drug of the calicheamicin class (Tsimberidou et 
al., 2006).  Mylotarg was FDA-approved on May 17, 2000 (FDA, 2000) under an accelerated 
FDA-approval process for two types of cancer patients: those over the age of 60 with relapsed 
acute myeloid leukemia (AML), and for AML patients not considered a candidate for standard 
chemotherapy (Bross et al., 2001).  However, in 2010, Mylotarg was withdrawn from the market 
when clinical trials showed it increased patient death and appeared to be no better than 
conventional therapies (Nelson, 2010; Richwine, 2010). The drug did not appear to extend 
survival for patients with previously untreated AML, and the fatality rate was 5.7% for Mylotarg 
patients compared to 1.4% for patients without the drug (Richwine, 2010). 
 
With respect to safety, during Mylotarg’s initial clinical trials, the most frequent side-
effects were relatively mild, including: shivering, fever, nausea, and vomiting.  But within a year 
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of Mylotarg’s approval in 2000, more serious adverse events were observed, including: adult 
respiratory distress syndrome (ARDS), hepatotoxicity, anaphylaxis, veno-occlusive disease 
(VOD), and death (Nelson, 2010). These serious effects resulted in the FDA requiring a “black 
box warning label” on the package (Giles et al., 2001; Wadleigh et al., 2003), and eventually 
the drug was withdrawn in 2010.  One key variable shown to be very important when observing 
VOD was whether the leukemia patient had undergone a bone marrow transplant within a short 
period of time after Mylotarg administration, in this situation 3 of 14 (21%) died of VOD 
(Wadleigh et al., 2003), compared to 14 of 119 patients (12%) who had not undergone a bone 
marrow transplant (Giles et al., 2001). 
 
Following Mylotarg’s withdrawal in 2010, four clinical trials were performed that may 
indicate the drug might be safer than originally thought. A 2012 Phase-III trial of 280 patients 
with newly acquired AML performed at 26 different hematology centers in France showed that 
Mylotarg increased the incidence of persistent thrombocytopenia from 3% to 16% (p<0.0001), 
however this did not increase patient death rate (Castaigne et al., 2012).  A 2013 Phase-III trial 
performed at the Fred Hutchinson Cancer Research Center (Seattle, WA) compared Mylotarg 
combined with “induction therapy” (daunorubicin and cytarabine) to induction therapy alone, in 
637 patients with (AML) (Petersdorf  et al., 2013).  The drug was shown to be as safe as the 
induction therapy, but provided no additional anti-cancer benefit.  A Phase-III trial in 2014 at 
Cardiff University (Cardiff, UK) performed a meta-analysis of PubMed reports supplemented 
with data obtained from individual trial lists of 3,325 AML patients (Hills et al., 2014).  The 
study compared Mylotarg combined with induction therapy versus a control of induction therapy 
alone. Their data showed that doses of Mylotarg at 3 mg/m2 produced fewer early deaths than 6 
mg/m2 yet was equally effective.  So, using the minimum effective dose appears to be an 
effective strategy.  A Phase-II study done in 2016 at the University of Texas MD Anderson 
Cancer Center (Houston, TX) of Mylotarg at a dose of 3 mg/m2 combined with decitabine (a 
DNA synthesis inhibitor) on 110 patients with either relapsed AML or high-risk myelodysplastic 
syndrome, showed that the most frequently observed side-effects were nausea, mucositis, and 
hemorrhage, each of which were treatable (Daver et al., 2016). 
 
Based on the overall safety and efficacy observed in the post-2010 clinical trials, in 
September of 2017, Pfizer re-submitted their application for FDA review as a Biologics License 
Application (BLA) (Stanton, 2017).  Pfizer expects an FDA decision on this re-submission by 
September, 2017. 
 
 
Safety of Brentuximab Vedotin (Adcetris, SGN-035) 
 
The second ADC drug approved by the FDA is Adcetris, a mouse-human chimeric 
monoclonal antibody against CD30 (Brentuximab or cAC10) linked to three to five units of the 
cytotoxic drug monomethyl auristatin-E (MMAE) (Francisco et al., 2003).  Adcetris is designed 
to treat patients with Hodgkin Lymphoma (HL) or patients with systemic anaplastic large-cell 
lymphoma (ALCL) that over-express CD30 on their tumor cells (Küppers and Hansmann, 2005).  
Adcetris is manufactured by Seattle Genetics, who received accelerated FDA-approval on 
August 19, 2011 (Genetic Engineering and Biotechnology News, 2011).   
 
With respect to safety, Adcetris has been studied alone and in combination with other 
chemotherapy agents.  The clinical trials were discussed in detail in Section-3 of the Literature 
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Review, but the safety information from them can be summarized.  A 2010 Phase-I clinical trial 
based at the University of Texas MD Anderson Cancer Center (Houston, TX) was performed on 
45 patients with refractory/relapsed HL and ALCL; the most common side-effects observed were 
fatigue, pyrexia (fever), diarrhea, nausea, neutropenia (decreased neutrophils) and peripheral 
neuropathy (irreversible tingling numbness and hyper-sensitivity to cold) (Younes et al., 2010). 
The same team performed a Phase-II trial in 2012 on 102 patients with refractory/relapsed HL 
who had received an autologous (self) stem cell transplant; the most common adverse effects 
were peripheral neuropathy, nausea, fatigue, neutropenia, and diarrhea (Younes et al., 2012).  
Another Phase-II trial was performed in 2012 at the Fox Chase Cancer Center (Philadelphia, 
PA) in 58 patients with elapsed/refractory anaplastic large-cell lymphoma (ALCL) (Pro et al., 
2012).  The adverse events observed in this trial included neutropenia (decreased neutrophils) 
(21%), thrombocytopenia (decreased platelets) (14%), and peripheral sensory neuropathy (12%) 
(all at grade-3 or -4).  In 2013, the MD Anderson team mentioned earlier also performed a 
Phase-I trial on 51 newly diagnosed patients with HL, using either Adcetris alone or in 
combination with standard treatments (Younes et al., 2013). The adverse events observed most 
frequently were grade-1 or -2 (mild), but occurred in 41% of all patients. The authors stated that 
an “unacceptable” number of patients showed pulmonary toxic effects (44%) when the ADC was 
combined with a chemotherapy containing bleomycin, so the authors recommended omitting 
bleomycin from the combination (Younes et al., 2013), and this safety recommendation is 
followed to this date. 
 
Thus, for Adcetris, several phase-I and II studies have been performed, and they show 
that the most common adverse reactions are neutropenia (decreased neutrophils), 
thrombocytopenia (decreased platelets), and peripheral sensory neuropathy. An independent 
review of Adcetris drug safety by scientists at the Comprehensive Cancer Center at the 
University of Alabama at Birmingham (Vaklavaas and Forero-Torres, 2012) concluded that the 
drug had an overall manageable toxicity profile, but that peripheral neuropathy remained an 
important consideration, so this may limit long-term administration of the drug.  On January 13, 
2012, the FDA announced that Adcetris had been linked to two cases of progressive multifocal 
leukoencephalopathy (defective formation of myelin), so the FDA now requires the manufacturer 
to add a “black box warning” to the drug packaging warning of this risk. 
 
 
Safety of Trastuzumab Emtansine (Kadcyla, T-DM1) 
 
The third ADC drug approved by the FDA is Kadcyla (Trastuzumab emtansine, T-
DM1).  The antibody portion of the drug was developed by Genentech (a subsidiary of Roche), 
and the linker and toxin were developed by ImmunoGen (Waltham, MA) (Pollack, 2013).  
Kadcyla contains a humanized mouse antibody (Trastuzumab or Herceptin) against surface 
protein Her2 linked to the cytotoxic drug emtansine (DM-1) that binds microtubules preventing 
their polymerization (Niculescu-Duvaz, 2010; Lopus, 2011; LoRusso et al., 2011). Kadcyla’s 
accelerated FDA-approval occurred on February 22, 2013, to treat women with Her2-positive 
metastatic breast cancer that does not respond to antibody treatment alone or to chemotherapy 
(National Cancer Institute, 2013; Pollack, 2013; Drugs.com, 2013). 
 
With respect to safety, much information has been gained on Kadcyla from clinical trials.  
The first Kadcyla clinical trial was performed in 2010 by scientists at the Dana-Farber Cancer 
Institute (Boston, MA) (Krop et al., 2010).  This team reported the findings of their Phase-I 
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dose-escalation study of breast cancer patients who relapsed after receiving antibody therapy 
alone. Their data showed that thrombocytopenia became dose-limiting at the highest dose tested 
(4.8 mg/kg), and concluded that the maximum tolerated dose (MTD) was slightly lower at 3.6 
mg/kg.  The most common drug-related side-effects were thrombocytopenia, elevated 
transaminases, fatigue, nausea, and anemia, which the authors concluded were mild and 
reversible.  In 2011, the same team did a Phase-II study of 112 breast cancer patients who had 
relapsed after receiving antibody therapy alone (Burris et al., 2011). They stayed with the 
previously identified maximum tolerated dose of 3.6 mg/kg once every 3 weeks. The drug 
appeared to be well tolerated; the most frequent side-effects were mild (grade-1 or -2) and 
treatable.  Less frequent side-effects were grade-3 (serious) problems such as hypokalemia 
(lowered serum potassium levels) (8.9%), thrombocytopenia (8.0%), and fatigue (4.5%), 
although these were in a small minority of patients. The authors concluded that the treatment was 
generally well tolerated.  In 2012, scientists at the Sunnybrook Odette Cancer Center (Toronto) 
performed a Phase-III trial on 991 patients with refractory breast cancer (Verma et al., 2012), 
comparing Kadcyla to chemotherapy. Kadcyla decreased the grade-3 (serious) adverse events 
from 57% to 41%.  Thrombocytopenia and liver damage were higher with Kadcyla, while 
diarrhea, nausea, vomiting, and erythrodysthesia were higher with the chemotherapy.  The 
authors concluded that Kadcyla significantly improved progression-free and overall patient 
survival, with less toxicity than chemotherapy.  In 2014, the same team mentioned above at 
Dana-Farber Cancer Institute (Boston) published their Phase-III data of 602 patients in 22 
countries for patients with refractory Her2-positive advanced breast cancer (Krop et al., 2014).  
They compared two patient groups: Kadcyla versus a physician’s choice chemotherapy.  Their 
data showed that Kadcyla decreased the level-3 adverse events from 43% to 32%, increased 
thrombocytopenia (5% versus 2%), but lowered neutropenia, and diarrhea.  Also in 2014, 
another team of researchers at the Mayo Clinic (Jacksonville, FL) published their Phase-II study 
on patients with previously untreated Her2-positive breast cancer, comparing patients treated 
with Kadcyla (N=67) to patients receiving antibody plus docetaxel (N=70) (Perez et al., 2014).  
They found that the side-effects were mostly manageable, and that the risk of cancer progression 
was low when the patients had high levels of Her-2 target antigen.   
 
Thus, Kadcyla comes with its own set of side-effects which must be weighed against the 
potential benefit of blocking the breast cancer growth.  During clinical trials, the drug 
manufacturer claims that the most common adverse effects seen were fatigue, nausea, muscle 
pain, thrombocytopenia (low platelet counts), headache, and constipation (Kadcyla Prescribing 
Information, 2013), however others showed that more severe adverse-effects can include liver 
damage, liver failure, nodular regenerative hyperplasia, heart damage, lung disease, and 
peripheral neuropathy (Amiri-Kordestani et al., 2014).  Most of the scientists seem to agree that 
the adverse effects were better tolerated than those caused by standard chemotherapies. In the 
U.S., Kadcyla packaging carries a black box warning for liver toxicity, heart damage, and fetal 
harm if given to pregnant women. 
 
 
Section-3 Conclusions 
 
This section of the Literature Review summarized some of the clinical trial data for 
various ADC drugs.  The focus was predominately on drugs having the largest numbers of 
clinical studies, but a few other ADCs were also discussed.  As expected, the two current FDA-
approved drugs (Adcetris and Kadcyla) showed the strongest data in clinical testing, showing 
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relatively mild and treatable adverse-effects, and strong activity.  Neutropenia (low neutrophil 
count) was almost universally observed among all the clinical trials as an adverse event, but it 
was not fatal.  Almost all of the clinical trials were performed on patients who had relapsed from 
cancer, or whose cancer did not respond to previous therapies; only one trial was performed on 
newly diagnosed patients. Thus, the overall patient prognosis was expected to be very low.  
Doubling patient survival rate, for example from an expected few months (controls) to almost a 
year (ADC), was deemed significant.  A few patients showed complete remission, although most 
studies at best showed stable tumor progression. 
 
Two best practices were identified in this review of the literature which may be worth 
following up in interviews.  The first pertains to measuring chromosome cytogenetic 
abnormalities in the patients.  Cytogenetic abnormalities include chromosome inversions, 
insertions, translocations, etc. Some of the Mylotarg clinical trials for leukemia patients showed 
that the survival benefit of the drug was most pronounced in patients with no additional 
cytogenetic abnormalities (other than the initial abnormality causing the leukemia).  While in 
patients with adverse cytogenetics, Mylotarg provided no detectable benefit. This may imply that 
patients with additional chromosomal inversions or translocations incur new changes in cellular 
biochemistry that increase drug resistance. So, perhaps in best practice, patients should be 
monitored for cytogenetic abnormalities to help determine which patients are most likely to 
improve with ADC treatment. 
 
 The second best practice observed in the clinical trial literature was the determination of 
the extent of over-expression of target antigen in the patients.  In several trials, patients with 
confirmed high expression levels of the target antigen showed higher response rates to the ADC, 
and the risk of cancer progression was lower.  Antigen levels were assayed by immuno-
histochemistry, reverse transcriptase polymerase chain reaction (RT-PCR), or in situ 
hybridization). Thus, pre-analyzing the patient’s tumor to determine the extent of antigen 
expression might help predict which patients are most likely to benefit from the ADC treatment. 
A patient whose tumor no longer expresses the target antigen obviously will not be targeted by 
the ADC drug.  This practice of assaying target expression levels should be continued.  If a 
patient no longer expresses the target antigen, another drug should be chosen. 
 
 With respect to safety, from the clinical trial data it can be seen that the side-effects 
caused by ADC drugs are not trivial. Of three ADC drugs approved by the FDA, one has been 
withdrawn from the market due to patient deaths and an apparent lack of efficacy. And all three 
FDA-approved drugs carry “black box warning labels” on their packaging, informing physicians 
of the most serious side-effects. The follow-up interviews will help weigh the adverse effects of 
the ADCs against the side-effects of standard chemotherapy treatments currently used to treat the 
cancer, and will also be weighed against the very poor prognosis of patients with these types of 
relapsed cancers who have few other options.  But overall, the ADC side-effects appear to be 
more manageable than those caused by current chemotherapy treatments, and are far better than 
the very poor prognosis of their relapsed cancer.   
 
However, it remains unclear from the literature what causes the ADC side-effects.  Are 
the adverse reactions caused by expression of the target antigen in normal tissues in addition to 
the cancer?  Or are the side-effects caused by non-target effects, such as the release of the 
cytotoxic cargo into the surrounding cells?  In the next phase of this IQP, information obtained 
from interviews may help resolve this issue, and will also help validate our conclusion that the 
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side-effects are relatively manageable. In addition, interviews with the researchers might help 
determine whether the benefits observed of slowing or eliminating cancer outweigh the negative 
side-effects, especially in view of the poor prognosis of a patient with recurring cancer. The 
researchers who design ADCs might also suggest directions for future research.  
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Section-4: ADC Legalities 
Austin LaBastie 
 
  
Currently, three different antibody-drug conjugates (ADCs) have been approved by the 
U.S. Food and Drug Administration (FDA) for treating various forms of cancer.  One of the 
ADC drugs was subsequently withdrawn from the market.  This section of the Literature Review 
focuses on the approval process for ADC drugs, and attempts to identify remaining hold-up steps 
for other ADC drugs. 
 
 
Summary of the FDA Drug Approval Process 
 
 The purpose of FDA approval is to help protect consumers from drugs that harm the 
consumer or are ineffective. Drug development and approval is a complex process involving 
several steps (Lipsky and Sharp, 2001); these steps are summarized in Table-I: 
 
Table-I:  Summary of the FDA Approval Process 
Adapted from: http://www.phrma.org/charts/approval.html 
 
Pre-Clinical Testing  →  File IND  →  Phase-I  →  Phase-II  →  Phase-III  →  File NDA 
 
Phase: Preclinical Phase-I Phase-II Phase-III 
Subjects: 
Lab and animal 
studies 
20-100 
healthy 
volunteers 
100-300 patient 
volunteers 
1,000-3,000 patient 
volunteers 
Purpose: 
Assess safety 
and preliminary 
activity 
Determine 
safety and 
dosage 
Evaluate 
effectiveness 
and side-effects 
Verify effectiveness 
and monitor long-
term side-effects 
Time Course: 
Prior to the 
FDA 
Modernization 
Act of 1997 
Year-1 and -2 Year-3 Year-4 and -5 Year-6, -7, -8 
% Drugs 
Passed: 
100% 70% of INDs 33% of INDs 27% of INDs 
 
The first phase of the FDA approval process is pre-clinical testing.  The FDA requires 
researchers to perform animal tests before humans are exposed to a new drug. Prior to the 
modernization act (discussed below), this stage typically lasted 1-2 years, and, for purposes of 
our ADC discussion, includes testing in vitro against cultured cancer cell lines, testing in mice 
engrafted with human cancer cells (xenograft mice), and (less frequently) testing in monkeys. 
The main objectives of this stage of the process are to obtain animal data on drug safety and to 
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obtain preliminary data on drug activity.  The tests must show that the drug is not toxic at the 
doses most likely to be effective.  
 
If the pre-clinical data look promising, the drug manufacturer files an Investigational 
New Drug (IND) Application with the FDA. This application includes drug chemical 
composition and manufacturing data, animal test results (including safety), the rationale for 
testing a new compound in humans, strategies for protecting human volunteers, and a plan for 
clinical testing (Stave and Joines, 1997). 
 
If the FDA approves the IND, the process heads into Phase-I.  This stage focuses on the 
safety and pharmacology of the drug in humans (Lipsky and Sharp, 2001). Typically, various 
doses of a drug are given to a small group of 20-100 healthy volunteers who are then closely 
supervised for adverse effects. In cases of severe or life-threatening illnesses, volunteers with the 
disease may be used in place of healthy volunteers. The Phase-I study begins with a small dose, 
which is then gradually increased until serious adverse effects are seen. On average, about 70% 
of Phase-I drugs are found to be safe enough to enter Phase-II. 
 
Phase-II studies are designed to obtain data on drug effectiveness. To avoid 
unnecessarily exposing a human volunteer to a potentially harmful drug, Phase-II experiments 
use the least number of patient volunteers to gain sufficient statistical power to determine 
efficacy. On average, Phase-II trials use 100-300 patients suffering from the disease the drug is 
designed to treat.  Variables tested in this phase can include optimum drug dose, best method of 
delivery (IV, oral, etc.), and dosing interval, all assayed while focusing on safety (Walters, 1992; 
Heilman, 1995).  Only 33% of IND drugs make it past this stage of the process, either because 
they turn out to be ineffective, or they have serious safety problems that were not apparent in 
Phase-I. 
 
During Phase-III, researchers attempt to confirm their previous Phase-II findings using a 
larger group of patients. This stage can last from 2 to 10 years, and can involve thousands of 
patients at multiple sites. Phase-III focuses more precisely on defining optimum dosage, while 
continuing to focus on safety. In fact, throughout the entire clinical process, safety comes first, so 
the FDA and investigators are constantly in communication with each other (Lipksy and Sharp, 
2001). However, when analyzing large patient populations, often the earlier encouraging Phase-I 
and II data fail to replicate, and only 27% of IND drugs make it past Phase-III. 
 
If the Phase-III data look promising, the drug manufacturer files a New Drug 
Application (NDA) with the FDA. An NDA contains all the preclinical and clinical information 
obtained during the testing phase, including drug chemical composition, manufacturing 
procedures, toxicity, human pharmacokinetics (half-life and bio-distribution), clinical trial results 
(within the U.S. and elsewhere), and proposed labeling (Lipksy and Sharp, 2001). The FDA 
either approves the NDA, rejects the NDA, or requests additional data before making a decision.  
If the drug is not approved, the applicant is given the reasons why, including information that 
could be provided by the manufacturer to allow acceptance. Sometimes the FDA makes a 
tentative approval recommendation, requesting that a minor deficiency or labeling issue be 
corrected before formal approval.  
 
Following acceptance (approval) of the NDA, the drug can be marketed.  Sometimes, the 
FDA requests a Post-Marketing Study (Phase-IV) to provide more data if something remains 
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unclear or if new problems are identified upon further use of the drug.  A Phase-IV might also be 
requested to study the drug in a specific population of individuals, such as high-risk individuals, 
pediatric patients, or elderly patients, or to follow the long-term use of the drug (Leonard, 1994).  
As a drug gains wider usage, a critical element of the approval is the “Medwatch requirement” 
stating that physicians must report any observed adverse complications at quarterly intervals for 
the first 3 years after a drug’s approval. 
 
The overall FDA approval process prior to the enactment of the FDA Modernization Act 
of 1997 (see below) took about 8-12 years (Heilman, 1995), but the review time has now been 
shortened to about 12.6 months for normal drugs, and 6 months for an accelerated review (see 
below) (Drugs.com, 2013).  A 1997 overview of the pharmaceutical industry performed by 
scientists at Glaxo Wellcome Inc. (Research Triangle Park, North Carolina) estimated the cost of 
developing a new drug to average $359 million (Stave and Joines, 1997). 
 
 
Expediting the Drug Approval Process  
  
All three of the current FDA-approved ADC drugs (Mylotarg, Adcetris, and Kadcyla) 
(discussed below) received FDA approval under an accelerated review process.  Accelerated 
reviews are sometimes granted when no other alternative drugs are available to treat a particular 
disease, or when the clinical trial data are very strong (Drugs.com, 2013). The Prescription 
Drug User Fee Act of 1992 (PDUFA) was designed to help shorten the FDA review time by 
allowing the FDA to collect user fees from IND filers to help enhance the review process 
(Walters, 1992). The act requires the FDA to review a “standard drug application” (if the drug 
is similar to other drugs already on the market) within 12 months, and requires review of a 
“priority drug application” (if the drug provides important new advances for treating a disease 
not available with other drugs) within 6 months. As with other reviews, the FDA often interacts 
with the drug manufacturer to obtain more information. 
 
 In addition, the Food and Drug Administration Modernization Act of 1997 (FDAMA) 
extended the use of the user fees, and streamlined the drug approval process (FDAMA, 1997). 
The act increases patient access to experimental drugs, and allows drug manufacturers to provide 
peer reviewed papers on diseases not included in the original IND application to expand the drug 
uses to other diseases.  Proponents of the accelerated review process argue it works fairly well; 
prior to the act, the average review time was 8-10 years, and in 1999 after passage of the act, the 
average review time lowered to 12.6 months.  As part of an accelerated review, the FDA requires 
the Phase-IV post-market study to confirm the accelerated data.   
 
Critics of the updated FDA approval process argue that allowing drugs to be approved 
based on a single clinical trial, expanding the use of special accelerated reviews, and allowing 
the use of alternative data end points, have allowed dangerous drugs to be approved (Lurie and 
Sasich, 1999). But others argue there is no hard evidence of increased drug risks following the 
changes (Friedman et al., 1999). 
 
 
 
 
78 
Gemtuzumab Ozogamicin (Mylotarg)  
 
The first ADC drug approved by the FDA was Mylotarg® (Gemtuzumab ozogamicin).  
Mylotarg is a humanized antibody against protein CD33 (frequently over-expressed on the 
surface of acute myeloid leukemia cells), linked to a cytotoxic drug of the calicheamicin class.   
Pfizer acquired Mylotarg when it bought Wyeth in October 2009 (Richwine, 2010). 
 
Based on the promising initial data observed in preliminary clinical trials, Mylotarg was 
FDA-approved on May 17, 2000 under an accelerated FDA-approval process (FDA, 2000).  It 
was approved for treating patients over the age of 60 with relapsed acute myeloid leukemia 
(AML), or for other AML patients not considered a candidate for standard chemotherapy (Bross 
et al., 2001). The approved dose was 9 mg/m2 intravenous over 4 hours, repeated in 2 weeks. 
 
As with all anti-cancer drugs, ADCs have side-effects.  These adverse events are weighed 
against the potential benefit of the drug. The most frequent side-effects initially observed with 
Mylotarg were relatively mild, including shivering, fever, nausea, and vomiting.  But within a 
year of Mylotarg’s initial approval, more serious adverse events were observed, including adult 
respiratory distress syndrome (ARDS), hepatotoxicity, anaphylaxis, veno-occlusive disease 
(VOD), and death (Nelson, 2010). The appearance of these more serious events resulted in the 
FDA requiring a “black box warning label” on Mylotarg’s package (Giles et al., 2001; 
Wadleigh et al., 2003).  
 
In June 2010, Mylotarg was voluntarily withdrawn from the market when additional 
clinical trial data and post-marketing experience showed the drug increased patient death and 
was no better than conventional therapies (Nelson, 2010; Richwine, 2010).  Mylotarg was the 
first drug withdrawn after being approved under the FDA’s accelerated review process 
(Richwine, 2010).  The drug did not appear to extend survival for patients with previously 
untreated AML, and the fatality rate was 5.7% for Mylotarg patients compared to 1.4% for 
patients without the drug (Richwine, 2010). 
 
In September 2017, almost 7 years after withdrawing it from the market, Pfizer 
resubmitted their application for FDA review as a Biologics License Application (BLA) 
(Stanton, 2017).  The resubmission is based on favorable data obtained from a recent randomized 
Phase-III study (ALFA-0701) in 280 adult patients with newly diagnosed AML, and a meta-
analysis of over 3,000 patients from some of the earlier trials.  Pfizer expects an FDA decision 
on this re-submission by September, 2017. 
 
 
Brentuximab Vedotin (Adcetris, SGN-035) 
 
The second ADC drug approved by the FDA is Adcetris®.  In North America Adcetris is 
marketed by Seattle Genetics Inc., and in the rest of the world by Takeda Oncology. It consists of 
a mouse-human chimeric monoclonal antibody against CD30 (Brentuximab or cAC10) linked 
via a cathepsin-cleavable linker to three to five units of the cytotoxic drug monomethyl 
auristatin-E (MMAE) (Francisco et al., 2003). MMAE very strongly binds tubulin and prevents it 
from polymerizing, leading to cell cycle arrest.  The antibody portion of the ADC is produced by 
mammalian Chinese Hamster Ovary (CHO) cells, while the linker and MMAE are produced by 
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chemical synthesis. Adcetris is administered intravenous (IV), and its half-life is about 4-6 days 
as it is slowly cleared by the liver.  Adcetris is designed to treat patients with Hodgkin 
Lymphoma (HL) and patients with systemic anaplastic large-cell lymphoma (ALCL). Protein 
CD30 often occurs on the surface of cells of these tumor types, but only rarely on normal cells 
(Küppers and Hansmann, 2005).   
 
The clinical trials for Adcetris were discussed earlier in the Literature Review, but here 
suffice it to say that the drug has undergone numerous trials, showing high efficacy and 
relatively manageable side-effects. For example, in a 2010 clinical trial of HL patients (Seattle 
Genetics Press Release, 2010), 34% of the patients showed complete remission, 40% showed 
partial remission, and 94% showed tumor reductions. With respect to safety, Adcetris has been 
studied both alone and in combination with other chemotherapy agents.  In two phase-II trials, 
the most common adverse reactions were chemotherapy-induced peripheral neuropathy 
(irreversible tingling numbness and hyper-sensitivity to cold), neutropenia (drop in neutrophil 
count), fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, fever, rash, 
thrombocytopenia (decreased platelet count), cough, and vomiting (Vaklavas and Forero-Torres, 
2012).  
 
Seattle Genetics submitted an FDA application on February 28, 2011, to treat HL and 
ALCL patients (Fierce Biotech, 2011), and on August 19, 2011, the drug was granted an 
accelerated FDA approval (Genetic Engineering and Biotechnology News, 2011).  However, on 
January 13, 2012, the FDA announced that Adcetris had been linked to two cases of progressive 
multifocal leukoencephalopathy (defective formation of myelin), so the FDA now requires the 
manufacturer to add a “black box warning” to the drug packaging warning of this risk. 
 
Recently, Seattle Genetics and Bristol-Myers Squib partnered to test a drug combination 
therapy of Bristol-Myers’ Nivolumab (Opdivo®) (a drug that blocks checkpoint inhibitor PD-1 
to stimulate the immune system) and Seattle Genetics’ ADC Adcetris® in patients with relapsed 
or refractory classical Hodgkin lymphoma (HL). The initial results of a Phase-I/II trial were 
reported at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, 
December 3-6, 2016 (ADC Review, 2017). The drug combination showed a 62% complete 
response rate with an acceptable safety profile.  According to Alex Herrera, M.D., lead trial 
investigator and assistant professor at the City of Hope Medical Center (Duarte, CA), “The 
[combination approach] is a promising investigational approach as it combines a targeted therapy 
with a therapy designed to activate the immune system, and the combination may have 
synergistic activity. The preliminary results are compelling and support further exploration of 
this novel regimen, free of traditional chemotherapy” (ADC Review, 2017).  On June 2, 2017, 
the two companies provided an update on their collaboration at the 53rd annual meeting of the 
American Society of Clinical Oncology, stating they plan to initiate a Phase-III trial of their drug 
combination beginning mid-2017 (ADC Review, 2017).  
 
 Adcetris has also been approved in Europe.  In Europe, drugs are approved by the 
European Medicines Agency (EMA).  In 2009, the drug initially received approval for use as an 
“orphan product” (a drug that is used to treat a disease that affects no more than 5 people in 
10,000) (Hofland, 2011).  But with favorable clinical data, in 2016 it was given EMA marking 
authorization.  The basis of the favorable review by the EMA was discussed in a 2016 European 
Public Assessment Report (EPAR) for Adcetris (European Medicines Agency, 2016).  The report 
stated they found Adcetris beneficial for HL and ALCL patients whose cancer had come back or 
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had not responded to previous therapy, but they also noted a relatively limited amount of clinical 
data and a lack of true controls (untreated patients) (although this is normal in cancer trials). The 
EMA strongly factored in the drug’s relatively manageable adverse effects, the patient’s poor 
expected outcomes during relapse, and the lack of other suitable drug treatments for relapsed 
patients. So, the EMA concluded that the benefits are greater than the risks, and Adcetris was 
given marketing authorization, although they await additional data on the long-term effects of the 
drug.  The drug will be reviewed annually by the EMA in view of any new information 
(European Medicines Agency, 2016). 
 
 
Trastuzumab Emtansine (Kadcyla, T-DM1) 
 
The third ADC drug approved by the FDA is Kadcyla® (Trastuzumab emtansine). The 
antibody was developed by Genentech (a subsidiary of Roche), the linker and toxin were 
developed by ImmunoGen (Waltham, MA), and the complete ADC is manufactured by Lonza 
(Pollack, 2013).  Kadcyla is ImmunoGen’s first FDA-approved product, although they have been 
working on ADC drugs for over three decades.  Kadcyla is a humanized mouse antibody against 
surface protein Her2 (Trastuzumab or Herceptin) linked to cytotoxic drug emtansine (DM-1) 
that binds microtubules preventing their polymerization (Niculescu-Duvaz, 2010; Lopus, 2011; 
LoRusso et al., 2011).   
 
Kadcyla underwent an accelerated 6-month FDA priority review, reserved for therapies 
for diseases with no alternative treatments, or that provide significant improvements over other 
marketed products (Drug.com, 2013).  In 2010, Genentech initially applied for accelerated FDA 
review on the basis of the results of a single Phase-II study, but on August 26th, 2010, the FDA 
refused to review it in accelerated mode because all available treatment choices had not yet been 
tested in their patients (News-Medical.net, 2010).  So, Genentech continued their studies with an 
amended Phase-III trial after treating the patients with other treatment options.  Kadcyla was 
approved on February 22, 2013, based on the positive clinical trial data of women with 
advanced Her2-positive breast cancer who were already resistant to antibody treatment alone 
(Verma et al., 2012).  In those studies, the data showed that Kadcyla improved the median 
patient survival by 5.8 months (30.9 months versus 25.1 months) compared to standard 
chemotherapy (National Cancer Institute, 2013; Pollack, 2013; Drugs.com, 2013). 
 
Kadcyla comes with its own set of side-effects which must be weighed against the 
potential benefit of blocking the breast cancer growth.  During clinical trials, the most common 
adverse effects seen were fatigue, nausea, muscle pain, thrombocytopenia (low platelet counts), 
headache, and constipation (Kadcyla Prescribing Information, 2013). Less common, but more 
severe, adverse effects included liver damage, liver failure, nodular regenerative hyperplasia, 
heart damage, lung disease, and peripheral neuropathy (Amiri-Kordestani et al., 2014).  
However, the adverse effects were tolerated better than those with standard chemotherapies. In 
the U.S., Kadcyla packaging carries a black box warning for liver toxicity, heart damage, and 
fetal harm if given to pregnant women. 
 
The high cost of ADC drugs is an important issue for consumers, and is perhaps worth 
pursuing in IQP interviews.  In the U.K., the National Institute for Health and Care Excellence 
(NICE) and the National Health Service England (NHS) determine whether a particular drug 
remains on the Cancer Drugs Fund (CDF) list of medicines paid by the government.  The normal 
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CDF cut-off for an end-of-life drug like Kadcyla is about £50,000 per year (The Guardian, 
2015). This is equal to about £30,000 per quality-adjusted life years (NICE, 2014).  Roche’s 
initial price was high, a reported £90,000 per patient per year (Pollack, 2013), nearly double the 
CDF cut-off, placing the drug in jeopardy for being removed from the list. In 2014, a draft 
guidance document produced by NICE concluded that Kadcyla’s price was too high for the CDF 
list (NICE, 2014). But in 2015, Roche compromised and lowered their price to £5,900 per 
month; for a typical 9.6 month treatment duration, this new price would be about £56,640, 
bringing the drug close to the CDF cut-off. So, the NICE and NHS England committees for now 
have left Kadcyla on the list (The Guardian, 2015). Hopefully, other pharmaceutical companies 
will follow Roche’s lead of cutting drug prices to be more affordable. 
 
Other ADC Drugs 
 
 Not all ADC drugs are being actively developed by biotech companies.  In some cases, 
the clinical trial data that initially looked promising did not repeat in larger trials, so the company 
stops developing the drug.  For example, in 2015 Sanofi began trimming its oncology division, 
abandoning the ADC drug SAR-3419 (Garde, 2015). SAR-3419 targets CD19 on the surface of 
diffuse large B-cell lymphomas and other blood cancers.  In 2014, the SAR-3419 Phase-II data 
looked promising, but after a series of setbacks, Sanofi decided to cut about 100 researchers from 
their oncology division, merging the remaining researchers within their global R&D divisions 
(Garde, 2015). 
 
 Another example of an ADC drug with mixed clinical trial data is the CD22-targeting 
Inotuzumab ozogamicin, used to treat non-Hodgkin’s lymphoma (NHL). On May 20, 2013, 
Pfizer announced they were discontinuing their Phase-III study of this drug because it did not 
meet the main objective of improving overall patient survival (Pfizer Press Release, 2013).  The 
company stated that there are over 70 different types of lymphoma, and they are trying to 
determine which type of lymphoma is best treated by Inotuzumab.  They did not mention 
whether they monitored their phase-III patients for over-expression of the target CD22 prior to 
treatment, although doing so appears to be a best practice. 
 
 
Section-4 Conclusions 
 
 This part of the Literature Review summarized the FDA approval process for ADC drugs, 
and discussed the three ADCs with FDA approval. All three of the FDA-approved ADC drugs 
were reviewed under an accelerated program, either due to strong and clear clinical data better 
than other available treatments, or because the drugs provided a treatment for a disease with no 
other options available at the time of the review.  Based on the information found in this section 
of the Literature Review, we believe that the three current FDA-approved ADC drugs have 
clearly documented serious side-effects, but they mostly appear to be manageable, transient, and 
less prevalent than those seen with current chemotherapy treatments.  We also believe that the 
patient’s extremely poor prognosis during relapse of the cancer should strongly factor into 
decision, and far outweighs the relatively minor adverse effects.  We predict that drug efficacy 
likely is the most important variable for FDA approval for ADCs, as a lack of it resulted in the 
withdrawal of Mylotarg.  We plan to pursue this point of improving ADC efficacy in IQP 
interviews. We also showed that a current ADC trend appears to be the testing of drug 
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combinations, as demonstrated by combining the ADC Adcetris with the immune checkpoint 
inhibitor Opdivo®, and will get further information on this promising combination approach in 
interviews.  
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Section-5: ADC Recent Advances and Future Directions 
Sean St. Pierre and Alex Kolodziejczak 
 
  
As discussed in the previous sections of the Literature Review, ADC drugs are an 
exciting advance in cancer therapeutics.  ADCs link a potent cytotoxic cancer-killing drug (the 
cargo) to an antibody that targets the cargo to a specific antigen which is over-expressed on the 
surface of the tumor.  But ADC drugs are not perfect. In all clinical trials performed to date, 
ADCs have caused side-effects in the patient, and in some cases the ADC is ineffective against 
the cancer.  In addition, some scientists have indicated that the future approval of numerous 
ADCs under development might depend on improving their clinical performances to produce 
stronger effects that warrants each drug’s use (Panowski et al., 2014).  Thus, there is room for 
continued improvement of ADC drugs.  The purpose of this section of the Literature Review is 
to summarize some of the problems seen with first generation ADC drugs, discuss some design 
advances found in the new second-generation ADCs, and discuss future directions for further 
ADC improvements. 
 
 
Comparison of First and Second Generation ADC Drugs 
 
 First generation ADC drugs (1o-ADCs) as originally developed came with a variety of 
problems, including lack of efficacy and adverse side-effects, so much research has gone into 
creating second-generation ADCs (2o-ADCs) with superior properties (Thomas et al., 2016). 
Table-I below compares some of the properties of 1o-ADCs and 2o-ADCs.  1o-ADCs usually 
contained mouse monoclonal antibodies against the target protein. But injecting a mouse 
antibody into human patients in some cases stimulated an immune response against the drug, 
lowering drug effectiveness. 2o-ADCs contain either mouse-human chimera antibodies or 
humanized mouse antibodies that produce less of a response in patients.  Using fully human 
antibodies, produced by mammalian cell culture, should produce even less of an immune 
response in the patient. 1o-ADCs also have short half-lives in the blood, releasing their toxic 
payload too soon into the circulation instead of in the tumor cell.  In some cases the linkers used 
released the payload too early, before reaching the tumor cell.  2o-ADCs use improved linker 
chemistries (such as the use of disulfide linkages, dipeptide linkages, and hydrazine linkages) to 
hold the payload tighter, releasing it only in the acidic environment of the internalization vesicle.  
In addition, 1o-ADCs use first generation cytotoxic payloads (such as doxorubicin, vinblastine, 
or methotrexate) with inhibitor concentration-50 values (IC50) in the micromolar range, while 2
o-
ADCs use newly designed payloads (such as Calicheamicin, Maytansine derivatives like DM1, or 
Auristatins like MMAE) that are far more toxic, with IC50’s in the nanomolar range (they have the 
same effectiveness at 1000-fold less concentrations).  
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Table-I: Comparison of First and Second Generation ADCs 
Adapted from Thomas et al., 2016. 
 
Property 
First Generation 
ADCs 
Second Generation 
ADCs 
Future ADCs 
Antibody: Mouse Antibody 
Mouse/Human Chimera 
or Humanized Mouse 
Antibodies 
Human Antibody 
Immunogenicity: Highly Immunogenic 
Decreased 
Immunogenicity 
Non-Immunogenic 
Half-Life: Unstable in circulation Longer Half-Life Longer Half-Life 
Linker: 
Drug release 
prematurely into the 
blood, low drug release 
inside cancer cell. 
Less drug release into 
blood and stronger 
release inside cell: 
Disulfide Linkages, 
Dipeptide Linkages, 
Hydrazone Linkages 
Structures that are more 
specifically lysed in the 
lysosomal environment 
Cytotoxic Cargo: 
Micromolar IC50: 
Doxorubicin 
Vinblastine 
Methotrexate 
Nanomolar IC50: 
Calicheamicin 
Maytansines: DM1 
Auristatins: MMAE 
Cargos with different 
mechanism of actions 
to kill the tumor cell in 
a variety of ways. 
 
 
ADC Problems 
 
Several key steps must occur for ADCs to work properly (Figure-1) (Loganzo et al., 
2016).  These steps include: movement of the ADC through the patient’s circulation without 
losing its toxic cargo, binding of the ADC to the target antigen on the surface of the tumor cell, 
lack of targeting of the ADC to normal cells, internalization of the ADC into an endocytic 
vesicle, binding of the endocytic vesicle to a lysosome to acidify the compartment and release 
enzymes into the endosome, degradation of the linker and sometimes antibody to release the 
toxic cargo, movement of the cargo into the cytoplasm, and targeting of the cargo to a cellular 
component such as DNA or tubulin to prevent cell division.  Inefficient function of any one of 
these steps can create an inactive drug.  Thus, each of these steps presents a research opportunity 
to improve second-generation ADCs relative to early versions of the drugs.   
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Figure-1: Diagram of Mechanisms of Resistance to ADC Drugs and Potential 
Solutions.  Shown in red numbers are several key steps where a tumor cell can adapt to 
or inactivate an ADC therapy.  Each of these steps is discussed below in the text.  The 
purple star symbol denotes the drug carried by the ADC.  Black initials denote: ADC, 
antibody-drug conjugate; CAV, caveolae; EE, early endosome; LE, late endosome; LY, 
lysosome; MT, microtubules; MITO, mitochondrion; NUC, nucleus.  Figure was adapted 
by DA from:  Loganzo et al., 2016. 
 
 
Problems independent of the tumor itself include: premature loss of the cargo drug into 
the blood, and poor pharmacokinetics (ADME) (poor absorption, distribution, metabolism, 
excretion) (Kraynov et al., 2016). In other cases, the environment surrounding the tumor limits 
access to large molecules like ADCs.  These environmental changes might include the increased 
formation of vascular barriers such as basement membranes or increased formation of 
extracellular matrix.  In other cases, the tumors themselves become resistant to the ADC 
treatment by altering one or more of the steps needed by ADCs to kill the cell (Loganzo et al., 
2016).  Each of these key steps is discussed below, along with a potential solution. 
 
1. Lowered Surface Antigen Expression: The ADC therapeutic molecule must 
successfully bind a tumor-specific antigen on the surface of the tumor cell.  As a tumor 
matures in the patient, if it lowers expression of the surface antigen, it lowers binding of 
the drug to the cell (Loganzo et al., 2015a).  For example, DNA changes that occur as a 
tumor evolves in a patient could result in down-regulation of a surface protein.  This has 
already been shown to be the case for ADC drugs.  For example, down-regulation of 
Her2 surface protein was shown to occur in cell models of ADC-resistant tumors 
(Loganzo et al., 2015b). And for the CD30-targeting ADC Brentuximab vedotin (BV), 
long-term treatment of CD30-positive cancer cells with an escalating dose of BV for 
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several months resulted in a 655-fold increased resistance to BV, accompanied by a 38% 
reduction of CD30-positive cells and a 79% reduction of CD30 fluorescence on the cell 
surface (Chen et al., 2015). Potential Solution:  Create ADCs that target different tumor-
specific antigens on the same cancer cell, or discover new tumor antigens that satisfy this 
requirement. 
 
2. Increased ADC Re-cycling to the Cell Surface without Drug Activation: The ADC 
drug must be internalized by receptor-mediated endocytosis (RME) into an endosome 
that eventually fuses with a lysosome.  The fusion process acidifies the compartment and 
releases degradative enzymes that digest the linker and/or antibody, releasing the drug 
into the cytoplasm.  If the drug is not released into the cytoplasm, it cannot kill the tumor 
cell.  Or if the drug is internalized but quickly returned to the cell surface, it will not 
become activated.  Potential Solution:  Use a drug to temporarily block non-RME uptake. 
 
3. Use of an Alternative Vesicle for Entrance:  If the ADC is not internalized by a 
vesicle that fuses with a lysosome, as mentioned in step-2 the drug does not become 
activated.  RME vesicles are usually coated by clathrin (clathrin-coated vesicles), but 
clathrin-independent uptake can occur in caveolae which do not fuse with lysosomes.  As 
an example, in an in vitro model of Her-2-positive cancer induced to be resistant to ADC 
drug T-DM1, proteomic sequencing showed alterations in several proteins involved in 
vesicle transport and lysosome/endosome biogenesis (Loganzo et al., 2015c). In addition, 
when gastric carcinoma cells were made resistant to T-DM1 by cyclical exposure to the 
ADC long-term over several months, the cells increased their resistance to the drug by 
more than 100-fold and upregulated several proteins including Caveolin-1 associated 
with the alternative caveolae vesicles (Sung et al., 2016). Potential Solution:  Use a drug 
to temporarily block caveolae uptake. 
 
4. Altered Cell Death or Cell Survival Pathways:  Some drugs kill the cell by 
activating cell death pathways (apoptosis) or by decreasing the cell’s survival pathways.  
If the tumor cell alters these pathways, the drug’s effectiveness can be lowered.  Potential 
Solution:  Engineer an ADC with a different drug that uses a different mechanism to kill 
the cell. 
 
5. Improper ADC Catabolism:  Any impairment of ADC antibody or linker degradation 
inside the RME vesicle will result in inactive drug.  In general, ADC drugs containing 
non–cleavable linkers require nearly complete catabolism of the antibody in the vesicle to 
release drug, while enzymatically-cleavable linkers merely need to be cleaved once to 
release drug (Doronina et al., 2006).  For example, in a T-DM1-resistant in vitro cancer 
model, using a T-DM1 drug prepared with a non-cleavable linker was less effective than 
using a drug made with a protease-cleavable linker (Loganzo et al., 2015a). Potential 
Solution:  Alter the type of linker present in the ADC to increase its activity. 
 
6. Improper Release of the ADC from the Vesicle:  The cytotoxic cargo must bind its 
cellular target (usually tubulin or DNA) to kill the cell.  This means that the drug must be 
released from the vesicle into the cytoplasm.  Loss of a lysosomal transporter protein 
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could reduce this necessary release step.  For example, Hamblett and colleagues 
identified SLC46A3 as a protein required for the transport of maytansine cargo from the 
lysosome to the cytoplasm (Hamblett et al., 2015).  When this protein was mutated in the 
tumor, the drug lost its effectiveness.  Potential Solution:  Use a drug to stimulate 
lysosomal protein transport, or deliver the required SLC46A3 transport protein by gene 
therapy. 
 
7. Increase in Drug Efflux Transporter Activity:  Drug transporters such as MDR1 and 
MRP1 transport drugs from the cytoplasm to the cell exterior which inactivates the drug.  
Increasing drug transporter activity lowers the drug concentration inside the cell, 
lowering its effectiveness. With respect to ADCs, chronic treatment of a mouse xenograft 
model of non-Hodgkin Lymphoma (NHL) using a CD22-targeting ADC increased the 
expression of MDR1 that exports toxins outside a cell (Yu et al., 2015).  Potential 
Solution:  Change the ADC drug to a different cargo that is not exported by the 
upregulated transporter, or use a drug to lower transporter activity. 
 
8. Alterations of Cargo Drug Target:  The ADC cargo requires a specific cellular target 
to kill the cell, usually DNA or tubulin. But some tumor cells can become resistant to a 
specific anti-cancer drug by altering the target (Gillet and Gottesman, 2010; Holohan et 
al., 2013).  In the case of ADCs, a drug might initially target tubulin to kill actively-
dividing cells, but upon maturation the tumor acquires tubulin mutations and no longer 
binds the drug (Kavallaris, 2010). Potential Solution:  Use a second ADC with a different 
cargo that binds a different cellular target. 
 
 
Tarveda Therapeutics 
 
ADC drug design is a subject of much research in the biotech industry. This includes the 
design of improved second-generation ADCs.  One example is Tarveda Therapeutics 
(Watertown, MA).  Tarveda is a clinical stage biopharmaceutical company developing second-
generation ADC drugs (Tarveda.com, 2017).  Their main technology is Pentarins™, which are 
potent, selective, miniaturized ADCs designed to penetrate more deeply into solid tumors than 
normal ADCs.  Data using first-generation ADCs against solid tumors indicated they were 
generally less effective than the ADCs against leukemia or breast tumors.  According to Richard 
Wooster, Tarveda’s President of Research and Development, “The result of our [Pentarin 
platform of miniaturization] is a drug that is about 15 times smaller [than antibodies], and are 
likely to penetrate deeper into the tumor” (Ledford, 2016).  
 
Tarveda is developing a pipeline of several different Pentarins to treat a wide range of 
cancers (Figure-2). The company’s lead Pentarin drug is PEN-221.  This drug is designed to 
target the somatostatin receptor over-expressed in neuroendocrine tumors and in small-cell lung 
cancers.  The drug is currently in Phase-I/II testing.  Tarveda’s next lead candidate is PEN-866, a 
Pentarin designed to target Heat Shock Protein-90 (hsp-90) located within a variety of solid 
tumors, including colorectal cancer, small-cell lung cancer, sarcomas, and pancreatic cancers.  In 
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earlier pre-clinical testing, PEN-866 induced complete tumor regressions in mouse xenograft 
models of small-cell lung cancer, pancreatic cancer, ovarian cancer, and sarcoma (Tarveda.com, 
2017). PEN-866 is currently in IND studies and is scheduled to enter clinical trials in 2017.  
Other Pentarins are also being developed by the company that carry a variety of extremely potent 
payloads (discovery stage), and Pentarins that target a variety of other tumor-specific proteins 
(discovery stage).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-2: Pipeline of “ADC” Pentarin Drugs Under Development at Tarveda 
Therapeutics.  Pentarin drugs are similar to ADCs except they are miniaturized.  Shown 
are the four classes of “ADC” Pentarin drugs being developed at Tarveda, including: 
PEN-221 (directed against somatostatin-presenting cancers including neuroendocrine 
tumors and small cell lung cancers) (Phase-I/II); PEN-866 (directed against hsp-90 on 
small cell lung cancer and pancreatic cancer) (IND studies), other HSP-90 Pentarins with 
a variety of potent cargos (discovery stage), and other Pentarin drugs against a variety of 
surface proteins (discovery phase) (Tarveda.com, 2017). 
 
 According to the company’s website, the Pentarin platform allows drugs to be designed 
for optimum efficacy while maintaining their miniature size to penetrate deeper into the tumors.  
Altering the synthetic components of the Pentarin allows more precise control of the 
pharmacokinetics, bio-distribution, tumor accumulation, tumor penetration, and cancer cell 
uptake of Pentarins, increasing cancer cell death. One of their patented procedures uses 
nanoparticles enclosing the Pentarins to penetrate the perivascular region of the tumor using the 
leaky tumor vasculature, then they release the Pentarin to bind the tumor cells. 
 
 
Mersana Therapeutics 
 
Another biotech company investigating second-generation ADC drugs is Mersana 
Therapeutics (Cambridge, MA). This company uses a patented Fleximer technology to design 
biodegradable ADC drugs with improved drug solubility, pharmacokinetics, reduced 
immunogenicity, and optimized drug loading (Mersana.com, 2017). The Fleximer platform 
allows an ADC to be custom designed with specific properties to overcome current ADC 
limitations. The platform attempts to increase control over when, where, and how the ADCs are 
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released. If the drug can deliver higher quantities of payload directly to a tumor, it could more 
effectively treat the tumor and reduce unwanted side-effects.  The ADC can be customized to 
vary the type and quantity of payload, or to alter the target antigen.  According to Timothy 
Lowinger, Chief Scientific Officer, “This [technology] allows the company to attach 15 
molecules of the drug to each polymer, rather than the usual 3-4 (Ledford, 2016).  Their most 
developed drug is XMT-1522 that targets Her-2 in some types of breast cancers.  This drug is 
currently in Phase-I clinical trials (Mersana.com, 2017). 
 
 
Switching Antibodies 
 
 As stated above, the first-generation ADCs used murine antibodies directed against 
human antigen targets. These early ADCs were evaluated in human clinical trials, but had limited 
success due to the ADC immunogenicity, a lack of potency, or insufficient selectivity for tumor 
versus normal tissue (Teicher et al., 2011). Fully human antibodies can now be produced in 
mice. Immuno-deficient mice (lacking their own immune system) are injected with human bone 
marrow cells containing hematopoietic stem cells (HSCs).  The human HSCs colonize the bone 
marrow of the mouse, and then differentiate into a functional immune system that includes the 
production of human antibodies from B-cells.  B-cells producing human antibodies can be 
isolated from these mice and fused with myeloma cells to make a cell line that is easy to grow in 
culture.  Procedures also exist for producing mouse-human chimera antibodies.  Both of these 
types of antibodies are less antigenic in patients than mouse antibodies and are 100 to 1000-fold 
more potent than first-generation ADCs.  An example of an ADC containing a mouse-human 
chimera antibody is Brentuximab vedotin (Adcetris), one of only two currently FDA-approved 
ADCs. It consists of a mouse-human chimeric monoclonal antibody directed against CD30 
(Deng et al., 2013).  An example of an ADC containing a fully human antibody is 
Glembatumumab vedotin (CDX-011).  It consists of a fully human monoclonal antibody against 
gpNMB conjugated to the potent microtubule inhibitor monomethyl auristatin-E (MMAE) 
(Naumovski and Junutula, 2010; Keir and Vahdat, 2012). 
 
 
Identifying New Target Antigens 
 
 A very important future direction for ADC research is the identification of new target 
antigens.  As mentioned previously, some of the off-target effects of ADC drugs occur when the 
targeted tumor antigen is also expressed to some extent in normal tissues.  An example of this 
problem was the initial use of ADCs against KS1 (for non-small cell lung cancer) and against 
BR96 (for breast cancer).  Both of those antigens are also found in normal tissues, and their 
presence resulted in ADC toxic side-effects (Elias et al., 1990; Tolcher et al., 1999). In other 
cases, only a portion of a patient’s tumor expresses the target antigen, so those tumor cells are 
not eliminated by the ADC drug.  In other cases, a tumor might initially express an antigen, but 
then down-regulate its expression as the tumor matures or metastasizes. 
 
 
93 
A recent example of the identification of a new target antigen Her-3. A team of scientists 
based primarily in the Department of Radiation Oncology at Massachusetts General Hospital 
(MGH) and Harvard Medical School (HMS) (Boston, MA) noticed in mouse models of breast 
cancer that Her-2-positive breast cancer cells (with an over-activated PI3K-pathway), were 
blocked by inhibition of PI3K, while breast cancer cells that had metastasized to the brain no 
longer responded to the PI3K inhibitors (even though the inhibitors penetrated those cells) 
(Kodack et al., 2017).  Upon further analysis, the authors determined that Her-3 had become 
over-expressed in the metastasized brain cancer cells.  Blocking Her-3 function produced 
significant tumor growth delay and improved mouse survival (Kodack et al., 2017). Thus, Her-3 
might be an effective antigen for targeting Her-2-resistant tumor cells as they start to 
metastasize. 
 
 Another recent example of the identification of a new target antigen is CD32a.  A team 
of scientists from the Institut de Génétique Humaine, Laboratoire de Virologie Moléculaire, 
Université de Montpellier (Montpellier, France) performed a gene expression profile on CD4-
positive human T-cells infected in vitro with HIV-1 (Descours et al., 2017).  HIV initially 
establishes a productive infection where the infected cells produce and release active virus.  But 
as the infection progresses further, the retrovirus establishes a quiescent or latent infection.  
Latently infected cells are not killed by the virus, nor are they eliminated by anti-retroviral drugs, 
so the presence of these latently infected cells is one of the major remaining hurtles for 
developing an HIV cure.  The Université de Montpellier team identified 103 genes specifically 
upregulated during latent HIV infection, including 16 transmembrane proteins.  Of the 16 
transmembrane proteins, CD32a was upregulated the strongest, and it was not present in normal 
cells or in lytically infected cells.  Although only 0.012% of the CD4-positive cells expressed 
CD34a, these cells represent a major source of HIV during rebounds if the antiretroviral drugs 
are withdrawn (Descours et al., 2017).  So, targeting CD34a with an ADC drug might help 
eliminate the HIV reservoir from the body. 
 
 
Dual-Targeting Approaches 
 
 Another ADC procedure that might be worth pursuing in the future is the use of dual-
targeting therapies.  This approach uses two ADCs against the same receptor but that work by 
two different mechanisms, or alternatively it uses two different ADCs that target different 
receptors on the same tumor.  An example of the first approach is the use of the ADC Kadcyla to 
target Her-2-positive breast cancer cells combined with Pertuzumab (Perjeta) that binds Her-2 
preventing its dimerization (Phillips et al., 2014).  Preventing Her-2 dimerization blocks the 
activation of signal transduction pathways that lead to cell growth.  The combined dual-ADC 
treatment inhibited cancer cell proliferation in vitro, enhanced anti-tumor activity in mouse 
xenograft models, and showed only mild grade-1 and -2 adverse effects in Phase-I/II clinical 
trials with preliminary evidence of efficacy (Phillips et al., 2014). 
 
 An example of the second dual-ADC approach that target different receptors has not yet 
been done, but in theory could be done with Kadcyla (targeting Her-2 breast cancer cells) 
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combined with an ADC against Her-3 (targeting metastasized cells) (not developed yet).  The 
study mentioned previously in the Department of Radiation Oncology at Massachusetts General 
Hospital (MGH) and Harvard Medical School (HMS) (Boston, MA) showed that Her-2 breast 
cancer cells increase their expression of Her-3 when they metastasize to the brain (Kodack et al., 
2017).  So, perhaps using two different ADCs might prevent the metastasis.  This second 
approach might also work in cancer patients where the tumor cells do not all express the target 
antigen, such as breast cancer patients where only a portion of the cells are Her-2 positive, or 
patients with large-cell lymphoma where only a portion are CD30-positive.   But this dual-ADC 
approach would necessitate identifying new tumor antigens for various cancers to serve as 
alternative ADC targets. 
 
 
Altering the Payload to Overcome Resistance 
 
If a cancer patient becomes resistant to a cytotoxic agent delivered by one type of ADC 
drug, perhaps using an ADC that targets the same antigen but carries a different payload might 
help overcome the resistance.  This altered payload approach has already been successful in the 
case in mouse models of non-Hodgkin lymphoma (NHL) that had become resistant to a CD22-
targeting ADC. Altering the payload from MMAE to nemorubicin (which targets DNA), while 
still targeting CD22, overcame the resistance even when delivering only half the payload per cell 
(Yu et al., 2015). 
 
 
Payload Advancements 
 
 The first-generation ADCs included cytotoxic payloads such as doxorubicin, vinblastine, 
or methotrexate.  These drugs inhibit cell growth with inhibitor concentration-50 values (IC50) in 
the micromolar range.  Second-generation ADCs use newly designed payloads such as 
Calicheamicin, Maytansine derivatives (DM1), or Auristatins (MMAE).  These new drugs target 
either DNA or tubulin, and are far more toxic than previous drugs with IC50’s in the nanomolar 
or picomolar range (same effectiveness at 1000-fold to 1,000,000-fold less concentrations).  
These payloads have proven very effective against a wide range of human tumor cells.  
 
Research continues to identify new types of payloads. One new type of payload is the 
Pyrrolobenzodiazepine class (PBDs).  PBDs are a class of naturally occurring anti-tumor drugs 
that bind DNA in a sequence specific manner in its minor groove (Flygare et al., 2012). This type 
of drug kills the cell by crosslinking opposing strands of the target cell’s DNA. PBDs have been 
shown to have picomolar activity against tumor cell lines. Another promising ADC payload is 
the RNA polymerase II inhibitor α-Amanitin (Flygare et al., 2012). This toxin is a cyclic peptide 
of eight amino acids, and is the most deadly of all the amatoxins found in mushrooms, such as 
the death cap or the destroying angel (Michelot and Labia, 1988).  α-Amanitin kills by inhibiting 
DNA transcription (the production of RNA from a DNA template), which is required by all cells.  
These payloads are in the early stages of testing, and have shown significant signs of success 
against a wide range of tumor cells. 
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Vascular Targeting ADCs 
 
 So far, most of the ADC research has focused on targeting tumor-associated antigens 
expressed on the surface of cancer cells (Casi et al., 2012). This type of ADC utilizes antibodies 
linked with a toxic payload which becomes internalized in the cell through receptor-mediated 
endocytosis. As discussed earlier in this section, the success of this type of ADC requires several 
steps to occur, including the movement through barriers associated with large solid tumors, 
binding to the cell surface, internalization into an endosome, fusion with a lysosome, and release 
of the drug into the cytoplasm.  But if any of these steps malfunctions, the cytotoxic payload will 
never reach the intended target. 
 
 An alternative approach has been developed that targets markers expressed in the newly 
forming tumor neo-vasculature. This strategy uses non-internalizing antibodies (Casi et al., 
2012).  Since the formation of new blood vessels (angiogenesis) is a common feature of all 
malignancies, and new vessel formation rarely occurs in normal adults, these markers might be 
excellent targets for ADC therapy (Casi et al., 2012). An advantage of neo-vascular targeting is 
that one ADC drug could be used to treat a variety of tumors, as most tumors need new 
vasculature.  Research on angiogenesis makers focuses on the sub-endothelial extracellular 
matrix (ECM). ECM markers are typically more stable than surface tumor markers, and this 
would allow the antibodies to have a residence time of days to weeks, which would increase the 
time the toxic drug could act. Work has already begun using human mAbs specific to the extra-
domain B (EDB) of fibronectin, which has been identified as a marker of angiogenesis (Palumbo 
et al., 2011). A team from the Swiss Federal Institute of Technology (Zurich, Switzerland) 
designed ADC SIP(L19)-PS, which combines PS (a photo-sensitizer that absorbs in the red 
spectrum), and L19 (a human monoclonal antibody against fibronectin-EDB). They tested their 
ADC in two mouse models of cancer (F9 and A431), and showed that activating the ADC by 
radiation causes disruption of the tumor vasculature, and produces complete and long-lasting 
cancer eradication (Palumbo et al., 2011).  
 
  
Linker Optimization 
 
An important ADC component that was slightly overlooked in first generation ADC 
drugs was linker chemistry. Linker stability is necessary to allow the conjugate to circulate in the 
bloodstream for an extended period of time without prematurely releasing its cytotoxic agent. 
Linker stability has a major influence on ADC properties such as pharmacokinetics, overall 
toxicity, and therapeutic index (Perez et al., 2014).  
 
ADC linkers currently under development fall under two main classes: cleavable linkers 
and non-cleavable linkers. There are three different release mechanisms for cleavable linkers: 
acid-sensitive linkers, lysosomal protease-sensitive linkers, and glutathione-sensitive linkers. 
Acid-sensitive linkers contain an acid labile group, such as a hydrazone, that easily undergoes 
hydrolysis in the low pH of the lysosomal compartment, releasing the drug into the tumor. This 
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type of linker was employed in first-generation ADCs such as the first FDA approved ADC, 
Mylotarg (Casi et al., 2012). Mylotarg’s clinical trials showed adverse effects due to linker 
instability, and it was withdrawn from the market. Research is currently being done to try to 
improve linkers that use this acid-labile drug release mechanism. Lysosomal protease-sensitive 
linkers initiate proteolysis after fusion with a lysosome. Lysosomal proteases, such as Cathepsin 
B, are used to recognize and cleave a specific dipeptide bond, releasing the drug from the 
conjugate. This method was used successfully in the FDA-approved Adcetris, which is currently 
still on the market. The third type of cleavable linker, glutathione-sensitive linkers, “exploit the 
high level of intracellular reduced glutathione to release free drug inside the cell” (Panowski et 
al., 2013). Disulfide bonds within the linker are stable in the bloodstream, but can be reduced by 
intracellular glutathione and release the free drug (Perez et al., 2014). 
 
The main advantage of non-cleavable linkers is their greater stability in the circulation 
than cleavable linkers. Their heightened stability prevents early release the drug potentially 
eliminating the bystander effect. This seems like a safer option, but the chemistry becomes a 
little more complicated since the linker is never detached. This process relies on complete 
degradation of the antibody once the ADC is internalized, and the payload must do its job while 
being chemically modified since its chemical structure is altered by the linker extension. 
 
Linker chemistry has become a major focus of ADC research and is forcing the evolution 
of the ADC field. New theories are currently being tested in preclinical trials, as well as 
optimization of proven technologies discussed previously. Other tumor-associated proteases, 
such as legumain, have been identified that release the ADC payload in non-lysosomal 
compartments, giving promise to finding more efficient linker release mechanisms (Perez et al., 
2014). Since the linker is mainly responsible for the intracellular release of the toxic drug, linker 
chemistry must be precisely engineered to control toxicity. Linker selection is not only 
dependent on the mechanism used for delivering the drug, but is also dictated by the choice of 
target antigen and the desired payload.  
 
 
Site-Specific Conjugation 
 
Conjugation chemistry is an area of ADC research that has recently started seeing 
advancements. The first-generation ADC production methods produced heterogeneous mixtures 
of molecules (Panowski et al., 2014). The traditional conjugation of drugs to antibodies occurs at 
solvent-accessible reactive amino acids. Those methods used non-specific acylation of lysine 
residues, and alkylation of cysteine thiols (Agarwal et al., 2015). As an example of drug 
heterogeneity, the attachment of a drug to lysine residues results in 0-8 conjugated drug 
molecules per antibody, on both the heavy and light chains, at 40 different locations (20 lysine 
residues per chain). This results in the production of more than one million different types of 
ADC molecules per reaction (Wu et al., 2005; Wang et al., 2005). Each type of molecule has 
distinct properties, resulting in a wide range of activities that produced somewhat unpredictable 
results in patients (Panowski et al., 2014). A diverse product such as this will contain a variety of 
conjugates that all have their own set of properties that affect pharmacokinetics, toxicity, 
aggregation, antigen affinity, and drug release (Agarwal et al., 2015). Cysteine conjugation 
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produces a slightly less diverse drug mixture than lysine-based conjugation due to a more limited 
number of reactive sites, but it still produces a heterogeneous mixture.  
 
The newer methods of drug attachment to antibodies use site-specific conjugations that 
eliminate product heterogeneity and improve conjugate stability. These new methods include: 1) 
engineered cysteine residues, 2) unnatural amino acids, or 3) enzymatic conjugation through 
glycol-transferases and transglutaminases.  In the first approach, extra cysteine residues are 
engineered into the antibody as sites for drug attachment, allowing the antibody to keep its 
normal disulfide bonds intact, maintaining its structure.  Cysteine residues can be engineered in a 
way that will make specific sites much more reactive than others, yielding a site-specific product. 
Using a cysteine residue engineering approach, a team of scientists at Genentech prepared 
homogeneous ADCs conjugated to IgGs, which they dubbed THIOMABs (Agarwal et al., 2015). 
They used a reduction/reoxidation approach in which they reduced engineered cysteine residues 
and inter-chain disulfide bonds simultaneously, and then used an oxidizing agent to reform only 
the inter-chain disulfide bonds, leaving open a specific reactive cysteine thiol that could be used 
for attaching the drug. This new method generated site-specific ADCs with 2.0 drug molecules 
per antibody (Casi et al., 2012). Genentech showed that the site-specific ADCs had a greatly 
improved therapeutic index.  
 
The second new site-specific strategy uses unnatural amino acids inserted at a desired 
location in the antibody.  The amino acids used to date include selenocysteine and 
acetylphenylalanine.  Seleno-cysteine is similar to cysteine, but contains selenium instead of 
sulfur. Its selenolate group is more reactive than its thiolate counterpart, so the drugs tend to add 
onto that site first (Panowski et al., 2014). The unnatural amino acid acetylphenylalanine 
contains a keto group that can be specifically conjugated to a drug through an oxime ligation 
(Panowski et al., 2014).  
 
 The third new site-specific strategy uses enzymatic conjugations with glycotransferases 
or transglutaminases.  Glycotransferase can attach a chemically active sugar residue to a 
glycosylation site on an antibody, and then the drug is conjugated to the chemical handle on the 
sugar residue. Alternatively, transglutaminase can be used to form a bond between an amine 
group on the linker or drug and an engineered glutamine residue on the antibody. Both platforms 
are being investigated for the production of ADCs. 
 
 
Radioimmunotherapy 
 
 Radioimmunoconjugates are radioactive isotopes conjugated to antibodies targeting 
tumor cells. Radioimmunotherapy (RIT) has been under development for over 30 years with 
little progress, but with new advancements in the field of targeted antibody cancer therapy, there 
is new excitement for RIT. Similar to ADCs, the choice of antibody and cytotoxic agent are 
critical for RIT efficacy. “The path length of penetration of the radioactive emission should 
match the size of the targeted tumor” (Kraeber-Bodéré et al., 2014). Clinical trials have shown 
some promising results for RIT drugs targeting antigen CD-20 in non-Hodgkin B-Cell 
Lymphoma using Yttrium-90 as the radionuclide (drug Zevalin®; Spectrum Pharmaceuticals, 
Henderson, NV). Zevalin is approved for use in the U.S. Europe, Asia, and Africa (Kraeber-
Bodéré et al., 2014).  
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Current research is directed toward development of radioimmunoconjugates targeting the 
Her-2 antigen expressed in breast cancer. The chosen cytotoxic radionuclide for this research is 
Lu-177 due to its favorable characteristics (Bhusari et al., 2017). In addition, isotopes with 
shorter tissue penetration, such as alpha emitters Bismuth-213 or Astatine-211, are being 
investigated for use with microscopic tumors.  Other developments in the areas of targeted 
antibody design, such as site specific drug (isotope) conjugation, will eventually be applied to 
RIT therapies. 
 
  
Immunotoxin Therapy for Cancer Treatment 
 
 Immunotoxins are very potent molecules consisting of an antibody (or antibody 
fragment) linked to a bacterial or plant toxin rather than a traditional chemotherapeutic drug 
(Hassan et al., 2015). Immunotoxins work in a manner similar to ADCs, targeting specific tumor 
antigens and internalization into a tumor cell.  But different than ADCs, the toxin kills the cell by 
inhibiting protein synthesis, not by binding tubulin to block cell division or binding DNA to 
cause its fragmentation. Because immunotoxins carry a cargo that kills a cell by blocking 
translation instead of blocking cell division like ADCs, this allows immunotoxins to be used 
against tumors that are no longer actively dividing (Hassan et al., 2015). 
 
Immunotoxins targeting CD-22 have produced complete remissions in refractory hairy 
cell leukemia and acute lymphoblastic leukemia in children (Wayne et al., 2011; Kreitman et al., 
2012).  But, similar to ADCs, immunotoxins have had less success with solid tumors (Hassan et 
al., 2015). Large molecules, such as ADCs and immunotoxins, have trouble penetrating inside 
solid tumors. So, some scientists have engineered smaller molecules with better penetration.  For 
example, a team of scientists at the Center for Cancer Research, National Cancer Institute 
(Bethesda, MD) used protein engineering to produce a small immunotoxin consisting of the Fv 
variable (antigen-binding) fragment of an antibody against a cancer protein fused to a truncated 
form of Pseudomonas exotoxin-A (PE) termed PE38 (Pastan et al., 2006).  Natural PE has three 
domains: Domain I binds the cell surface of most cells, Domain II enables the toxin to be cut by 
furin, separating the Fv from the toxin, and Domain III catalyzes the inactivation of translational 
elongation factor-2, inhibiting protein synthesis.  The authors removed Domain-I to prevent the 
toxin from attaching to the surface of normal cells, and replaced it with the Fv domain of 
antibodies against various cancer proteins, including interleukin-6 and TGF-alpha (Kreitman et 
al., 1992), and against erbB2 (Batra et al., 1992). 
 
 The same team of scientists from the National Cancer Institute discussed above has also 
investigated the use of immunotoxins against mesothelioma by targeting the mesothelin protein.  
Mesothelin is highly expressed in many human malignancies including mesothelioma, and 
cancers of the pancreas, lung, stomach, ovary and bile duct (Ordóñez, 2003). The team created 
an immunotoxin, named SS1P, consisting of the Fv fragment that binds mesothelin conjugated to 
their truncated Pseudomonas toxin PE38. In their initial clinical trials, SS1P had limited activity 
because 90% of the patients developed antibodies against the immunotoxin, lowering its 
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effectiveness.  So the team testing an immunosuppressive regimen to lower the T and B cell 
responses to allow longer term use of the drug (Mossoba et al., 2011; Hassan et al., 2013).  Using 
mice with a functional immune system, the team showed that pretreatment with a drug 
combination of pentostatin (that kills T cells) and cyclophosphamide (that kills B cells) 
eliminated anti-SS1P antibody formation (Mossoba et al., 2011). And in patients with advanced 
treatment-refractory mesothelioma, treatment with pentostatin, cyclophosphamide, and SS1P 
together significantly decreased the formation of anti-SS1P antibodies allowing more cycles of 
SS1P to be given, which resulted in durable and major tumor regressions in three of the ten 
evaluable patients (Hassan et al., 2013).  
 
In addition, the same team identified residues in the PE Pseudomonas toxin that were 
being recognized by T and B cells as foreign and removed them to create a less immunogenic 
toxin.  The team determined that most of the toxin Domain II could be deleted, so long as they 
retained 11 residues required for furin processing. Not only was the altered toxin less 
immunogenic, it was also more active in killing cancer cells, 8-fold less toxic to mice, and it 
greatly diminished capillary leak syndrome in rats (Weldon et al., 2013). With respect to B-cell 
binding, the team identified several residues in Domain-III that were being recognized by B-
cells; they mutated seven hydrophilic residues to hydrophobic alanine residues to reduce the 
binding (Liu et al., 2012). The new toxin was too small, 43-kDa, which would rapidly be 
removed from the circulation by the kidneys, so the team collaborated with Roche Diagnostics to 
produce a larger molecule which they fused to an antibody against mesothelin to produce 
immunotoxin RG7787 with a size of about 72-kDa. RG7787 is currently in phase I testing 
against mesothelin-positive malignancies (Hassan et al., 2015).  
 
 
Section-5 Conclusions 
 
This section of the Literature Review identified several different steps that are required 
for an ADC drug to function.  Loss of any one of these steps can result in an inactive drug.  
Second-generation ADCs are being designed to overcome tumor resistance, be more active, and 
have fewer side-effects.  One area that needs much more research is the identification of more 
tumor-specific antigens not found in normal tissues. This will allow ADCs to better target the 
tumor instead of normal tissues, and will also allow the use of more than one ADC to target a 
tumor if resistance against one antigen arises. In addition, more research should be performed to 
identify mechanisms for how tumors become resistant to ADCs.  To facilitate this, in vitro and in 
vivo mouse models could be developed for ADC resistance for various types of tumors by 
treating them long-term with an ADC drug until resistance occurs, and then characterizing the 
mechanism of the resistance.  In the future, to increase the effectiveness, the ADC could be 
combined with an immunotoxin or radioimmune drug targeted to the same tumor cells but which 
kills the cell by a different mechanism.  This strategy would be particularly important if some of 
the tumor cells have become resistant to the ADC. 
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METHODS 
 
To accomplish objective-1, we performed an extensive review of the current research 
literature, including reputable academic journal articles, relevant books, scholarly websites, 
newspaper articles, and other pertinent materials. 
 
To accomplish objective-2, we conducted interviews with various academic or medical 
researchers who had developed or used antibody-drug conjugates on animals or humans, or who 
are FDA legal experts, to determine their range of opinions on the strengths and weaknesses of 
this technology, and to identify remaining problems for gaining FDA approval for new ADC 
drugs. 
 
Who:  The interviewees included academic and industry experts on antibody-drug 
conjugates, and legal experts on the FDA approval process for new drugs. The technical experts 
will help answer questions identified from our Literature Review search, and will help prioritize 
the problems.  The legal experts will help discern the remaining legal hurdles for gaining 
approval to use more ADCs in the U.S.  Some of the interviewees will initially be identified by 
referral from the project advisor, Dave Adams.  Other interviewees will be identified from the 
published literature as authors on key scientific papers, or by referral from the initial interviews. 
 
Where and When:  Whenever possible, interviews were conducted in person, but the 
majority were performed by email, phone, or Skype. 
 
How:  We developed our interview questions based on our background research.  A 
preliminary set of questions is shown in the Appendix.  Based on our background search of each 
interviewee, we designed a pertinent initial question.  Any subsequent questions were based on 
the interviewee’s response to the initial question.  The Appendix shows the range of topics 
covered in our interviews. 
 
With respect to the method of the interview, after establishing contact with an 
interviewee, we informed the interviewee about the purpose of our project, and asked for 
permission to quote them (see interview preamble in the Appendix).  If the need arose for 
confidentiality, we protected the interviewee by either not quoting them directly, or by giving 
them the right to review any quotations used in the final published report, explaining that the 
interview is voluntary, and explaining that they may stop the interview at any time or refuse to 
answer any question.  To further increase the number of interviewees, at the end of an interview, 
we sometimes asked the interviewee to recommend other potential stakeholders we might 
interview. 
  
With respect to the total number of interviews performed for our project, we discontinued 
our interviews once we had obtained sufficient information to represent all sides of the ADC 
problem, or when the unclear points had been clarified. 
 
To accomplish objectives-3 and 4, the IQP team synthesized all of the collected 
information in our literature research, interviews, and follow-up interviews to ascertain the 
strength of the evidence for and against ADC drugs, and created recommendations for further 
research. 
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RESULTS / FINDINGS 
 
 
 Our review of the ADC literature identified several problems that needed clarification in 
subsequent interviews.  The problems we chose to focus on in interviews were: 1) Why, in 
general, don’t antibodies alone (naked antibodies without payload) kill tumor cells? 2) Why are 
only two ADC drugs approved by the FDA? 3) What causes the ADC side-effects? 4) What are 
some of the problems associated with the high cost of ADC drugs? 5) Are ADC drugs included 
for funding in President Obama’s Cancer Moonshot program? 6) What are some future 
directions for ADC research? We performed interviews with scientists who helped develop ADC 
drugs, doctors who performed human ADC clinical trials, and legal experts who participated in 
the approval of ADC drugs. 
 
 
Antibodies Alone versus ADCs 
 
Our review of the literature remained unclear about why, with few exceptions, treating 
cancer patients with “naked” antibodies alone (not conjugated to a payload) typically do not kill 
cancer cells.  After all, shouldn’t the body manufacture antibodies against the body’s forming 
tumor and kill it?  To increase our understanding of this issue, we interviewed Dr. Dario Neri, a 
Professor in the Department of Chemistry and Applied Biosciences at the Swiss Federal Institute 
of Technology (Zürich).  Dr. Neri was the corresponding author on a 2012 article published in 
the Journal of Controlled Release, July 20; 161(2): 422-428, “Antibody-Drug Conjugates: Basic 
Concepts, Examples and Future Perspectives”. Dr. Neri responded to our question about “naked” 
antibodies by saying: 
 
In principle, anti-cancer “naked” IgG’s would be the perfect drug, as they would be 
“silent” (i.e., not toxic) until they (i) bind to a surface antigen on the tumor cell; (ii) 
recruit NK cells through the interaction of the Fc portion of the antibody molecule with 
Fc-gammaRIII receptors on NK cells; and (iii) cause the killing of tumor cells by targeted 
degranulation of the recruited NK cells.  Unfortunately, this strategy does not work 
effectively against the majority of cancers, for a number of reasons: 1) Antibodies 
typically show suboptimal accumulation on tumor cells, because of a slow and inefficient 
extravasation and diffusion into tumor masses, and 2) There is an insufficient number of 
NK cells within the tumor mass [to perform the killing].   
 
Thus, Dr. Neri’s explanation about why “naked” antibodies are generally less effective  than 
ADCs is that antibodies show poor accumulation on the tumor surface, and the killing without a 
conjugated payload is dependent on natural killer (NK) cells whose concentrations are low in the 
tumor environment. Presumably by linking a highly potent cytotoxic payload to the antibody for 
ADCs, the attachment of only one antibody to the cell surface in theory can kill the cell. 
 
 On the same topic, we also interviewed Dr. Anna M. Wu, PhD, a Professor at the Crump 
Institute for Molecular Imaging in the David Geffen School of Medicine, UCLA (Los Angeles).  
Dr. Wu was a  corresponding author on a 2005 article in Nature Biotechnology, 23: 1137-1146, 
“Arming Antibodies: Prospects and Challenges for Immunoconjugates”.  When asked the “naked 
antibody” question, Dr. Wu indicated that some of the same ways that tumors avoid the body’s 
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immune response in the first place which allows tumor growth, such as “downregulating MHC to 
avoid antigen detection, engaging immune checkpoint inhibitors, and secreting immuno-
suppressive cytokines”, may explain why antibody formation against surface antigens is low.  
Although this information did not directly address our question about naked antibodies versus 
ADCs, because both of those therapies use delivered antibodies, not antibodies induced in vivo, 
she made a very important point about why antibody formation against surface tumor antigens is 
generally low in vivo. 
 
 On this same topic, we also interviewed Dr. Beverly A. Teicher, PhD, Chief of the 
Molecular Pharmacology Branch at the National Cancer Institute (Bethesda).  Dr. Teicher was 
corresponding author on a 2011 article in the journal of Clinical Cancer Research, Oct 15; 
17(20): 6389-6397, “Antibody Conjugate Therapeutics: Challenges and Potential”. Dr. Teicher’s 
response to our question about naked antibodies provided examples of several antibodies that, by 
themselves, sometimes work against cancer, even when not conjugated to a cytotoxic payload.  
Her examples of sometimes effective naked antibodies included: trastuzumab [Herceptin, binds 
HER2], cetuximab [binds the epidermal growth factor receptor], rituximab [binds CD20], 
bevacizumab [binds VEGF-a], alemtuzumab [binds CD52], and panitumumab [binds the 
epidermal growth factor receptor]. She stated that “all of these ‘naked’ antibodies target cell 
surface proteins, and block/inhibit pathways that are critical for cell survival and/or 
proliferation”, and went on to say that the advantage of ADCs is they “open the possibilities to 
targeting abundant cell surface proteins that are not directly involved in critical cell survival 
pathways. So, the advantage of ADCs over “naked” antibodies is they can kill a cell by 
physically tethering to it, without regard to the function of the tumor antigen itself. 
 
 Thus, with respect to the naked antibody question, we conclude that to kill a tumor cell, a 
naked antibody bound to a tumor cell needs an active NK cell population, and these cells are low 
in concentration in the environment surrounding tumors.  In addition, relatively few antibodies 
bind to the surface of the tumor cell.  ADCs, being conjugated to highly potent drugs, need 
relatively few (or one) antibodies bound to the tumor cell to kill it, and do not need NK cells. 
Moreover, to kill a cell, naked antibodies need to block growth pathways, while ADC target 
antigens can have any function. 
 
 
Why Are Only Two ADC Drugs Approved? 
 
Currently, only two ADC drugs have been approved by the FDA.  A third ADC was 
originally approved, but was subsequently withdrawn.  With approximately 40 ADC  drugs 
currently under development, and the ADC antitumor mechanism apparently straightforward, we 
were puzzled as to why so few ADCs have been approved.  To shed light on this, we interviewed 
Dr. John M. Lambert, of ImmunoGen, Inc. (Waltham, MA).  Dr. Lambert was one of two 
corresponding authors on a 2014 paper in the Journal of Medicinal Chemistry, Aug 28; 57(16): 
6949-6964, “Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for 
HER2-Positive Breast Cancer”.  When asked his opinion about why only two ADC drugs are 
currently approved, he replied: 
 
You ask a fundamental question for the field!!  My short answer is: the biggest hurdle in 
my opinion is to identify the right target antigen for optimal activity of an ADC.  CD30 
(on Hodgkin Lymphoma) and HER2 (on HER2-positive breast cancer) are “good” 
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targets: they have high surface density, uniform expression on 100% of the tumor cells, 
they internalize sufficiently well to import the cytotoxic payload, and those antigens are 
located on tumors that seem readily accessible to antibodies.  After these ADC successes, 
the field made ADCs to all sorts of targets on the surface of many different types of 
cancer cells – but in the end, many of the targets do not bring into the cell enough 
payload to kill the majority of the tumor in an in vivo setting.  To get FDA approval, one 
needs to have good anti-tumor activity at well tolerated doses.  Many of the targets 
chosen for the current ADC technologies turned out to have insufficient anti-tumor 
activity at the maximum tolerated doses. 
  
The field now has lots of “tools”, such as different payloads, linkers, etc.  The trick is 
finding the right target on a type of tumor that is susceptible to the payload class, and 
where the target allows delivery of sufficient payload to kill most all the tumor cells.  
  
Another point is it has proven really hard to extrapolate the parameters of anti-tumor 
activity, and overall toxicity, from preclinical animal models to humans.  ADCs combine 
characteristics of large antibody molecules with characteristics of small molecule 
cytotoxics which, I think, makes it hard to judge the probability for clinical success from 
preclinical information. 
  
Perhaps, with ImmunoGen’s maytansinoid [payload] technology…the first patient was 
dosed with a maytansinoid-ADC in December 1999, we can now begin to understand this 
a little better.  There is now clinical information for several different ADCs to compare 
with the corresponding preclinical data.   We are also optimistic about mirvetuximab 
soravtansine [an ADC against folate-alpha-positive cancers], now in a phase 3 clinical 
trial.   
 
 On this same topic, we also interviewed Dr. Ian E. Krop of the Dana-Farber Cancer 
Institute, Harvard University School of Medicine (Boston, MA). Dr. Krop was the corresponding 
author on a 2014 paper in Lancet Oncology, 2014 Jun; 15(7): 689-699, “Trastuzumab Emtansine 
versus Treatment of Physician's Choice for Pretreated HER2-Positive Advanced Breast Cancer 
(TH3RESA): A Randomised, Open-Label, Phase 3 Trial”. When asked his opinion about why 
only two ADC drugs had been approved, he responded: “Good question. There will be others 
approved soon, I think. The delays happened mainly because they needed to develop better 
payloads (toxins) and identify good targets besides HER2 and CD30”.  So, Dr. Krop agrees with 
Dr. Lambert that the early approved ADC drugs had excellent surface targets. 
 
We also interviewed Dr. Thomas H. Pillow, a scientist in the Department of Research & 
Early Development, Genentech, Inc. (South San Francisco, CA).  Dr. Pillow was a 
corresponding author on a recent article in Chemical Science, 2017 Jan 1; 8(1): 366-370, 
“Decoupling Stability and Release in Disulfide Bonds With Antibody-Small Molecule 
Conjugates”. When asked his opinion about why so few ADCs have received approval, he stated: 
  
“Good question. There are a couple of things to consider with regard to only two ADCs 
being FDA approved. One is the long time it takes to achieve approval. Research on 
linking HER2 to drugs started in the late 90s, and took until 2013…more than 10 years. 
Now consider that most of the ADC research has been really done after 2010, you can 
imagine that the impact of this research will take some time to bring new approved drugs 
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to the market. The other thing to think about is that HER2 and CD30 are some of the best 
targets for ADCs (due to many reasons, among them being copy number, access to 
antigen, etc.). Other solid tumor targets are much more challenging, and have been 
limited in general to the toxicity caused by the agents. A narrow therapeutic index has 
been a constant challenge [most ADCs show a narrow window of effective 
concentrations before becoming toxic], and research is trying to understand and expand 
on it. I think we're making progress but time will tell”.  
 
 
The next interview was with Dr. Alfred Zippelius of the Department of Biomedicine, 
University Hospital and University of Basel, Switzerland.  Dr. Zippelius was a corresponding 
author on a 2015 paper in Science Translational Medicine, 7(315): 315ra188, “Trastuzumab 
Emtansine (T-DM1) Renders HER2+ Breast Cancer Highly Susceptible to CTLA-4/PD-1 
Blockade”, which involved pre-clinical animal testing.  When asked his opinion about why more 
ADC drugs have not been approved, he stated it was “probably due to a lack of [good] tumor 
antigens, and the ADC technology which still needs to be improved, especially regarding 
instability.  
 
 On this same topic we also interviewed Dr. Daniel J. DeAngelo, MD, PhD, in the 
Department of Medical Oncology, Dana-Farber Cancer Institute (Boston, MA).  Dr. DeAngelo 
was corresponding author on a 2003 paper in Blood, 102(5): 1578-1582, “Prior Gemtuzumab 
Ozogamicin Exposure Significantly Increases The Risk of Veno-Occlusive Disease in Patients 
Who Undergo Myeloablative Allogeneic Stem Cell Transplantation”.  Gemtuzumab ozogamicin 
is an ADC consisting of a monoclonal antibody against CD33 conjugated to a cytotoxic drug 
from the class of calicheamicin that damages DNA.  It was designed to be used against CD33-
positive acute myelogenous leukemia (AML). When asked about why so few ADCs have FDA 
approval, he stated “there is a barrier to approval….the need to show an overall survival benefit 
in the absence of toxicities, which is not trivial”.  
 
The next interview was with Dr. Stephen M. Ansell, MD, PhD, in the Division of 
Hematology, Mayo Clinic (Rochester, MN). Dr. Ansell was sole author on a summary article in 
2014 in the journal Blood, Nov 20; 124(22): 3197-3200, “Brentuximab Vedotin”. When asked 
why so few ADC drugs have been approved, and what is the biggest hurdle for gaining approval, 
he stated that “the target antigen to which the ADC is directed determines the efficacy, and the 
results with different targets vary”. 
 
 The last interview in this section was with Dr. Alan K. Burnett, a Professor in the 
School of Medicine, Cardiff University (Cardiff, UK). Dr. Burnett was corresponding author on 
a 2014 paper in Lancet Oncology, 2014 Aug; 15(9): 986-996, “Addition of Gemtuzumab 
Ozogamicin to Induction Chemotherapy in Adult Patients With Acute Myeloid Leukaemia: A 
Meta-Analysis of Individual Patient Data From Randomised Controlled Trials”. When asked 
about why so few ADCs are approved, and the remaining hurdles, he stated: 
 
 “In the case of gemtuzumab [in the U.S.], it was approved by the FDA in a single arm 
study nearly 20 years ago, mostly because it was novel. [It was later withdrawn]. In 
Europe, it also got a favourable opinion around then, but the company could not 
guarantee the manufacturing, so the CHMP [Committee for Medicinal Products for 
Human Use] looked at it again, and the members had changed, and they voted it down. It 
110 
was approved in Japan...and still is. We import it for all our UK trial patients. The general 
question of the paucity of immunoconjugates in AML may reflect that there is no clear 
leukaemia-specific antigen to target. So all [the targeted antigens] are also present on 
normal cells. Anti-CD123 may work, but the Seattle Genetics drug recently failed on 
toxicity grounds and those studies are now closed. ADCs are also expensive to 
manufacture”.  
 
Thus, for the question as to why only two ADC drugs have been approved, the consensus 
appears to be that the two successful ADCs (targeting CD30 and HER2) were developed early on 
(when ADCs were relatively novel, making approval easier, and providing more time for the 
approval), and the CD30 and HER2 target antigens are among the best in the field: they are 
abundant on the tumor cell surface, expressed by a majority of the tumor cells, highly accessible 
to the ADC antibody, and can internalize the ACD drug.  Subsequent ADC targets have not been 
able to provide the high degrees of efficacy and survival improvements that are needed for 
gaining FDA approval.  Other interviewees (discussed below) indicated they felt that more ADC 
drug approvals will occur very soon. 
 
 
Causes of ADC Side-Effects 
 
 Our review of the literature showed that all ADC drugs showed side-effects in clinical 
trials, but it remained unclear what caused the side-effects.  Were they caused by the presence of 
the target antigen on normal cells, so the ADC drug kills them too?  Or were they caused by off-
target effects of the toxic payload, with the toxic payload diffusing out of the target cell to kill 
normal cells?  To shed light on this problem, we interviewed Dr. David M. Goldenberg, a 
scientist at Immunomedics, Inc. (Morris Plains, NJ). Dr. Goldenberg was corresponding author 
on a 2015 paper in Clinical Cancer Research, 21(17): 3870-3878, “First-in-Human Trial of a 
Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of 
Diverse Metastatic Solid Tumors”. Their study observed neutropenia as a side-effect of the ADC 
treatment.  When asked his opinion about what caused the neutropenia, Dr. Goldenberg 
responded: “[The neutropenia is caused by the] SN-38 [payload] drug.  It can also be induced by 
[administering] the pro-drug Irinotecan by itself [the chemical precursor for active SN-38]”.  
Thus, Dr. Goldenberg thinks the neutropenia he observed is not caused by normal healthy 
neutrophils expressing the Trop-2 target antigen, but is an off-target effect caused by the toxic 
payload lowering neutrophil numbers after its release from the cell. The neutropenia is also 
observed when treating patients only with the payload drug unbound to antibody. 
 
The next interview on this topic was with Dr. Sven Golfier of Bayer HealthCare 
Pharmaceuticals (Berlin, Germany). Dr. Golfier was corresponding author on a 2014 paper in 
Molecular Cancer Therapeutics, 13(6): 1537-1548, “Anetumab Ravtansine: A Novel 
Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target 
Expression Favored by Bystander Effect”. The authors developed a new ADC (Anetumab 
Ravtansine, BAY 94-9343), consisting of a human antibody against mesothelin conjugated to the 
maytansinoid tubulin inhibitor DM4.  Mesothelin is frequently over-expressed in mesothelioma, 
ovarian, pancreatic, and lung adenocarcinomas, with limited expression in normal cells. A test of 
the ADC in patient-derived xenograft mouse models showed efficient drug internalization and 
complete tumor eradication in most of their mouse models, but also showed a by-stander effect.  
When asked to clarify whether the by-stander effect might be caused by toxic DM4 diffusing 
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from the mesothelin-positive target cell after release from the ADC to damage surrounding 
mesothelin-negative cells, he stated: 
 
“I am happy to learn that our publication raises your interest, and I am glad to respond to 
your question. It is correct, that neighboring mesothelin-negative cells are killed by DM4, 
which has been previously taken up as an intact ADC by a mesothelin-positive cell and is 
then degraded.  In fact, SPDB-DM4 degradation results in a cell permeable metabolite 
with a bystander effect. In contrast, the proteolytic cleavage of e.g. Kadcyla 
(Trastuzumab-SMCC-DM1) leaves a Lysine attached at DM1. Therefore this metabolite 
is not cell permeable and has no bystander effect. We [also] believe that killing of target-
negative cells in close proximity to target-positive cells is desirable….assuming that it is 
also a malignant proliferating cell. In fact, we believe that [our ADC] Anetumab 
Ravtansine is characterized by a double specificity: First targeting mesothelin-positive 
cells by the antibody, and second killing proliferating cells by the DM4 toxophore.  We 
treated mesothelin-positive primary mesothelial cells with Anetumab-Ravtansine, and it 
did not kill those cells under conditions which kill proliferating cancer cells”.   
 
 We next interviewed Dr. Linda T. Vahdat, MD, of the Weill Cornell Medical College 
(New York, NY).  Dr. Vahdat was corresponding author on a 2015 paper in the Journal of 
Clinical Oncology, 33: 1609-1619, “EMERGE: A Randomized Phase II Study of the Antibody-
Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast 
Cancer”. The authors described the results of their phase-II randomized trial of the ADC 
Glembatumumab vedotin in patients with refractory breast cancer.  When asked her opinion 
about ADC side-effects, she stated they “vary by which drug is conjugated to the antibody, but I 
would not say they are uniformly better when the drug is conjugated to an antibody versus not”.  
With respect to whether the side-effects are caused by antibody targeting normal cells or by-
stander effects, she stated “It is probably all of the above”.  When asked whether the side-effects 
can be avoided in patients, she stated “Sometimes”.  Are target-negative tumor cells killed by the 
ADC?  “I am not sure. There is something called “innocent bystander” effect, and that may have 
a more global effect when using these targeted agents”. 
 
 We next interviewed Dr. Anjali Advani, MD, of the Cleveland Clinic, Department of 
Hematologic Oncology and Blood Disorders, Taussig Cancer Center (Cleveland, OH). Dr. 
Advani was corresponding author on a 2010 paper in the Journal of Clinical Oncology, 28(12): 
2085-2093, “Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab 
Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin’s Lymphoma: 
Results of a Phase I Study”. In this paper, the authors reported their Phase-I data on maximum 
tolerated dose, safety, and pharmacokinetics (distribution in the body) of the ADC Inotuzumab 
ozogamicin (CMC-544) (a humanized antibody against CD22 conjugated to cytotoxic agent 
calicheamicin). The drug was tested in patients with relapsed or refractory CD22 B-cell non-
Hodgkin’s lymphoma (NHL). When asked about side-effects seen with Inotuzumab, he replied 
they are “manageable” and “vary based on the actual ADC construct and what the target is”. He 
agreed with our assessment that in this case the side-effects were caused by targeting of 
Inotuzumab to normal cells, but thinks Inotuzumab “will likely get FDA approved soon for 
treating acute lymphocytic leukemia (ALL); the Phase 3 ALL trial was just completed and 
published in NEJM this year”.  
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Thus, with respect to causes of ADC side-effects, we conclude that the side-effects 
observed vary with each ADC, and sometimes are caused by off-target effects (Dr. Goldenberg’s 
Trop-2 example), and in other cases are caused both by off-target effects and by normal cells 
expressing the target antigen. At least, in some cases, the side-effects appear to be manageable.  
One important point for reducing potential off-target effects is to conjugate the cytotoxic drug to 
the antibody using a linker that produces a charged residue when cleaved; the charge makes the 
drug unable to diffuse from the target cell to the surrounding cells.  Although, in some cases, it 
might be desirable to target dividing cells surrounding the target cell. 
 
 
ADC Funding Issues 
 
 The development and testing of ADC drugs is expensive, and so is the cost of ADC drugs 
to cancer patients.  The problem of the high cost of ADC drugs to patients is best exemplified by 
the example of Kadcyla in the United Kingdom. Delyth Morgan is the Chief Executive of 
“Breast Cancer Now”, the largest breast cancer charity in the United Kingdom. Ms. Morgan was 
quoted in an article in The Guardian on November 4, 2015, “Breast Cancer Drug Kadcyla to 
Remain on NHS After Manufacturer Lowers Price”.  Kadcyla, the ADC targeting HER2 in 
breast cancer, is manufactured by Roche, and was scheduled to be dropped from England’s 
Cancer Drugs Fund (CDF), a list of drugs the British government pays for.  England’s National 
Institute for Health and Care Excellence (NICE) had determined that Kadcyla was no longer 
cost-effective (it was too expensive). According to the article, cost appeared to be the only 
reason Kadcyla was going off the approved list, because “NICE recognized that Kadcyla works 
well, and can significantly extend women’s lives without severe side-effects”.  Kadcyla is given 
to women only if the drug Herceptin (the Her2 antibody alone) fails to work. The original price 
for Kadcyla, according to the article, was £5,900 (pounds) per month, which over an average 
treatment time of 9.6 months would total about £56,640.  An earlier article from NICE dated 8-8-
14 stated the cost was somewhat higher at £90,000. Breast Cancer Now organized a petition to 
Roche to drop the price of Kadcyla. The petition was signed by more than 42,000 people.  The 
focus of the 2015 article was that Roche finally agreed to lower the cost of Kadcyla down to 
£50,000, the threshold for approved drugs used for end-of-life treatments, to allow it to remain 
on the list of drugs paid by the government. The Chief Executive of Breast Cancer Now, Delyth  
Morgan, was quoted in the article, saying: “We’re pleased that our voices have been heard. It’s 
encouraging to learn that Roche and NHS England [who will actually do the financing] have 
been able to come to a deal, but patients relying on other delisted drugs, such as the breast cancer 
drug Avastin [kicked off the list] for future treatments will no doubt be devastated. There’s a 
bigger problem with our drug access and pricing system that will not go away”.  When we 
contacted Ms. Morgan, she agreed with our summary of the problem, and gave us permission to 
quote her. 
 
 
Are ADC Drugs Included in the Cancer Moonshot Program? 
 
The “Cancer Moonshot” was former President Obama’s charge to then Vice President 
Joseph Biden to achieve the ambitious goal of making a decade’s worth of cancer research 
progress in five years, and to bring the most promising science and clinical developments to all 
cancer patients in the near term. The “Cancer Moonshot Blue Ribbon Panel” published a report 
in 2016 describing their recommendations for accelerating cancer research in the U.S. The Blue 
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Ribbon Panel and its seven working groups were given the very important charge of assessing 
where we are fighting cancer today, and to imagine what could be done if the entire cancer 
community was galvanized by the support, coordination, and infusion of funding that the Cancer 
Moonshot promised. One of the recommendations of the panel was to organize a “Cancer 
Immunotherapy Translational Science Network” that would “develop and implement a national 
strategy to discover and evaluate novel immune-based approaches to treat and prevent both adult 
and pediatric cancers.” The network would facilitate tumor procurement and comprehensive 
profiling, including cancers from diverse populations (including racial and ethnic minorities and 
other underserved patient populations), and develop and implement a national strategy to 
discover new immune targets and evaluate novel immune-based approaches.  It was not clear 
from our reading of the report whether the “immune-based approaches” slated for development 
included ADCs.  Most of the detail cited in that section of the report referred to T-cell therapies 
against cancer, not ADCs.   
 
To attempt to clarify whether the Cancer Moonshot initiative includes ADC drugs, we 
interviewed Dr. Elizabeth Jaffee, MD, Professor and Deputy Director for Translational 
Research at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University 
School of Medicine.  Dr. Jaffee is an international leader in the development of immune-based 
therapies for pancreatic and breast cancers, and was one of three Co-Chairs of the Cancer 
Moonshot Blue Ribbon Panel. When asked her opinion about whether the moonshot program 
and its funding would include developing new ADCs, Dr. Jaffee replied “yes, it would”.  
However, this point was not agreed to by another co-chair of the same panel, Dr. Dinah S. 
Singer, PhD, Deputy Director (Acting) of the National Cancer Institute, and Director, Division 
of Cancer Biology, National Institutes of Health (Bethesda, MD).  When asked the same 
question, Dr. Singer replied “As you’ve noted, the focus of the recommendation is on approaches 
to T-cell activation and relief of immunosuppression. While ADC approaches are not explicitly 
excluded, it is unlikely that they would be considered immunotherapies”.  
 
So, at this point it remains unclear whether the substantial Cancer Moonshot funds will 
include developing new ADC drugs.  So, developing new ADCs may need to rely on other 
sources of funding. 
 
 
Combination ADC Therapies 
 
One of the future directions for ADC research identified in our search of the literature 
was the potential use of dual ADC therapies….the use of two different ADC drugs targeting two 
different antigens on the tumor cells.  To determine whether experts in the ADC field consider 
this a serious idea, we interviewed a leading ADC scientist (who wishes to remain anonymous) 
in the Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical 
School (Boston, MA).  This scientist was a corresponding author on a 2017 paper in Science 
Translational Medicine, whose lab has identified HER3 as a marker for breast cancer cells that 
have metastasized to the brain.  When asked whether his lab has considered doing a combination 
therapy of an ADC directed against HER2 (a common marker for breast cancer) plus an ADC 
directed against HER3, he replied: “That is a very good question. The antibodies that we use 
block HER3 signaling, and are not yet ADCs. As you suggest, it could be interesting to explore 
HER3 ADCs for this indication, but I think one would have to perform careful experimentation 
to make sure that the combo of HER2 and HER3 ADCs are not too toxic, and they maintain the 
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same level of activity as we observed in the mouse studies with the naked antibodies”. So, in 
theory this scientist agrees that a combination ADC approach might be useful, but cautions 
against toxicity. 
 
 On this same topic of dual therapy, we also interviewed another ADC scientist 
(anonymous), of the Edwin L. Steele Laboratory, Department of Radiation Oncology, 
Massachusetts General Hospital and Harvard Medical School (Boston, MA).  When asked the 
same question about dual ADC therapies, he replied: 
  
Thank you for your interest in our work!  Based on our findings, dual inhibition of HER2 
and HER3 is necessary to achieve efficacious signaling inhibition. In the case of ADCs, 
their efficacy is mostly driven by the delivery of their cytotoxic component, and 
monotherapy may be sufficient to control brain metastatic disease. We recently showed 
for example that the ADC T-DM1 (ado-trastuzumab emtansine) alone can control brain 
metastases from HER2-positive breast cancer in preclinical models, a result which is 
supported by further preclinical and clinical findings.  We do not have data on the 
combination of anti-HER2 and anti-HER3 ADCs. While such a combination could be 
effective, the toxicity associated with it should be critically considered.   
 
On the same topic, we also interviewed Dr. Scott J. Dylla, PhD, Vice President of R&D, 
Chief Scientific Officer, AbbVie Stemcentrx LLC, 450 East Jamie Court, South San Francisco, 
CA 94080.  Dr. Dylla was corresponding author on a 2015 paper in Science Translational 
Medicine, 7(302): 302ra136, “A DLL3-Targeted Antibody-Drug Conjugate Eradicates High-
Grade Pulmonary Neuroendocrine Tumor-Initiating Cells In Vivo”.  Their article describes the 
development of ADC “SC16LD6.5”, comprised of a humanized antibody against DLL3 
conjugated to a DNA-damaging toxin pyrrolobenzodiazepine (PBD).  They tested their drug in 
mouse xenograft models containing patient-derived human tumor cells (patient-derived 
xenografts, PDXs) with high grade pulmonary endocrine tumors.  Their results showed evidence 
of “durable tumor regression”.  When asked whether they have identified other potential target 
antigens on this type of tumor or tested a combination therapy, he stated they “have identified 
several potential targets, some which have largely non-overlapping expression with DLL3”. But 
he provided no indication they had tested a combination therapy. 
 
We also interviewed Dr. Vaskar Saha, a scientist in Paediatric Oncology, Division of 
Molecular & Clinical Cancer Sciences, University of Manchester (UK).  Dr. Saha was 
corresponding author on a 2017 article in Haematologica, Jun; 102(6): 1075-1084, “Targeting 
the 5T4 Oncofetal Glycoprotein With an Antibody Drug Conjugate (A1mcmmaf) Improves 
Survival in Patient-Derived Xenograft Models of Acute Lymphoblastic Leukemia”. Dr. Saha has 
done much pre-clinical testing of ADC drugs.  When asked whether he had tested a dual therapy 
with one ADC targeting antigen 5T4 and another ADC targeting a leukemic marker (such as 
CD22), he replied that he had “not tested that yet”.  We also interviewed the other co-
corresponding author on the same paper, Dr. Peter L. Stern of the same university.  When asked 
the same question about he had tested dual therapies, he replied “the short answer is no, but it 
[dual ADC approach] might be a useful approach”. 
 
So, with respect to combination ADC therapies, the scientists we interviewed indicated in 
general it might be a good idea, but cautioned against potential toxicities of using two different 
ADCs, each causing their own set of side-effects.  So, toxicity would have to be monitored 
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carefully.  In an example case, using two different antibodies (against HER2 and HER3) was 
shown to be required for blocking growth-inducing signal transduction pathways, so in this case 
the dual ADC approach might strongly help block the growth-inducing signal transduction and 
also kill the tumor cells. 
 
 
Non-Internalizing ADCs 
 
Most ADC drugs developed to date target antigens on the surface of tumors.  In these 
cases, the ADC must be internalized by receptor-mediated endocytosis (RME) to kill the cell. 
But this approach does not always work well for large solid tumors with physical and kinetic 
barriers, and does not work well for many types of tumor antigens (thus the problem of getting 
more ADCs approved by the FDA). Our review of the literature identified non-internalizing 
ADCs as a potential future direction for research.  Non-internalizing ADCs target antigens in the 
extracellular matrix (ECM) outside cells, or on endothelial cells lining tumor capillaries, and are 
not necessarily internalized by a cell.  A particularly interesting application of non-internalizing 
ADCs is to target special angiogenesis markers in the sub-endothelial ECM (surrounding new 
capillaries) to block the formation of new blood vessels during tumor expansion. Since most 
solid tumors require an expanding blood supply, these ADCs would have the advantage of being 
active against a variety of tumors.   
 
To obtain more information on the importance of this topic, we interviewed Dr. Dario 
Neri of the Department of Chemistry and Applied Biosciences, Swiss Federal Institute of 
Technology (Zürich). Dr. Neri was corresponding author on a 2012 review article in the Journal 
of Controlled Release, 161: 422-428, “Antibody-Drug Conjugates: Basic Concepts, Examples, 
and Future Perspectives”. Targeting the ADC to endothelial cells that line tumor capillaries has 
potential, but the cytotoxic drug might be released directly into the circulatory system and 
damage healthy cells.  The authors suggested that perhaps a better strategy is to target 
angiogenesis markers in the sub-endothelial extracellular matrix (ECM).  These targets are more 
stable than antigens on the surface of tumor cells, so the ADC drug lasts longer in that location.  
The authors also provided an example of antibody L19 that targets “extra domain-B” (EDB) of 
fibronectin, a marker of angiogenesis. EDB is not present in normal tissue, but becomes inserted 
into fibronectin during angiogenesis, and is highly abundant in many aggressive tumors.  Dr. 
Neri’s lab is developing antibodies against EDB-fibronectin.  When Dr. Neri was asked about his 
team’s progress on developing ADC’s targeting ECM proteins, he indicated that his lab has just 
published some work on an ADC containing an antibody (F16) targeting tenascin-C, a 
glycoprotein present in the ECM: Gébleux R, Stringhini M, Casanova R, Soltermann A, Neri D, 
2017, “Non-Internalizing Antibody-Drug Conjugates Display Potent Anti-Cancer Activity Upon 
Proteolytic Release of Monomethyl Auristatin E in the Subendothelial Extracellular Matrix”,  
International Journal of Cancer, 2017 Apr 1: 140(7): 1670-1679. Because the ADC is not 
expected to become internalized in a cell, which normally would cleave the linker in the vesicle), 
they equipped the ADC with a “self-immolative spacer”.  At a dose of 7 mg/kg, the ADC cured 
tumor-bearing mice containing human tumors U87, A431, and MDA-MB-231. The authors 
stated that they were surprised that their valine-citrulline linker was cleaved in the extracellular 
environment, as it is normally cleaved inside an intracellular vesicle.  So, more research is 
needed to determine the mechanism of linker cleavage.  If this class of ADC could be developed, 
it might provide a treatment for a variety of tumors that share the need for increased vasculature. 
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Immunotoxins 
 
 Immunotoxins (ITs) are a type of cancer therapy consisting of an antibody targeting a 
tumor antigen conjugated to a cytotoxic bacterial toxin (like diptheria toxin) that kills the tumor 
cell.  ITs are different than ADCs, the latter are conjugated to cytotoxic drugs instead of bacterial 
toxins.  Initially, the usefulness of IT’s was limited by the strong antigenicity of the bacterial 
toxin payload; the patients mounted an immune response against the drugs, lowering IT 
effectiveness.  To determine whether scientists have overcome this initial limitation, we 
interviewed Dr. Ira Pastan, MD, NIH Distinguished Investigator, Co-Chief, Laboratory of 
Molecular Biology, National Cancer Institute, National Institutes of Health (Bethesda, MD).  Dr. 
Pastan was corresponding author on a 2015 review article in Clinical Cancer Research, 22(5): 
1055-1058, “New Life for Immunotoxin Cancer Therapy”.  Dr. Pastan’s lab is currently 
developing alternative strategies for IT’s, including: 1) delivering the IT drug combined with 
chemotherapy agents (pentostatin and cyclophosphamide) to temporarily lower the patient’s 
immune response so they don’t mount an immune response against the drug, and 2) using 
recombinant DNA technology to make recombinant toxins that are less immunogenic. When 
asked whether ITs are more effective than ADCs, he replied “You are looking at it the wrong 
way: It is not either/or. Cancer is complicated, and most drugs do not work or do not work very 
well, so different approaches are needed.  Each has advantages and disadvantages”.  So, Dr. 
Pastan believes that there is a need to develop both ITs and ADCs to fight cancer, to not just 
focus on single ADC treatments, but multi-mechanism approaches. 
 
 
Site-Specific Drug Conjugation 
 
Our review of the literature also showed that the activity of ADCs might be improved by 
controlling the number of drugs attached to each antibody, and controlling the site of attachment.  
First-generation methods attached the drugs to random positions on the antibody, but newer 
approaches attach the drugs to specific locations. To help determine how important controlling 
drug attachment sites to antibodies are to the ADC field, we interviewed Dr. Carlos Garcia-
Echeverria of the Lead Generation to Compound Realization Group at Sanofi (Vitry-sur-Seine, 
France).  Dr. Garcia-Echeverria was corresponding author on a 2014 review article in Bioorganic 
and Medicinal Chemistry Letters, 24: 5357-5363, “Antibody-Drug Conjugates: A New Wave of 
Cancer Drugs”.  When asked about the importance of site-specific conjugations, he replied: 
 
“We know that the drug-to-antibody ratios (DAR’s) significantly impact the anti-tumor 
activity and tolerability of ADCs.  This is a parameter that needs to be optimized on a 
case-by-case basis for each ADC. Similarly, it is fair to assume that not all of the 
molecules in an ADC mixture at a given average DAR value may have the same activity 
(e.g. processing after internalization may be affected by the positioning of the modified 
lysine), but macroscopically we are measuring the activity of the total mixture. I do not 
recall articles describing how the positioning of a modified cysteine (in the case of a thio-
mAb ADC) affects the biological activity, although I briefly described this approach in 
the article, and this type of information would be needed to properly address your 
question”.   
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Thus, Dr. Garcia-Echeverria agreed with our assessment that the position of attachment of the 
cytotoxic drug to the antibody can affect ADC activity.  So, this variable needs to be tested and 
optimized for each ADC drug by creating ADCs with drugs attached to known locations on the 
antibody.  He also stated that even if we achieved a homogeneous ADC product (where the drug 
is attached to a known location on the antibody), there would still be a heterogeneous 
activity….with some molecules being taken up by the cell and processed, while other molecules 
are not.  So, using site-specific conjugation would improve ADC activity, but other variables 
also remain important to overall activity. 
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CONCLUSIONS and RECOMMENDATIONS 
 
Based on the research performed for this project, our team has made several conclusions 
and recommendations.  It was initially unclear from our review of the literature why, with few 
exceptions, naked antibodies (not conjugated to a cytotoxic drug) do not efficiently kill cancer 
cells.  Once an antibody correctly targets a cancer cell and binds to it, natural killer cells (NKs) 
roaming the body should bind to the Fc portion of the antibody and facilitate the killing.  Our 
interviews with immunologists and oncologists indicated that indeed, an active NK population is 
critical for killing the cancer cell, but NKs are low in concentration in the tumor environment.  In 
addition, relatively few antibodies actually bind to the surface of the tumor cell.  ADCs, 
conjugated to highly potent drugs, need relatively few antibodies bound to the tumor cell to kill 
it, and do not need NK cells. The cytotoxic payload by itself can kill the cell once internalized.  
So, ADCs in general are more efficient at killing tumor cells than “naked” antibodies.  ADCs are 
used to treat patients only after they do not respond to “naked” antibody treatments.  ADCs also 
have the advantage of killing a tumor cell regardless of the function of the surface antigen, while 
naked antibodies need to block cell growth pathways.  So, ADCs can target a wider range of 
antigens. 
 
But if ADCs are such a good idea, why are only two currently approved?  From our 
interviews, the consensus appears to be that the two successful ADCs (targeting CD30 and 
HER2) were developed early on, when ADCs were relatively novel.  At that time, few other 
drugs had been developed to treat relapsed cancer, so there was less competition.  And the early 
development allowed more data to be included in the FDA application.  In addition, the CD30 
and HER2 target antigens are among the best in the entire cancer field: they are abundant on the 
tumor cell surface, expressed by a majority of the tumor cells, highly accessible to the ADC 
antibody, and are capable of internalizing the ADC.  Subsequent ADC targets have not been able 
to provide the high degrees of efficacy and survival improvements that are needed for gaining 
FDA approval.  Other interviewees indicated they felt more ADC drug approvals will occur very 
soon, as more data is obtained.  The interviews underscore the importance of target antigen 
selection for ADC performance and approval, and we recommend research be continued to 
identify new target antigens on various types of tumors. 
 
Our review of the literature showed that all ADC drugs tested to date have adverse side-
effects.  Even the two currently approved ADCs have “black box” warnings on their packages 
concerning their side-effects.  But it was unclear from the literature what caused the side-effects.  
Our interviews with physicians using ADCs in clinical trials indicated that the side-effects vary 
with each ADC: in some cases they are caused by off-target effects, where the cytotoxic drug 
released from the ADC diffuses out of the target cell into a nearby cell, thus killing it.  In other 
cases, the physicians stated the side-effects were caused by the surface antigen being present on 
normal cells, so the ADC targets normal cells, diminishing their functions.  Importantly, 
regardless of the cause, several interviewees indicated their side-effects were manageable by 
using other drugs.  One important finding from the interviews is to use a newly designed linker 
that leaves a positive charge on the drug when it is cleaved.  This makes the cargo unable to 
diffuse out of the original target cell, and we recommend using this new type of linker if off-
target effects are a problem.  One interviewee stated that he actually liked the off-target effects, 
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as they allowed the ADC to kill nearby dividing cells (presumably cancer cells) surrounding the 
target cell, even if they don’t express the target antigen. 
 
 Our review of the literature showed that ADCs are expensive drugs.  For example, in the 
U.K., the original price for Kadcyla was £5,900 (pounds) per month, which over an average 
treatment time of 9.6 months totals about £56,640.  Kadcyla was in the process of being dropped 
from the list of drugs paid by the British government, but the charity “Breast Cancer Now” 
organized a petition to Roche to drop the price.  The petition was signed by more than 42,000 
people, and eventually Roche agreed to lower the cost of the drug down to £50,000, the threshold 
for drugs used for end-of-life treatments, to allow it to remain on the list. We hope that other 
ADC manufacturers follow suit.  Unfortunately, ADC research is expensive.  In the U.S., former 
President Obama initiated the “Cancer Moonshot” program, a charge to former Vice President 
Joseph Biden to achieve the ambitious goal of making a decade’s worth of cancer research 
progress in five years, and to bring the most promising science and clinical developments to all 
cancer patients in the near term. This program would provide significant funds for cancer 
research.  How the money was to be spent was summarized in a report of the “Cancer Moonshot 
Blue Ribbon Panel”, but following our reading of the report, it remained unclear whether the 
moonshot would include ADC research; frequently mentioned were T-cell therapies.  We 
interviewed two of the co-chairs of the panel, one agreed the funds would include ADC research, 
and the other disagreed. So, developing new ADCs may need to rely on other sources of funding. 
 
Our review of the literature also identified several potential new directions for ADC 
research.  One is the use of combination ADC therapies, the use of two or more ADCs targeting 
different antigens.  This trend was especially prevalent in the pre-clinical animal experiments.  
Several of our interviewees doing clinical trials indicated this might be a good idea, but 
cautioned against potential toxicities of using two different ADCs (each causing their own set of 
side-effects).  So, toxicity would have to be monitored carefully using this approach.  In one 
interesting case, our interviewee used two different antibodies (against HER2 and HER3 in 
breast cancer) and showed that both antibodies are required for fully blocking growth-inducing 
signal transduction pathways.  So, in this case the dual ADC approach might strongly block the 
growth-inducing signal transduction plus kill the tumor cells with the payload drug. 
 
 Another potential future direction investigated in our interviews was the use of non-
internalizing ADCs.  Most ADC drugs developed to date target antigens on the surface of 
tumors, but these must be internalized to kill the cell.  This approach does not always work well 
with large solid tumors with limited surface access to the ADC.  Non-internalizing ADCs target 
antigens in the extracellular matrix (ECM) outside cells.  A particularly interesting application of 
non-internalizing ADCs is to target special angiogenesis markers in the sub-endothelial ECM 
(surrounding new capillaries) to block the formation of new blood vessels during tumor 
expansion. Since most solid tumors require an expanding blood supply, these ADCs would have 
the advantage of being active against a variety of tumors.  Our interview with a scientist using 
this approach indicated that these ECM markers are more stable than antigens on the cell surface, 
so the ADC lasts longer in position.  He also indicated his lab just published their work on an 
ADC targeting tenascin-C, a glycoprotein present in the ECM.  If this class of ADC could be 
developed, it might provide a treatment for a variety of tumors that all share the need for 
increased vasculature. 
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 Another direction for future research is immunotoxins (ITs).  ITs are a type of cancer 
therapy consisting of an antibody against a tumor antigen conjugated to a cytotoxic bacterial 
toxin (like diphtheria toxin) that kills the tumor cell.  ITs are different than ADCs, the latter are 
conjugated to cytotoxic drugs instead of bacterial toxins.  ITs initially were ineffective, as they 
were inactivated by the host immune response against the toxin.  But new research focused on 
altering the toxin to make it less immunogenic. Our interview with a scientist using this approach 
indicated he felt it was important to develop both ADCs and ITs for fighting cancer, as each has 
advantages and disadvantages. 
 
Our review of the literature also identified site-specific attachment as a future direction 
for ADC research.  New chemical bonds allow researchers to control the number of cytotoxic 
drugs attached to each antibody, and to control the exact site of attachment.  Our interview with 
scientists using this technology indicated that the number of drugs per antibody, and their 
locations, strongly affect ADC activity.  So, we conclude that these parameters must be 
optimized for each ADC drug. 
 
Overall, we conclude that ADCs represent an interesting method for fighting cancer that 
in most cases more efficiently kill tumor cells than “naked” antibodies alone.  The few ADCs 
already FDA approved likely did so because of their excellent choice of target antigen and their 
long history of research prior to approval.  Although all ADCs currently have adverse side-
effects, they appear to be manageable in most cases, and are far better than the patient’s poor 
prognosis without treatment.  Future areas for ADC research include the use of combination 
therapies, non-internalizing ADCs that target the tumor vasculature, the use of immunotoxins 
and radioimmune therapies to complement ADCs, and site-specific conjugations to control the 
number and locations of drug attachments to the antibodies. 
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APPENDIX   
 
Example Questions for Academic and Industry Scientists Who Helped 
Develop or Test ADC drugs: 
 
1. Pre-Clinical Experts: 
A. In your opinion, which cancers are the best candidates for ADC treatments? 
B. How strong is the evidence for antigen specificity?  For example, how strong is the 
evidence that CD30 is strongly upregulated in Hodgkin lymphoma, but not in 
normal tissue? 
C. Do you agree that more research should be funded to identify a wider variety of 
tumor-specific antigens, for example to treat patients that have down-regulated 
the initial target antigen? 
D. Which ADC drugs do you think have the strongest data? 
E. Have you observed any off-target killing in any of your mouse experiments? 
F. Do you think that new chemical technologies that allow the drug to be added to a 
specific location on the antibody will allow a more uniform drug production, and 
allow the most optimum site to be determined? 
 
2. Clinical Trial Experts: 
A. Do you agree that most ADCs seem to produce manageable side-effects that are mild 
compared to the relapsed cancer itself, or compared to the side-effects of current 
chemotherapy treatments? 
B. What is your opinion on what causes the side-effects?  Are they caused by the 
expression of the target antigen in normal tissues, or due to release of the 
cytotoxic drug prematurely into the surrounding tissue? 
C. What is your opinion on why more ADC drugs have not received FDA approval?  If 
your ADC drug has not yet been approved, what data is needed to gain approval? 
 
3. Combination Treatments: 
A. Some clinical trials have been successful using an ADC drug followed by a traditional 
chemotherapy agent.  Should this combination approach be used more often? 
B. If two different types of tumor-specific antigens could be identified for a given tumor, 
would a combination approach using two different ADCs improve efficacy? 
 
 
Example Questions for FDA Legal Experts 
 
1. New Drug Approvals:   
A. For the two ADC drugs that have been FDA-approved, what was so enticing about 
their data to warrant approval?  What data was most crucial in the approval? 
B. Since only two ADC drugs have been approved so far, are the laws regulating new 
drugs too stringent?  If so, what changes do you think should be implemented? 
C. Are ADC experiments not providing strong enough data to warrant more ADC 
approvals?  Do the clinical trials show side-effects that are too severe? 
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D. Are combination drug approaches more difficult to get FDA approval? 
 
2. Cost:   
A. Do you think pharmaceutical companies have set too high a price for ADC drugs?  In 
England Roche lowered their price for Kadcyla to fall underneath the threshold 
limit for drugs paid by the government. 
B. Do you think the cost of ADCs will come down as we get better at manufacturing? 
 
3. Compassionate Use Protocols:   
A. To your knowledge, have “compassionate use” protocols been used for an ADC drug 
when it does not have full FDA approval but it was needed for a dying patient and 
no other alternative drugs are available? 
B. Do you think this approach could provide more badly needed data on patients treated 
with ADC drugs?   
 
 
 
INTERVIEW PREAMBLE 
 
We are a group of students from the Worcester Polytechnic Institute in Massachusetts, 
and for our research project we are conducting a series of interviews to investigate problems 
associated with antibody-drug conjugates for specifically targeting cancer cells. 
 
Your participation in this interview is completely voluntary, and you may withdraw at 
any time. During this interview, we would like to record our conversation for later analysis. We 
will also be taking notes during the interview on key points. Is this okay with you?  
 
Can we also have your permission to quote any comments or perspectives expressed 
during the interview? This information will be used for research purposes only, and we will give 
you an opportunity to review any materials we use prior to the completion of our final report, 
which will be published on-line in WPI’s archive of projects.  
 
If the subject does not agree to be quoted, we will respond as follows: “Since you would 
not like to be quoted during this interview, we will make sure your responses are anonymous.  
No names or identifying information will appear in any of the project reports or publications.” 
 
Your participation and assistance is greatly appreciated, and we thank you for taking the time to 
meet with us. If you are interested, we would be happy to provide you with a copy of our results 
at the conclusion of our project. 
 
